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ABSTRACT
Identification of potential protein markers for cancer is a prerequisite for decreasing the 
mortality rates and improve outcome. Biomarkers hold great potential in serving as early 
diagnostic, prognostic and therapeutic tools for cancer. Lack of clinically usable markers for 
cancer detection and the lack of a suitable platform for validating the existing pool of 
identified markers are the two major areas that need immediate attention. To this end, 
proteomic tools such as 2D gel electrophoresis (2-DE) and mass spectrometry were used to 
identify differentially expressed proteins in cancer. Proteome-wide profiling of tumor and 
normal tissue obtained from oral cancer patients was performed to identify an array of 
candidate biomarkers that can be used for diagnosis of oral cancer. 20 significantly 
upregulated proteins were identified in oral squamous cell carcinoma including heat shock 
proteins 70 and 27, cytokeratin 19 and 14, EGFR, Galectin-1 and stathmin. Immunoassays 
were performed to further validate candidate protein markers. Sandwich ELISA assays 
confirmed the upregulation of heat shock protein 70 and EGFR. A vast amount of literature 
suggests the upregulation of EpCAM (epithelial cell adhesion molecule) and survivin in most 
human carcinomas. Therefore expression analysis of EpCAM and survivin was further 
evaluated in oral squamous cell carcinomas samples using immunoassays. Significantly 
higher expression levels of EpCAM and survivin was also identified with these 
immunoassays suggesting their potential clinical applicability in oral cancer diagnosis and 
management.
The search for a panel of well-studied, clinically-validated, non-invasive markers for oral 
cancer that can help in early diagnosis or better clinical judgment is still ongoing. It is 
important that there be rapid advancements in personalized point-of-care diagnostics to 
reduce mortality rates caused by cancer. The development of a high-throughput, automated 
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and an in-expensive screening method for cancer has been a major focus for many 
researchers since the recent advancements in the field of micro-fluidics and micro-
fabrications referred to as lab-on-a-chip. Microfluidics has revolutionized the field of 
biomarker identification and rare cell capture techniques with minimal use of sample and 
time at reduced costs. Microfluidics based assays hold immense potential as validation tools 
for evaluating the clinical applicability of the vast pool of existing candidate biomarkers. 
Therefore a well-designed microfluidic device that can specifically and efficiently capture 
rare cells to be used as biomarkers or as a source for identified biomarkers would be highly 
beneficial. There is a need for development of a simple easy-to-fabricate microfluidic device 
that besides allowing high capture sensitivity and specificity also enable on-chip 
characterization of captured cells (for known cancer biomarkers or stem cell markers) and 
subsequent release and culture of cells in vitro for further analysis. For this purpose three 
simple microfluidic devices were designed and fabricated that showed efficient on-chip 
capture of specific cells. This involved affinity based capture of cells on microchannel 
surfaces modified with antibodies against known markers.  As proof of concept for evaluating 
the capture efficiency of these microfluidic devices, Caco-2 cells (human colorectal cancer 
cells) were introduced into the microfluidic devices functionalized with anti-EpCAM 
antibodies. Optimization was performed using various flow rates ranging from 5 to 30μl/min
to obtain high capture efficiency of Caco-2 cells while minimizing non-specific binding of 
FHs 74 Int cells (normal intestinal epithelial cells). It was seen that a flow rate of 10μl/min 
showed the best capture efficiency and specificity, thus used for all the subsequent 
experiments. Sensitivity of capture was evaluated for cell suspensions with cells as low as 10-
100 cells/ml and also for cells ranging from 103 to 106 cells/ml. These devices also allowed 
the cells to remain viable during the cell capture and release processes (with trypsin post-
capture) thus enabling the subsequent in vitro culture and characterization. Besides this, these 
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microfluidic devices enabled on-chip characterization of captured cells for protein expression 
analysis for various stem cell markers such as survivin and CD133. 
It is also of vital importance to develop a microfluidic platform that is robust and allows 
reusability without the need for modifying the microchannel surfaces after each run. Such a 
device that does not require critical storage and transport conditions will allow its 
applicability in remote areas without the need for sophisticated facilities. Use of aptamers as 
a more robust platform for rare cell capture was evaluated. Increased thermal stability, 
resistance to degradation, ease of synthesis and strong binding to modified glass surfaces are 
some of the reasons that prove aptamer functionalized microfluidic devices as efficient cell 
capture platforms. Aptamers targeting EpCAM and Nucleolin were immobilized on Silylated 
glass slides separately to validate the reusability of the modified microfluidic devices. 
Trypsin-mediated release of captured cells was performed after each run to remove all bound 
cells on-chip. With optimized flow rates and cell concentrations obtained from previous 
studies it was seen that the aptamer modified devices offered reusability for upto six times 
while maintaining optimal capture efficiency percentage. To simulate the rarity of occurrence 
of circulating tumor cells (CTCs), whole blood spiked with Caco-2 cells at concentrations 10, 
50, 100 cells/ml was flowed through the device to evaluate capture sensitivity. Efficient 
capture sensitivity and specificity was observed with the aptamer functionalised devices. Like 
with the antibody studies, cells post-capture remained viable that allowed subsequent in vitro 
cell culture. Ultimately, CTC isolation and characterization was performed with blood 
samples obtained from head and neck cancer patients. Use of EpCAM LNA aptamer 
functionalized chip 1 showed efficient capture of CTCs from 22/25 cancer samples used. The 
authenticity of the captured cells as CTCs (and not haemocytes) was confirmed using 
confocal microscopy for specific cell surface markers. High capture specificity was observed 
when the device was flowed with whole blood samples. Various cancer cells expressing stem 
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cell markers were also flowed through the aptamer modified devices along with normal cells 
to validate capture sensitivity and specificity. Percentage capture markedly increased when 
cells expressing stem cell markers (EpCAM, CD133, CD44) were flowed through the device 
in comparison to unsorted-cancer cells. These results suggest that the novel microfluidic 
devices designed in our study can be used to study the heterogeneity that occurs within the 
circulating tumor cells, to further identify the protein signatures specific to each cancer type 
or a subtype. This will enable better clinical decision making and designing better treatment 
strategies based on patient CTC and circulating cancer stem cell profile, ultimately aiding in 
personalized treatment. These devices can also be used as a platform to validate the pool of 
existing candidate markers for their clinical applicability with limited use of samples that can 
be obtained non-invasively. These devices can be of maximum applicability in rural areas 
with limited need to expertise, equipment and reagents.
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1. LITERATURE REVIEW
1.1. Introduction
Cancer has been the prime focus for medical and scientific research due to its high incidence 
and its incurability for several decades now. Global cancer statistics showed approximately 
12.7 million cancer cases and 7.6 million cancer related deaths in 2008 with breast cancer as 
a leading cause of mortality in females and lung cancer in males (Jemal et al. 2011). Studies 
for developing anti-cancer treatment strategies, clinical biomarkers for early diagnosis, 
preventive measures for cancer that can be affordable and easily available have received 
increased attention and financial support over the last decade (Zhang & Nagrath 2013).
Biomarkers, defined as any factors which can quantitatively or qualitatively differentiate 
normal from disease associated biological processes can include physical symptoms, single 
nucleotide polymorphisms, alterations in DNA (deoxyribonucleic acid) methylation patterns 
or mRNA (messenger-ribonucleic acid) (Sawyers 2008), microRNA (Bartels & Tsongalis 
2009), proteins, cellular processes such as apoptosis or division, circulating tumor cells, 
circulating nucleic acids (Schwarzenbach, Hoon & Pantel 2011) and variation in 
concentrations of small biomolecules in body fluids (Rusling et al. 2010; Seigneuric et al.
2010). Developments in the various ‘omics’ technologies including genomics, 
transcriptomics, proteomics, and metabolomics have led to easier identification and 
monitoring of biomarkers that can be used for early stage disease diagnosis or for predicting 
the invasiveness of cancer and the appropriate target specific therapy (Xiao et al. 2005).
Proteomics based biomarker identification for cancer has received added attention as proteins 
signify the biological endpoint for any abnormal processes occurring in the cells and also 
because the levels of functional proteins does not always correspond with the mRNA levels
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prior to translation (.RþHYDU +XGOHU 	 .RPHO ). Understanding critical changes 
occurring at the protein level may therefore be of crucial importance for diagnosis, prognosis 
and personalized treatment of cancer (Admon 2011; Rusling et al. 2010; Simpson et al. 2008;
Srinivas et al. 2002). Diagnosis of cancer usually requires collection of tumor tissue samples 
and body fluids for protein quantification involving invasive sampling methods that not only 
cause discomfort to the patients but also limit the availability of samples for inaccessible 
tumor tissues. Despite the number of potential protein markers identified for various cancers 
in tissues and body fluids  using ‘omics’ technologies, very few markers have reached 
clinical utility. There is an immediate need for a point-of-care device that can take advantage 
of the existing candidate markers to develop a quick, simple, easily measureable, robust non-
invasive diagnostic assay that can ultimately aid in developing personalized treatment 
strategies (Zhang & Nagrath 2013).
1.2. Biomarkers for oral cancer detection using proteomics
1.2.1. Oral Cancer - Introduction
Oral cancer, primarily a squamous cell carcinoma, falls under the group head and neck 
malignancies which could develop in the tongue, lip, or mouth. For the advancement of oral 
cancer from pre-cancerous lesions to a malignant carcinoma, it is suggested that a multi-step 
passage is required caused by the amassment of a wide range of mutations (J. M. Braakhuis, 
René Leemans & H. Brakenhoff 2004; Nagpal & Das 2003; Seema et al. 2013). Oral pre-
cancerous lesions that are of significance to oral cancer include leukoplakia (Neville & Day 
2002) oral lichen planus and erythroplakia (Dissemond 2004; Reichart & Philipsen 2005)
which can be diagnosed at various stages of malignancy ranging from mild dysplasia to 
carcinoma in-situ (Mignogna et al. 2001).
Oral squamous cell carcinoma (OSCC) ranks fifteenth among the various 
malignancies in the world and accounts for two percent of total cancers every year (Jemal et 
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al. 2011), although it falls in the top three malignancies in high incidence areas including 
South Asian countries, Melanesia, central and eastern Europe (Warnakulasuriya 2010).
Approximately 263,900 oral cancer cases were recorded in 2008 worldwide. Developing 
countries including Sri Lanka, India, Pakistan and Bangladesh are major contributors for 
increased OSCC mortality worldwide occurring mostly in men (Ahmed, Mubeen & Jigna 
2009). The prognosis remains poor, most of which die within 5 years owing to relapses of 
tumor at the primary site, metastasis, or field cancerization (Mognetti, Di Carlo & Berta 
2006; Rautava et al. 2007). People in the Southeast Asian countries extensively use 
smokeless tobacco or betel quid and tobacco smoking which are major risk factors. Hence, 
mucosal lining of the cheek is the primary site for cancer in Southeast Asia (Saran et al.
2008). Other common risk factors include excessive alcohol consumption, human 
papillomavirus infection. More recently factors such as immunosuppression, inadequate diet 
and nutrient intake and lower socio-economic status have also been attributed to the cause of 
oral cancer (Petti 2009; Warnakulasuriya 2009a). Early detection of oral cancer is usually 
done by careful screening programs for any unusual discolorations and lesions or by use of 
specific diagnostics aids. (Mehrotra & Gupta 2011). In spite of all the developments in 
diagnosis and oral cancer management, global survival rates are still low. Most of the oral 
cancers are diagnosed only at an advanced stage leading to high mortality rates. Hence, early 
diagnostic tools are of utmost importance in reducing the mortality rates and to improve the 
quality of life of the patients (Neville & Day 2002).
1.2.2. Proteomic technologies and Cancer Biomarkers
Biomarkers are gaining importance becoming increasingly important for cancer detection, 
diagnosis, treatment and prognosis, accessibility of such biomarkers would greatly benefit the 
patients (Aebersold et al. 2005). Biomarkers not only indicate physiologic state of a cell but 
also correlate with essential disease related pathways and disease consequences. Biomarker 
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discovery has been taken to the next level after the end of the Human genome project, which 
is represented by functional genomics or proteomics. (Cho 2007; Srinivas et al. 2002).
“Biomarkers are quantifiable measurements of biologic homeostasis that define what is
‘normal,’ thereby providing a frame of reference for predicting or detecting what is 
‘abnormal’.” (Dalton & Friend 2006). Biomarkers include single nucleotide polymorphisms 
(SNPs) or changes in DNA methylation patterns or alterations in mRNA, protein, or 
metabolite levels which are specific to a particular disease state. Use of numerous omics tools 
including genomics, transcriptomics, proteomics, metabolomics are underway for identifying 
early stage biomarkers, for prediction  of invasive potential and signaling mechanisms 
involved in development of cancer from clinical specimens such as tumor tissue samples and 
body fluids. The multifaceted character of cancer asks for a mixture of several 
biomarkers/indicators that will together help early detection and diagnosis of cancer (Xiao et 
al. 2005). Proteomic assays have been a chief support in the diagnostic field for several 
decades now, the reason being very direct. Interpreting the critical changes at the gene level 
alone is not enough to understand the process of cancer progression, due to the intricacy of 
the mammalian systems, Hence, expression analysis at the protein level is essential. mRNA 
abundances do not often correlate with the amount of the functional proteins existing in the 
cell (Kocevar, Hudler & Komel 2013; Lu et al. 2007). Protein biomarkers present in tissue 
and blood may therefore play an important role in early detection, monitoring and treatment 
of cancer. The most commonly used methods for protein marker identification include use of 
gel based methods such as 2-dimensional gel electrophoresis (2-DE) followed by mass 
spectrometric analysis. 2-DE allows separation of proteins based on their iso-electric points 
and molecular weights. This is usually followed by peptide mass fingerprinting (PMF) using 
mass spectrometry for protein identification (Kocevar, Hudler & Komel 2013; Rabilloud et 
al. 2010).
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1.2.3. Biomarkers in Oral cancer
1.2.3.A. Salivary Proteomics
Saliva has been studied for many years as a medium of diagnosis of local and systemic 
diseases. It has been found to contain hundreds of macromolecules, it is an ultra-filtrate of 
blood plasma, and contains proteins, peptides and mRNA secreted from salivary glands and 
cells present in the oral cavity (Wong, Segal & Wong 2008). When compared to tissue 
biopsies which involve a non-invasive procedure, saliva samples can be easily obtainable 
thereby eliminating the need for stringent ethical procedures. Hence, huge amount of saliva 
samples can be collected and analyzed. Several studies indicating the usefulness of saliva for 
identifying potential markers have been reported (Liu & Duan 2012; Zhang, Sun, et al. 2013).
A recent study employed the use of 2-DE electrophoresis and peptide mass fingerprinting 
with matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF/TOF) to identify salivary markers for tongue squamous cell carcinoma. Differential 
protein expression was seen between oral cancer patients and healthy volunteers, and also 
between saliva samples obtained before and after the surgery. Enolase 1 was found to be 
significantly overexpressed in preoperative saliva of oral cancer patients. These results were 
further confirmed by immunohistochemical staining of tumor tissue samples and real time 
polymerase chain reaction (PCR) analysis of RNA extracted from these tumor tissues. It is 
however important to investigate if the same trend is seen in other cancers of the oral cavity 
(Katakura et al. 2013). A similar methodology was used by Jarai et al. 2012 for profiling 
protein expression levels in saliva obtained from patients with head and neck squamous cell 
carcinoma. Expression levels of proteins including annexin 1, zinc finger protein 28, 
regulator G-protein 3, indoleamine were found to be upregulated in saliva from cancer 
patients (Jarai et al. 2012). Shintani et al. 2010 have reported the identification of protein 
markers in un-stimulated saliva using surface-enhanced laser desorption/ionization time-of-
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flight mass spectrometry (SELDI-TOF) ProteinChip system. SELDI-TOF, a combination of 
chromatography and mass spectrometry allows rapid, accurate, high throughput protein 
identification from various complex biological samples. This method besides being capable 
of identifying low molecular weight proteins, also allows protein profiling from a small 
sample volumes (Issaq et al. 2002). A 14 kDa protein was found to be significantly 
overexpressed in the preoperative saliva samples that was later identified as cystatin SA-1
with three amino acids of the N-terminal (amino terminal) end deleted (Shintani et al. 2010).
This study needs further validation in a larger sample number to evaluate the clinical utility 
of this marker and the proposed method. However this is the first study that reported the use 
of SELDI-TOF for profiling protein markers in saliva.  
Improving survival rates with better treatment strategies for oral cancer patients is greatly 
dependent on early diagnosis of pre-malignant/malignant lesions. However, there is currently 
no available technique to differentiate pre-malignant form malignant lesions. A study carried 
out by de Jong et al. 2010 was the first to identify differentially expressed protein markers in 
pre-malignant and malignant lesions. Proteins extracted from saliva samples of subjects with 
premalignant and malignant lesions were digested followed by labeling with isobaric tag for 
relative and absolute quantification (iTRAQ) reagents. iTRAQ reagents besides being a gel 
free method, allows protein profiling from up to four different samples simultaneously along 
with post translational modifications. The iTRAQ labeled peptides when fragmented in 
MS/MS produce four different reporter ions that can later aid protein quantification. (Wiese et 
al. 2007). The labeled peptides were then mixed and subjected to fractionation using 
preparative isoelectric focusing, strong cation exchange and liquid chromatography, followed 
by mass spectrometric analysis with electron spray ionization ESI-MS/MS. They have 
reported higher expression levels of actin and myosin in saliva obtained from subjects with 
malignant lesions when compared to that of pre-malignant lesions. This protein abundance 
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levels also correlated with those of the exfoliated cells present in the saliva samples. Actin 
and myosin are important cytoskeletal proteins that aid in cell migration and determine their 
invasive potential. These results suggest that development of an effective diagnostic method 
for early diagnosis of oral cancer is achievable (de Jong et al. 2010).
Dowling et al compared the salivary proteomes of head and neck cancer individuals and 
the control group involving individuals with non-malignant forms of head and neck. This 
kind of a study group helps in identifying only those proteins that are tumor specific and 
excluding acute phase proteins or others that are involved with immune or inflammatory 
responses. Whole proteome analysis of the case and control groups was carried out using 2D-
DIGE (difference in gel electrophoresis) followed by LC-MS/MS analysis, with the aim of 
identifying a panel of tumor specific markers for head and neck squamous cell carcinoma 
(HNSCC). Of the six proteins that were found to be significantly overexpressed in all the 
HNSCC samples, a S100 calcium binding protein, S100A9 was of highest significance with 
more than a 5-fold difference in the abundance levels. This was further confirmed with 
western blot analysis. S100 calcium binding proteins have been reported to be associated with 
various cellular operations including cell cycle progression, differentiation and also in 
malignant transformation of the cell (Dowling et al. 2008).
Genetic alterations in the tumor suppressor p53 gene have been reported in most human 
cancers, resulting in the aggregation of a defective p53 protein in the neoplastic cells. This 
accumulation of the altered gene product leads to the production of seric anti-p53 antibodies, 
as a result of its increased half-life period in comparison to the normal protein. Rahlan and 
coworkers suggested that the rate of occurrence of p53-Abs in the tumor is indicative of the 
frequency of p53 mutations (Ralhan et al. 2001). Results generated from two independent 
studies suggest that the detection of p53 protein in leukoplakias is an indicator of potentially 
malignant-precancerous lesions and can be helpful for early stage diagnosis. Premalignant 
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and malignant lesions of patient with betel, areca nut and tobacco chewing habits had higher 
levels of p53 protein (Kaur, Srivastava & Ralhan 1996; Saranath et al. 1999). Tavassoli and 
his group in 1998, identified the presence of p53-Abs in saliva of those OSCC patients who 
were positive for serum p53-Abs. If this was to be further validated and proven correct, a 
completely non-invasive diagnostic assay can be developed for screening individuals with 
precancerous lesions and also those who are heavy eaters of betel/areca nut/tobacco 
(Tavassoli et al. 1998).
Several studies have been carried out targeting Telomerase as a possible approach for 
HNSCC therapy. However, a complete elucidation on the role of telomerase and its clinical 
utility in tumor progression and/or diagnosis is still not available. Telomeres are specialized 
structures with tandem repeats at chromosomal ends that help neutralize the effects of end 
replication problem at each replication cycle.  Cells undergo senescence after a definite 
number of cell divisions due to chromosomal instability (as a result of repeated telomere 
shortening), which ultimately leads to cell death. Synthesis of telomeric repeats at the 
chromosomal ends occurs in the presence of Telomerase, a ribo-nucleoprotein complex. 
Telomerase activation leads to cell immortalization and studies on most human cancers have 
confirmed the same. Patel et al. 1999, carried out telomeric repeat amplification protocol 
assay using Telomerase-PCR-ELISA kit on tissue samples obtained from head and neck 
cancer patients, from oral precancerous lesions and healthy surrounding tissue collected from
most of the patients referred to at Gujarat Cancer and Research Institute, India. Telomerase 
activity was seen in 80% of the head and neck malignancies and 100% of oral premalignant 
lesions, 20% of the cancer tissues were telomerase negative which is probably mediated 
through a novel telomerase-independent pathway for immortalization (Patel et al. 1999),
supporting findings of Bryan et al. (Bryan et al. 1995). However, this study also found a large 
number of normal surrounding tissues to be telomerase positive, which is because of the 
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genetic alterations brought about by repeated carcinogenic insults results in development of 
benign and malignant lesions in the normal tissue as well as benign lesions. Several other 
groups have reported similar findings, a Fluorescence based TRAP method by Fujita et al
established that telomerase levels were significantly higher in malignant lesions than in non-
malignant lesions of OSCC patients (Fujita et al. 2004). Chen and co-workers have suggested 
that estimation of cytoplasmic or nuclear human telomerase reverse transcriptase protein 
levels may act as indicators for tumor progression, recurrence in OSCC patients (Chen et al.
2007). A study on oral malignant tumors, leukoplakias, pleomorphic adenomas and normal 
tissues of the oral cavity suggested that the telomerase activity was highest in malignant 
tumors whereas it was completely absent in normal tissues and leukoplakias showed mild 
telomerase activity, suggesting telomerase activation as a phenomenon closely associated 
with final stages of oral pre-malignancy and its subsequent use in characterizing clinically 
malignant from benign and normal tissues (Miyoshi et al. 1999; Mutirangura et al. 1996).
Despite being the focus of several research groups, telomerase has not yet emerged as a 
promising marker for head and neck cancers. The current state of knowledge on telomeres, 
telomerase and its components and their role in oral cancer progression must be evaluated in 
larger population sets to get better insights for its use as an attractive target for therapeutic 
inhibition. 
Research by Hu et al. 2008 at UCLA, using a subtractive proteomics approach to 
profile salivary proteins from pooled oral cancer and matched healthy subjects revealed a 
panel of five candidate protein biomarkers namely M2BP, MRP14 (or S100A9), CD59, 
catalase, and profilin for detection of OSCC. The inherent simplicity of subtractive 
proteomics makes it a fascinating approach for research on biomarker discovery. It does not 
involve the use of gels or covalent labeling and requires a very little sample preparation prior 
to MS analysis. This approach involves direct profiling of proteins expressed in samples from 
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two pathologically different states using LC-MS/MS analysis. The pooled samples were also 
separated using the 2-DE approach which showed remarkable similarities to the LC-MS/MS 
results. The six upregulated proteins were further validated using ELISA assays and 
immunoblotting. Considering the revealing of low abundant protein expression, this study 
reports that subtractive proteomics is more feasible approach than 2D-PAGE/MS, as the 2D 
gel images of control and OSCC samples did not show a striking difference, also the presence 
of high abundant proteins attenuated the analysis of low abundant proteins (Hu et al. 2008).
Several research groups have worked independently on identifying methods that are 
feasible for analysis of the whole salivary proteome. Use of traditional 2-dimensional gel 
electrophoresis followed by trypsin digestion of desirable spots for peptide mass 
fingerprinting (Ghafouri, Tagesson & Lindahl 2003) or MS/MS pattern analysis (Huang 
2004; Vitorino et al. 2004) has been attempted. All these studies had been successful in 
identifying a large number of proteins, some that have not been reported earlier in saliva and 
some that were upregulated when bleeding occurred were also characterized.  Wilmarth et al.
2004 identified 102 salivary proteins using 2D liquid chromatography method. The proteins 
were first extracted from saliva followed by tryptic digestion. The 1st dimension separation of 
peptides was carried out in a strong cation exchange resin column followed by the 2nd
dimension separation in a reverse phase liquid chromatography which in turn was followed 
by analysis on electrospray mass spectrometry. The various proteins identified include 
commonly known salivary and serum proteins and several other proteins that might have 
gone unnoticed after a 2-DE experiment due to their relative abundances (Wilmarth et al.
2004).
Another group employed a combination of a free flow electrophoresis (FFE) system 
for preparative isoelectric focusing of peptide mixtures and linear ion trap tandem mass 
spectrometry for whole proteome analysis. A FFE system does not require the presence of a 
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stationary phase and works in a procedure working continually by separating the charged 
particles based on their electrophoretic mobilities (EPMs) or isoelectric points (pIs). This 
approach identified 437 proteins with high confidence. The use of FFE systems allows 
highest possible resolution (based on pI in this study) along with aiding in the separation of 
low abundant protein fractions as well (Xie et al. 2005). Hu et al 2005, established the use of
shotgun proteomics where the proteins from whole saliva were pre-fractionated based on 
their molecular weights, fractions with proteins >3kDa were digested prior to LC-MS/MS 
analysis. This was done in addition to 2-DE-MALDI-MS analysis. Employing these two 
methods listed out more than 300 different proteins in human whole saliva that varied in size 
from as small as <10kDa to as large as >100kDa, which would not have been possible by 2-
DE alone, suggesting a high need for betterment (Hu et al. 2008). Guo et al 2006, combined 
capillary isoelectric focusing with nano-reverse phase liquid chromatography attached to ESI-
tandem MS (electrospray ionization tandem mass spectrometry). This set up enhanced MS 
estimations by improving the range and detection sensitivity. One of the largest ever 
published report on proteins catalogued from single human saliva has been shown in this 
study (Guo et al. 2006).
1.2.3.B. Tissue Proteomics
Although several protein markers have been reported to be differentially expressed in oral 
cancer tissue specimens, none of them have reached clinical utility for efficient diagnosis. 
This could partially be attributed to the heterogeneity in the protein profiles of cancer of 
different sub-locations in the oral cavity. Thiel et al. 2011 employed proteomics tools to 
study disease mechanism in tongue cancer. 2-DE and MALDI-TOF/TOF were used to 
identify markers of significance. Over 30 protein were identified to be overexpressed in 
tongue cancer samples in comparison to the healthy tissue, of these the significant markers 
were cytokeratin 6 and 13, beta globulin, alpha-2-actin and heat shock proteins 70kDa and 
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90kDa (Thiel et al. 2011). A group of 52 differentially expressed proteins were identified in 
OSCC tissue samples using similar techniques in another study. Eight of these proteins 
including S100 family proteins, peroxiredoxin-4, RACK1, calcium binding protein P22 were 
reported for the first time in OSCC tissues. Overexpression of RACK1 was further validated 
using IHC, western blotting and semi-quantitative RT-PCR. It was seen that increased 
RACK1 expression was associated with the advanced stages of cancer, metastasis to lymph 
nodes and cancer relapse. Tca8113 cell line (poorly differentiated lingual SCC cells) showed 
programmed cell death when transfected with RACK1-specific small interfering RNA. 
These results show that RACK1 is associated with increased cell proliferation and metastatic 
potential of OSCC cells, suggesting its potential as a diagnostic and prognostic marker of 
OSCC (Wang, Jiang, et al. 2008).  Use of advanced proteomic techniques such as iTRAQ 
labeling and LC-MS/MS have also been reported for head and neck squamous cell 
carcinoma. S100A7/Psoriasin was identified as being overexpressed in HNSCC and oral 
premalignant lesions. S100A7 is a low molecular weight protein found in the keratinocytes 
of human epidermis which has been reported to be overexpressed in several malignancies 
including the lung, skin, bladder, esophageal (Tripathi et al. 2010). Another independent 
study using the same methodology reported predictive markers for malignant transformation 
of leukoplakias. A RNA-binding protein called heterogeneous ribonucleoprotein K (hnRNP 
K) was seen to be upregulated in leukoplakias as compared to normal tissue. Leukoplakias 
showed lower levels of this protein in the nucleus in comparison to HNSCC samples and this 
is related with reduced prognosis of HNSCC. The cytoplasmic abundance of this protein was 
also associated to disease recurrence in HNSCC patients (Matta et al. 2009). hnRNP K was 
also reported in another study as one of the three biomarker panel including stratifin and 
YWHAZ for differentiating oral pre-malignant lesions from that of a healthy tissue (Ralhan
et al. 2008). Availability of a large number of fresh human tissues for proteomic analysis 
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although beneficial, is usually very difficult. To overcome this limitation Patel et al. 2008 
developed a method for extracting proteins for mass spectrometric analysis from easily 
available formalin-fixed paraffin-embedded (FFPE) tissues. This method involved the use of 
laser capture microdissection (LCM) to identify and isolate specific cell regions (tumor and 
healthy adjacent cells) from the deparaffinized FFPE section, followed by tryptic digestion 
to produce peptides that can be used for subsequent mass spectrometric analysis (Patel et al.
2008). This method of protein extraction from FFPE tissues followed by a mass 
spectrometry based method named as 2DICAL (2-dimensional image-converted analysis of 
liquid chromatography and mass spectrometry) was employed by Negishi et al. 2009 to 
identify protein biomarkers in FFPE tissues of OSCC (Negishi et al. 2009). 2DICAL is a 
recently developed label free protein quantification method that allows analysis of large 
amounts of protein data generated by a nanoflow LC-MS with the combined use of several 
software elements (Ono et al. 2006). This method revealed down regulation of three 
different proteins namely Transglutaminase 3 (TGM3), Cytokeratin 4, Cytokeratin 12 and 
Annexin 1 in FFPE tissues of squamous cell carcinoma of the tongue. IHC studies further 
proved that decreased TGM3 expression correlated with dedifferentiation. Reduced TGM3 
expression has also been reported in other head and neck carcinomas which are associated 
with the loss of differentiation, increased metastatic potential and poor prognosis. It can be 
deduced from these results epigenetically silenced TGM3 gene plays a crucial role in oral 
cancer progression (Negishi et al. 2009). Lundy et al., (2004) identified and quantified the 
role of Į-defensins- human neutrophil peptides (HNP)1, 2 and 3 in the tumor and non-
malignant adjacent tissues from the same patient group diagnosed with the squamous cell 
carcinoma of the tongue. A combination of high performance liquid chromatography
(HPLC), MALDI-MS, IHC and amino acid sequencing was used to confirm these results. A 
proteomic based approach was employed as HNP-2 is derivative of post translationally 
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modified HNP 1 and 3, so mRNA analysis would not yield the levels of HNP-2. HPLC was 
used to generate peptide profiles, rather than the most preferred 2D-PAGE because of its 
inefficiency in the optimal resolution of high and low molecular weight peptides. The study 
revealed that HPN 1,2 and 3 were elevated by similar levels in the tumor  samples. These 
results suggest the role of Į-defensins as a host defense mechanism against OSCC (Lundy et 
al. 2004).
Several groups have studied the role of EpCAM in cancer development. Unlike 
cadherins which are calcium-dependent cell-cell adhesion molecules, epithelial cell adhesion 
molecule (EpCAM) is 40-kDa epithelial glycoprotein which is calcium independent 
intracellular molecule which is able to participate in assemblage of cells and inhibits cell
dispersion (Litvinov et al. 1994; Litvinov et al. 1997). Cells that are deficient in intracellular 
adhesion properties have showed better adhesion in the presence of EpCAM. Adult squamous 
epithelial cells lack EpCAM expression, however it has been reported that anew expression 
of EpCAM occurs in cells undergoing malignant transformations, for instance as seen in most 
squamous cell carcinomas of head and neck, colorectal, breast, lung and hepatic carcinomas.
EpCAM positive cells show elevated levels of EpCAM during neoplastic changes in the cells, 
for example polyp development in the colon causes elevation of this protein. Scattering of 
EpCAM positive cells from a mixed population of cells expressing both EpCAM and 
cadherins has been reported. This occurs in cancer cells co-expressing cadherins and elevated 
levels of EpCAM, due to the loss of adhesion properties of cadherin as a result of cadherin-
catenin complex formation. Since EpCAM lacks strong adhesive properties like cadherins the 
cancer cells develop a proliferative/invasive phenotype (Munz et al. 2004; Went et al.
2006b). Yanamoto et al carried out EpCAM expression analysis in primary tongue cancer 
samples obtained from 48 individuals and normal epithelium collected from 10 individuals as 
controls. Immunohistochemical analysis showed that 62.5% of the tongue cancer samples had 
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elevated levels of EpCAM whereas expression levels in normal epithelium were almost 
undetectable. This overexpression in cancer samples correlated with the size of the tumor, 
nodal metastasis, differentiation and metastatic potential. Increased EpCAM levels were 
identified at the invasive front.  EpCAM levels were also studies in four human tongue cancer 
cell lines by using semi-quantitative reverse transcriptase-polymerase chain reaction (RT-
PCR). All the cell lines showed detectable EpCAM mRNA levels. Matrigel based invasion 
analysis was carried out to study the invasive potential of these cell lines, and it was seen that 
cell lines with higher EpCAM levels were more invasive than the other. The cell line with 
highest invasive potential was then treated with EpCAM siRNA to determine the possibility 
of targeted therapy for tongue cancer. Definite reduction in EpCAM m RNA was seen with 
siRNA transfection. Another Matrigel invasion assay analysis confirmed that there was a 
decrease in the invasive potential of the EpCAM siRNA transfected cell line. This reduction 
in EpCAM levels also correlated with the decrease in the proliferative capacity of these cells. 
These results suggest that higher EpCAM levels correlate with increased invasive potential of 
tongue cancer; also the use of EpCAM for tongue cancer gene therapy has been elucidated in 
this study (Yanamoto et al. 2007).
1.2.3.C. Serum/Plasma Proteomics
Recent investigations of the saliva Cyfra21-1 levels in oral squamous cell carcinoma 
patients and healthy individuals by Zhong and co-workers revealed that OSCC subjects had 
elevated levels of this protein in comparison to healthy individuals (Zhong et al. 2007). Cyfra 
21-1 a 40kDa protein, is a soluble fragment of cytokeratin 19 which is expressed on most 
epithelial tissues (Sawant, Zingde & Vaidya 2008). Huang et al reported upregulation of 
Squamous cell carcinoma antigen 1 in tongue cancer patients and also in tongue cancer 
bearing nude mice, suggesting its possible role as a marker for tongue cancer (Huang et al.
2006). Results generated by a recent study by Chen et al. 2008 show that serum protein 
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samples from HNSCC patients and healthy individuals were separated well by 2-DE. The 2-
DE maps showed that there were significant changes in the expression of proteins in the 
lower molecular weight range. These proteins included three different isoforms of
apolipoprotein, haptoglobin chain. It was seen that even in the presence of high abundant 
protein like Albumin (depletion of plasma sample was not carried out prior to IEF) the 
proteins separated well into their isoforms. The differentially expressed spots were excised 
from the silver stained gel and tryptic digestion was carried out. LC-MS analysis of these 
tryptic digests confirmed the presence of haptoglobin alpha2. Such markers can be used 
independently or as a part of an array of markers identified in other studies for better 
diagnosis and prognosis of oral cancer (Chen, Su, et al. 2008).
Wadsworth and group developed a new method for protein profiling in 2004. 
ProteinChip surface-enhanced laser desorption/ionization time of flight mass spectrometry 
(SELDI-TOF-MS) was used for profiling serum samples from HNSCC patients, healthy 
controls as well as healthy smokers. Serum samples were obtained from the subjects and 
loaded on the proteinchip after making required dilution. This allows selected proteins on the 
surface with enhanced properties to bind based on chemical properties such as hydrophobic, 
cationic, anionic, or metal-binding molecules, whereas loosely bound nonspecific proteins 
and contaminants are washed away. The proteins were then subjected to SELDI followed by 
mass spectrometric analysis. A large number of proteins encompassing wide molecular 
weight ranges were observed to be variably expressed between the HNSCC and normal 
samples. A classification tree algorithm was generated based on the variations in the protein 
profiles and it was shown that a sensitivity of 83.3% and a specificity of 90% were achieved 
in differentiating HNSCC from normal and healthy smoker controls. A well-known tumor 
marker metallopanstimulin- 1 (MPS-1) was also detected. From these results it can be said 
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that this technique may be used to develop a solid unfailing assay for early detection and 
diagnosis of HNSCC (Wadsworth et al. 2004).
To overcome the major challenges faced during serum proteome profiling Fu et al
developed a rapid, reproducible method that involved lipid removal, depletion of high 
abundant proteins such as human serum albumin (HSA) and IgG followed by 2-DE.
Although several chromatographic techniques are currently available to deplete the serum off 
the HSA, the use of these techniques is objectionable because of their non-specific 
interactions and poor reproducibility. Other antibody based affinity binding methods involve
too much expense for regular usage (Fu et al. 2005). Yocum et al conducted a study to 
analyse the effect of immunoaffinity based depletion of human serum. The results suggested 
that on one hand depletion of six major serum proteins improved protein identification by 
revealing greater number of proteins but on the other hand also led to non-selective loss of 
certain proteins which could be of vital importance. Hence as a prerequisite for protein 
biomarker studies it is necessary that a simple, reliable, reproducible and economically 
feasible method be developed for better sample preparation and processing (Yocum et al.
2005). The current method was developed to answer most of these issues. Serum was 
centrifuged at high speeds to remove lipids and aggregated proteins, incubated with protein G 
resin to remove IgG, and finally precipitated with sodium chloride (NaCl)/ethanol to deplete 
albumin. This delipidated/IgG, HSA depleted serum was used for iso electric focusing 
followed by separation on an SDS-polyacrylamide gel electrophoresis. The 2D images 
obtained for three different serum samples run on three consecutive days show that this 
method is highly robust and reproducible and this method can be used for disease specific 
biomarker studies. 
Yu et al used 2D-DIGE and MALDI-TOF/TOF for proteomic analysis of serum 
samples from pancreatic cancer patients. Chromatographic removal of five most abundant 
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serum proteins was carried out using immunoaffinity columns, prior to differential in gel 
electrophoresis (DIGE). This method helped identify several upregulated and down regulated 
proteins in the cancer samples, suggesting its suitability in identifying differentially expressed 
proteins in disease condition (Yu, Rustgi & Blair 2005). Cheng and co-workers developed a 
bead based affinity fractionation method for plasma proteins before being subjected for 
analysis on MALDI-TOF/TOF.  Plasma samples from 57 oral cancer patients and 29 healthy 
volunteers were obtained for this study. The albumin was depleted from the samples prior to
fractionation with chemically coated magnetic beads. The resulting proteins after elution was 
diluted and analyzed on MALDI-TOF/TOF. The results showed 100% specificity and 97% 
VSHFLILFLW\IRUD'DSURWHLQLGHQWLILHGDVDIUDJPHQWRIILEULQRJHQĮ-chain in the cancer 
samples. Overexpression of fibrinogen in breast and lung cancer, elevated levels of 
ILEULQRJHQĮ-chain in gastric cancer and melanoma has been reported earlier. In accordance 
ZLWKWKHUHVXOWVREWDLQHGLWFDQEHVDLGWKDWILEULQRJHQĮ-chain could be used as an indicator 
of tumor progression in oral cancer patients. The actual onset time of this protein, whether it 
is seen as a result of malignant transformation or is seen from early precancerous stages itself 
is yet to be answered. However, the high sensitivity and specificity obtained in this study is 
indicative of the fact that this method of plasma protein profiling is quite reliable and 
convenient for tumor marker studies and its use in characterizing proteins in various body 
fluids has been encouraged (Cheng et al. 2005). Another group reported a new method with 
the intention of developing high-throughput technique for a thorough proteomic analysis of 
human plasma suitable for biomarker discovery. Removal of albumin and IgG was first 
carried out followed by multi-lectin affinity chromatography (M-LAC). The fractions 
obtained were further separated using a nano flow liquid chromatography followed MS/MS 
analysis of peptides and quantitation was carried out without any labeling procedures. 
Proteins with a concentration of as low as 10-100 ng/ mL were identified in normal plasma 
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using this method, which may be of high significance while carrying out a comparative 
analysis of protein profiles in diseased and matched normal samples or also comparing 
different disease states. This method was used to identify candidate biomarkers for psoriasis; 
which showed a larger number of proteins with very low concentration (Plavina et al. 2006).
The study that has developed one of the most comprehensive plasma proteome maps using a 
multidimensional liquid chromatography coupled with mass spectrometry was carried out in 
2007 by Liu et al. This method used ion mobility spectrometry as a third dimension for 
separation of proteins along with the most commonly used strong cation exchange 
chromatography and reverse phase liquid chromatography. Almost 3000 proteins with high 
confidence were identified using this method (Liu, Valentine, et al. 2007).
The advancement in biomarker discovery in oral cancer has been slow. Although several 
putative biomarkers have been identified in OSCC, none of them have clinical utility so far. 
Many of these markers are not specific to OSCC and have been reported to be present in 
other cancers as well. Absence of an organized attempt to advance biomarker discovery from 
development to validation and clinical application, is the cause for the nonexistence of 
relevant biomarkers for oral cancer. High morbidity rate of oral cancer patients is because 
most patients are diagnosed at a very late stage, suggesting an immediate need for sensitive 
biomarkers to improve early detection of oral cancers. There is also a need for clinical 
validations in a large sample sets to be able to use these markers in a clinical setting. Salivary 
proteomics is a promising platform not only to identify markers for early diagnosis of OSCC 
but also to develop a non-invasive diagnostic procedure.
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Table 1.1. Protein markers identified for Oral squamous cell carcinoma.
Protein Biomarkers Specimen type Techniques Reference
Įȕ- crystallin OSCC tissue 2-DE, 
Nanoelectrospray MS, 
Real time RT-PCR
(Lo et al. 2007)
HSP60, HSP27, Įȕ-crystalline, 
ATP synthase ȕcalgranulin B, 
myosin, tropomyosin and 
galectin 1
OSCC tissue 2-DE, MALDI-TOF 
MS
(He et al. 2004)
Thioredoxin, Epidermal fatty 
acid binding protein
HPV-positive 
OSCC tissue
SELDI-TOF MS (Melle et al. 2009)
Cofilin, C-reactive protein 
precursor, creatine kinase m-
chain, fatty acid-binding protein, 
keratin type II, myosin light 
chain 2 and 3, nucleoside 
diphosphate kinase A, 
phosphoglycerate mutase 1,
plakoglobulin, and retinoic acid-
binding protein II
OSCC tissue 2-DE, MALDI-TOF 
MS
(Turhani et al.
2006)
&UHDWLQLQHNLQDVH0VWUDWL¿Q
CRP precursor, glutathione S-
transferase, nucleoside 
diphosphate kinase A, 
retinoblastoma-like protein 2, 
retinoic acid-binding protein II
OSCC tissue 2-DE, MALDI-TOF 
MS
(Koehn et al. 2008)
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p53 antibodies OSCC and 
leukoplakia tissue 
PCR, 
Immunohistochemistry 
(IHC), ELISA
(Nylander, 
Dabelsteen & Hall 
2000; Ralhan et al.
2001),
EpCAM OSCC tissues Anti-EpCAM IHC, 
RT-PCR and western 
blotting
(Laimer et al. 2008;
Yanamoto et al.
2007)
Colligin/HSP-47 Oral submucous 
fibrosis tissues
IHC (Kaur et al. 2001)
HSP-27 OSCC tissue IHC (Suzuki, Sugimura 
& Hashimoto 2007)
Galectin 1 OSCC tissues IHC, Laser 
microdissection, RT-
qPCR
(Chiang et al. 2008;
Saussez et al.
2008a)
Superoxide dismutase [Mn] OSCC tissue 2-DE, 
Nanoelectrospray MS, 
Real time RT-PCR
(Lo et al. 2007)
Psoriasin (S100A7) OSCC tissue Real time RT-PCR,  
Immunofluroscence 
with psoriasin Abs.
(Kesting et al.
2009)
Annexin A2 OSCC tissue 2-DE, LC-MS/MS, 
Western blot, real time 
PCR, IHC.
(Zhong et al. 2009)
p53-HSP70 complex OSCC tissue Immuno precipitation, 
immunoblotting    
(Kaur, Srivastava & 
Ralhan 1996)
RACK1 OSCC tissue Immunohistochemistry (Wang, Zhang, et 
al. 2009)
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Cathepsin B Cell lines: 
HIOECs, HB56, 
HB96; OSCC 
tissue
2-DE, LC-MS/MS, 
Western blot, real time 
PCR
(Yang et al. 2010)
Lin -7C Cell lines: Ca9-
22, Ho-1-N-1,
Ho-1-u-1, HSC-2,
HSC-3, HSC-4,
OK92, Sa3, and 
H1
2-dimensional 
differential in-gel 
electrophoresis (2D-
DIGE), MALDI-TOF-
MS
(Onda et al. 2007)
Transferrin Whole saliva 2-DE MALDI-MS/MS (Jou et al. 2010)
STAT3, RIPK2, IKBK Whole saliva Free flow 
electrophoresis, strong 
cation exchange, LC-
ESI-MS/MS
(Xie et al. 2008)
Zinc finger protein 510 peptide Whole saliva C8- reversed phase 
magnetic beads; 
MALDI-TOF
(Jou et al. 2011)
S100 Calcium binding protein Whole saliva 2D-DIGE, LC-MS, 
Western blotting
(Dowling et al.
2008)
p53-Antibodies Whole saliva ELISA (Tavassoli et al.
1998)
Complement factor B Whole saliva LC-MS/MS, Western 
blotting.
(Ohshiro et al.
2007)
M2BP, MRP14, CD59, catalase, 
and profilin
Whole saliva LC-MS/MS, Western 
blotting, ELISA,
(Hu et al. 2008)
Haptoglobin Į-2 chain Serum 2-DE, LC-MS/MS, (Chen, Su, et al.
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PCR 2008)
Squamous cell carcinoma 
antigen 1
Serum, human 
tongue cancer cell 
line (Tca8113) 
2-DE, MALDI-TOF, 
RT-PCR, Western 
blotting
(Huang et al. 2006)
Fibrinogen Įchain fragment Plasma Affinity purification of 
plasma with magnetic 
beads and MALDI-
TOF MS
(Cheng et al. 2005)
Abbreviations: 2-DE: 2 dimensional gel electrophoresis; MS: Mass spectrometry; RT PCR: Reverse 
transcription polymerase chain reaction; MALDI-TOF: matrix assisted laser desorption/ionization 
time-of-flight; SELDI-TOF: Surface enhanced laser desorption/ionization time-of-flight; ELISA: 
Enzyme linked immune sorbent assay; IHC: Immunohistochemistry; DIGE; Differential in-gel 
electrophoresis; LC: Liquid chromatography; ESI: Electrospray ionization.
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Figure 1.1. Typical workflow involved in proteomics based biomarker discovery from 
clinical samples.
Abbreviations: iTRAQ: Isobaric tag for relative and absolute quantification; ICAT: Isotope-coded 
affinity tag; DIGE; Differential in-gel electrophoresis; SCX: Strong cation exchange chromatography; 
LC: Liquid chromatography; MALDI-TOF: matrix assisted laser desorption/ionization time-of-flight; 
MS: Mass spectrometry; ESI-TOF: Electrospray ionization time-of-flight; nano LC-ESI-MS/MS; 
nano liquid chromatography electrospray ionization
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1.3. Microfluidics
1.3.1. Background
Microfluidics is a technology that is capable of handling and manipulating small volumes of 
fluids ranging from 10-9 to 10-18 litres in specially designed microchannels that have a size 
ranging from 1μm to 1000μm. This system offers higher accuracy and sensitivities in sample 
detection, separation and analysis with minimal use of samples and reagents using controlled 
fluid flow (such as laminar flow), besides being cost-effective and less time consuming 
compared to conventional large-scale laboratory techniques (Tehranirokh et al. 2013;
Whitesides 2006).  Developments in the areas such as molecular analytical methods (such as 
capillary based gas chromatography, high-pressure liquid chromatography etc.), defence 
against biological warfare during the late twentieth century, molecular biology techniques 
(such as high-throughput DNA sequencing, microarray) and microelectromechanical systems 
(MEMS) engineering had led to the birth of microfluidics. Although glass and silicon were 
most commonly used in the earliest microfluidic systems, they are now being replaced with 
elastomers or polymers such as polydimethylsiloxane (PDMS) which are inexpensive, can be 
easily processed and fabricated, optically transparent, permeable to gases and are also 
compatible with biological material (Hong & Quake 2003; Reyes et al. 2002; Whitesides 
2006; Zhang & Nagrath 2013).
Advancements in microfabrication and microfluidic technologies have been extensively 
applied to scale down existing biotechnological, analytical and chemical processes. A lab-on-
a-chip also referred to as micro total analysis system (μ-TAS) when fully functional allows 
sample loading, pre-treatment, fractionation or separation, post-treatment and analysis on a 
single device. Such a system can be put to use for biological applications that can integrate 
sample preparation (labelling cells, or biomolecules such as DNA, RNA or proteins), sorting 
based on fluorescence of the labelled dye, based on size and density or affinity to modified 
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chip surfaces, culture and growth of captured cells, on-chip DNA/RNA amplification of 
genes of interest or analysis of cells for treatment response etc. on a same platform (Lee & 
Lee 2004). The eventual aim of using such an integrated μ-TAS is to have a fast sample-
inlet/result-outlet system. Besides the integrated microfluidic devices there are Point-of-care 
devices (POC) and digital microfluidics (DMF). POCs like most integrated microfluidic 
devices help in rapid results generation for various clinical uses, whereas DMF is a distinct 
branch of microfluidics that focusses on delivering liquids in the form of nanolitre drops that 
are analysed and processed independently to increase throughput at reduced costs. μ-TAS has 
also been used to develop bio-mimetic systems for cell co-culturing as tissues or organ 
systems and for studying cell-cell or cell-extracellular matrix interactions (Culbertson et al.
2013).
1.3.2. Cell Analysis
1.3.2.A. Cell Culture
Microfluidics allows culture and proliferation of small number of cells in very specifically 
controlled atmosphere that can be monitored continuously using very small quantities of 
media and reagents. Microfluidics has been used enormously for cell culture, patterning, stem 
cell studies and also for generating gradient systems using various biomolecules and growth 
factors (Culbertson et al. 2013; Tehranirokh et al. 2013). Use of microfluidic devices with 
microperfusion allows continual delivery of nutrients and media to the growing cells and 
waste disposal from the device under sterile conditions. Use of 2D cultures to grow cells as a 
monolayer for example to study drug responses and 3D cultures to mimic in vivo
environment to study cell-cell and cell-extracellular matrix interactions have also been 
reported. 3D cell culture devices developed using extracellular matrix (ECM) gels such as 
collagen help retain the differentiated state of cells compared to that of monolayer 2D 
cultures. PDMS based devices, manufactured using soft lithography functionalized with 
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valves that allow manipulation of fluid flow and generation of gradient systems is one of the 
major approaches for cell culture applications (Huh, Hamilton & Ingber 2011; Mehling & 
Tay 2014). The proficiency of generating linear and abrupt non-linear gradient systems in 
such confined spaces under precisely controlled conditions has been used to culture cells and 
study cell viability at different chemical concentrations for example viability of fibroblasts 
was studied in response to hydrogen peroxide (6HOLPRYLü et al. 2011), motility of cells like 
neutrophils in response to chemotactic stimuli such as interleukin-8 (Jeon et al. 2002; Wu et 
al. 2014), microglial migration in response to amyloid-ȕ IRU XQGHUVWDQGLQJ SDWKRORJ\ RI
Alzheimer’s disease (Cho et al. 2013), similarly chemotaxis has also been studied  for 
migration of bacterial, immune, stem and cancer cells in response to stimuli (Wu, Wu & Lin
2013).
Micro-fabricated devices has also been used to understand complicated behavioural patterns 
of stem cells such as mesenchymal stem cell differentiation patterns in response to matrix 
with varying stiffness gradients (Justin & Engler 2011), responses of hematopoietic stem 
cells obtained from chronic myeloid leukaemia patients to dasatinib as single cell arrays 
(Faley et al. 2009), for maintaining clonal cultures from single hematopoietic stem cells to 
reduce heterogeneity for better analysis (Lecault et al. 2011),  culture of human embryonic 
stem cells with and without flow conditions to show conservation of self-renewability and the 
capacity to differentiate into any of the three germ cells (Villa-Diaz et al. 2009), effects of 
controlling the size of embryonic bodies and embryonic stem cell colonies to regulate 
differentiation into specific lineages guided by WNT signalling pathway (Hwang et al. 2009),
analysis of cell to cell interactions in regulating differentiation of stem cells into specific 
lineages (Tang, Peng & Ding 2010), effects of various guidance cues and chemogradients on 
neurite responses and axon growth have also been studied on microfluidic systems 
(Bhattacharjee et al. 2010; Kothapalli et al. 2011; Millet et al. 2010).
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Scaffolds made of biological/biocompatible material mimicking ECM in vitro in 
microfluidic devices not only increase surface area for cell growth but also help in creating a 
microenvironment similar to in vivo conditions to allow cell adhesion and tissue regeneration. 
ECM plays several important roles including assemblage of cells to form various tissues and 
organ systems besides enabling growth and cell-cell interactions. Several studies have 
reported the potential of using hydrogels in simulating microenvironments like that of natural 
ECM (Geckil et al. 2010; Lee, Cuddihy & Kotov 2008).  Microfluidic scaffold structures 
were engineered to be placed within hydrogels made of calcium alginate seeded with 
chondrocytes as a strategy for tissue engineering (Choi et al. 2007), similarly alginate and 
chitosan based hydrogels were used to create a 3D structures for trapping and growth of cells 
that can be used for in vitro studies and ultimately for understanding signalling pathways and 
studying drug responses (Cheng et al. 2012). Another alginate based 3 dimensional scaffold 
system was developed to aid cartilage tissue engineering using chondrocyte culture for 
treating osteoarthritis, which showed efficient maintenance of chondrocytes without change 
in morphology and good secretion of ECM (Wang, Yang, et al. 2011). A multilayered 
approach using poly(dimethylsiloxane) and poly(ethyleneglycol) diacyrlate to produce a 
microfluidic PEGDA hydrogel network with microperfusion systems to enable diffusion into 
complex scaffolds as that in tissues in vivo was developed for in vitro based diagnostics 
(Cuchiara et al. 2010). Other examples include use of Agarose hydrogel and fibroblasts to 
develop a simple microfluidic device with helical microchannels that showed improved 
microperfusion ability and cell viability (Huang, Wang, et al. 2013), a biomimetic hydrogel 
prepared by acrylation of hyaluronic acid to study the assembly and invasive potential of 
glioma cells that secreted matrix metalloproteases to remodel the nanofibre embedded 
hydrogel for migration (Lee, Lee, et al. 2013), an agarose-alginate hydrogel system to 
develop a multilayered scaffold system for patterning cortical neurons and for studying 
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neurite growth responses to B27 (Kunze et al. 2011), a collagen based 3D scaffold system to 
mimic the intestinal villi as model for culturing colorectal carcinoma cells (HwanáSung 
2011), a cellulose-collagen hybrid hydrogel system with biomimetic and biocompatibility 
(Pei et al. 2013), a carbohydrate glass based lattice system to generate patterns of endothelial 
cells similar to vascular channels with enhanced perfusion (Miller et al. 2012) and a 
Hyaluronic acid-collagen hydrogel for migration assay of endothelial cells (Jeong et al.
2011). Micro-engineering has also been recently extended to simulate organ structures and 
functionality on-chip to generate model systems that can mimic in vivo organ conditions 
(Moraes et al. 2012). Microfluidics based model systems for organs-on-a-chip such as lung-
on-a-chip, heart-on-a-chip, Liver-on-a-chip and blood vessel-on-a-chip have been developed 
(Agarwal et al. 2013; Huh et al. 2010; van der Meer & van den Berg 2012).
1.3.2.B. Cytometry
Cytometry is one of the major applications of μ-TAS for cellular analysis. Several studies 
have reported the use of microfluidics for high throughput cell sorting and analysis. Zhao et 
al have recently reported an enumeration system for detecting circulating tumor cells (CTCs) 
from blood samples obtained from breast cancer patients using an on-line confocal
microscopy. Improved on-chip CTC detection was reported in this study using fluorescently 
labelled antibodies (Zhao, Schiro, et al. 2013). A microfluidics based cytometer for detection 
of anaemia in mice was also reported recently. Sorting of reticulocytes was performed based 
on epifluorescence induced by binding with fluorescently labelled antibodies (Ju et al. 2012).
Another study used an integrated approach that combined cell culture, cell stimulation, on-
chip flow cytometry and optical imaging to analyse cell signalling in response to stimulus in 
a single cell. Heterogeneity in cellular responses to stimuli was studied using IgE mediated 
signalling for eliciting allergic reactions (Liu, Barua, et al. 2013). The first study reporting 
the direct detection of microRNAs in single cells using flow cytometry on a microfluidic 
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device was published by Wu et al in 2013. An integrated approach involving the use of flow 
fluorescent in situ hybridization (flow-FISH) with locked nucleic acids as the hybridization 
probes and rolling circle amplification as the detection method for the presence of microRNA 
miR155 and CD69 markers on activated Jurkat cells. Multiplexed analysis of miRNAs and 
cell surface markers on a single cell described in this study, is of tremendous importance to 
study heterogeneity existing within a cell population (Wu et al. 2013). Some of the 
commercially available systems with integrated microfluidics and cytometry include Agilent 
2100 Bioanalyzer (Agilent technologies), and Fishman-R (On-Chip Biotechnologies Co. 
Ltd.) which is a more recent and advanced platform in terms of sensitivity and high analysis 
rates (Piyasena & Graves 2014). Analysis of multiple parameters such apoptosis (activation 
of caspase) and DNA ploidy analysis in human hematopoietic cancer cells using 2 
dimensional hydrodynamic focussing performed on a microfluidics based flow cytometer 
Fishman-R was also recently reported (Akagi et al. 2013; Skommer et al. 2013). Unlike the 
above mentioned studies for detection of cells, Kemna et al reported the use of a label free 
method for detection of viable cells in droplets based on electrical impedance. Detection and 
separation of cells based on their dielectric properties is referred to as single-cell impedance 
cytometry (Kemna et al. 2013). Similar studies were carried out to characterize the 
subcellular location, distribution and morphology of vacuoles in single yeast cells  
(Haandbæk et al. 2014) and also for analysis of platelets using an impedance cytometer 
(Evander et al. 2013).
1.3.2.C. Cell Sorting
Microfluidics has been used extensively for cell sorting, enrichment and further culture and 
analysis. Use of integrated microfluidics optoelectronic tweezers platform was reported to 
prepare single cell sample which was subsequently encapsulated in liquid plugs for 
downstream processes such as RT-qPCR (Huang, Wu, et al. 2013). Similar work was carried 
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out by Wang et al using optical tweezers and microfluidics to manipulate single cells for a 
low cell population sorting. The proposed method enables separation based on multiple 
parameters including cell size and fluorescent tags besides being able to recover cells 
efficiently with high purity (Wang, Chen, et al. 2011). Deformability of circulating 
leukocytes was used to separate non-adherent cells on a microfluidic device consisting of a 
series of filters with decreasing pore size. This method was developed to separate circulating 
leukocytes from the plasma of patients suffering from acute respiratory distress syndrome 
(Preira et al. 2013). Endocytosis of magnetic nanoparticles based sorting of monocytes and 
macrophages using a chip based free-flow magnetophoresis was developed to sort 
subpopulations based on the amount of nanoparticle intake. This method showed high 
efficiency and purity in sorting cells (Robert et al. 2011). A system that allows sorting of 
cells 2-dimensionally based on their size and surface marker expression using hydrodynamic 
filtration and magnetophoresis respectively was developed by Mizuno et al. This system was 
used to sort human lymphocyte cells with greater than 90% purity without the need for 
complex engineering and operations (Mizuno et al. 2013). A method to isolate cells based on 
imaging the fluorescence localization following two photopolymerization steps, one using a 
resin to create microwells to capture cells and the second using a hydrogel to trap unwanted 
cells was described by Sun et al. (Sun, Kovac & Voldman 2013). Sepsis, a condition caused 
due to microbial infection of blood, usually requires large volumes of blood samples from 
patients and many days for diagnosis. To address this issue a microfluidic device was 
developed for continuous sorting and enrichment of Escherichia coli from blood samples 
based on dielectrophoresis. Significant concentration of the microbe in the target stream 
compared to that of the waste stream was reported with this method (Kuczenski, Chang & 
Revzin 2011). A droplet based microfluidic device that can sort single cells and 
compartmentalize them to study the proteins released by them would be highly beneficial. 
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Such a system was developed by Mazutis et al. to analyse antibodies secreted by single 
mouse hybridoma cells. The working of this device depends on the capture of the secreted 
antibodies from single cells on bead that then bind to fluorescent probes that enables sorting 
of droplets and cell enrichment based on localization of fluorescence. Besides antibodies, this 
method can be used to detect and analyse subcellular, cell surface or secreted markers 
(Mazutis et al. 2013). A microfluidic cell separation system to sort cells based on their 
deformability was reported by Zhang et al.  The flexible cells that were isolated from a 
mixture of breast cancer cell lines with different deformabilities and malignancies showed 
expression of genes involved with cancer cell motility, invasive potential and tumor initiating 
capacity (Zhang, Kai, et al. 2012).
1.3.3. Circulating Tumor Cells (CTCs) based Cancer Diagnostics
Microfluidics has increasingly been used for cancer diagnostics because of its ability to 
analyse biomarkers and bio-molecules in complex biological fluids such as blood, saliva and 
urine in vitro using low sample and reagent volumes with integrated separation, 
identification, detection and analysis platforms for the development of sensitive non-invasive 
assays (Sorger 2008). The small-scale design of a microfluidic device similar to that of cells 
and blood vessels helps mimic a tumor microenvironment that can be used for studying 
growth, invasive potential and response to various treatment strategies of cancer cells. 
Several reports have also indicated that microfluidic devices can be used to incorporate the 
various ‘omics’ tools into one platform that will help identify and categorize potential 
biomarkers for cancer (Ying & Wang 2013). Applications of microfluidics to cancer 
diagnostics can be broadly classified into areas such as isolation of circulating tumor cells 
(CTCs), molecular diagnostics, tumor biology and high-throughput screening assays (Zhang 
& Nagrath 2013).
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It has been well established that small number of tumor cells disseminate from tumorous 
tissues and enter the circulating system causing distant metastasis. CTCs can be shed as early 
as during the formation of the primary tumor which then get blood-borne and can cause 
micrometastases that may remain hidden for a very long time or even after the thorough 
surgical removal of the primary tumor (Alix-Panabières & Pantel 2013). Role of CTCs in 
disease diagnosis, prognosis, monitoring of the therapeutic efficacy, clinical decision making 
and for evaluating the metastatic spread of cancer is immense, hence attracting tremendous 
focus in the last decade (Alix-Panabières & Pantel 2014; Gröbe et al. 2014). Detection and 
enumeration of CTCs from peripheral blood non-invasively referred to as “liquid biopsy” for 
molecular characterization has been the forefront of cancer research in the recent years. 
Capture of CTCs not only allows assessment of metastasis but also aids in monitoring the 
tumor before and after therapy, to design appropriate treatment strategies for patients based 
on drug sensitivity and resistivity (Maheswaran & Haber 2010). The presence of 
disseminated tumor cells can be identified in bone marrow, lymph nodes and circulating 
blood. However the invasiveness of bone marrow needle aspiration has led to increased focus 
on blood as the matrix for CTC detection that is not only less invasive but also allows follow-
up with patients for serial studies (Pantel & Brakenhoff 2004; Ross & Slodkowska 2009).
Role of CTCs as biomarkers has been well elucidated in several cancer types including breast 
cancer (Ramirez et al. 2014), gastric cancer (Galletti et al. 2014), prostate cancer (Friedlander
et al. 2014), oral cancer (Gröbe et al. 2014), colorectal cancer (Raimondi et al. 2014), lung 
cancer (Krebs et al. 2011), ovarian cancer (Poveda et al. 2011) and melanomas (Kiyohara et 
al. 2014),
The rarity of occurrence (approximately 1-100 CTCs/mL of blood) and the high levels of 
heterogeneity of CTCs are some of the major challenges in developing a CTC based cancer 
detection assay with the limited available sample. (Li, Stratton, et al. 2013; Lianidou, Strati & 
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Markou 2014). An ideal CTC enumeration system should allow rapid capture and isolation of 
CTCs besides having high capture efficiency (capturing all the CTCs from the available 
sample volume) and high capture purity (capturing only CTCs) while maintaining cell 
viability. Several methods have been used for isolation of CTCs based on the physical 
properties such as shape, size and deformability; dielectrophoretic signatures of cell 
membranes, immunospecific surface markers or magnetic nanoparticle based immunoaffinity 
(Chen et al. 2014; Hyun & Jung 2014).
1.3.3.A. Immunoaffinity based separation
The most commonly used platform for isolating CTCs is based on antigen-antibody 
interactions. The large surface to volume ratio of microfluidic devices increases the cell-
surface (modified with antibodies) interactions there by enhancing the capture efficiencies. 
Modification of the microchannel surfaces minimises the need for modifying/labelling cells 
prior to capture, consequently minimizing loss of cells and reducing analysis times. This 
adhesion based isolation depends on the variation in the affinities of the target cells to the 
microfluidic surfaces in comparison with that of non-target cells. High flow rates enhance 
capture purity and lower flow rates enhance capture efficiency, optimizing shear stress by 
varying the flow rates in the microchannels is necessary to have good capture efficiency 
while maintaining the purity of the cells captured (Chen et al. 2014; Didar & Tabrizian 
2010).
EpCAM (epithelial cell adhesion molecule) is the most commonly used marker for 
separation of CTCs because of its frequent expression on most human carcinomas (Went et 
al. 2004b). To improve the cell-surface interactions in a microchannel device driven by 
laminar fluid flow Nagarath et al. designed a microfluidic device with several micro-pillars 
coated with anti EpCAM antibodies. This device referred to as ‘CTC-Chip’ showed efficient 
capture of CTCs from unprocessed peripheral blood samples of metastatic lung, prostate, 
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breast, pancreatic and colon cancer and also from early stage prostate cancer. It was also 
reported that there was significant decrease in the CTC number in blood samples of early 
stage cancer patients in response to treatment (Nagrath et al. 2007). The same CTC-Chip has 
also been used to capture rare cells from blood samples of prostate cancer patients using 
immobilized anti-EpCAM antibodies followed by staining with anti-prostate specific antigen 
(PSA) antibodies that is highly specific to prostate cancer cells (Stott, Lee, et al. 2010) and 
also from blood samples of non-small-cell lung cancer patients followed by DNA analysis for 
studying mutations in epidermal growth factor receptor (EGFR) gene that can help in better 
therapeutic planning (Maheswaran et al. 2008). Another device referred to as the 
herringbone-chip consisting of herringbone pattern (irregular zig-zag grooves) based 
micromixers immobilized with anti-EpCAM antibodies was developed by Stott et al. that 
showed efficient capture of prostate cancer cells spiked in whole blood and also CTCs from 
blood samples of prostate cancer patients. This herringbone based micropatterning designs on 
the microchannels creates a micro-vortexing system during fluid flow in the device, ensuring 
increased interaction time between CTCs and the channel surfaces. This PDMS based 
optically transparent device allows subsequent imaging and analysis on-chip (Stott, Hsu, et 
al. 2010). Adams et al. designed a microfluidics device with a series of microchannels coated 
with anti-EpCAM antibodies to separate breast cancer cells, MCF-7 from whole blood 
samples followed by a label free on-chip enumeration of single cells. This device showed 
rapid processing of large sample volumes to give >97% capture efficiency (Adams et al.
2008). A similar microfluidics approach using anti EpCAM antibodies to capture colorectal 
cancer cells spiked in whole blood was integrated with an CTC enumeration, enrichment and 
a molecular profiling system that enables on-chip sorting of captured cells based on their 
conductivity followed by analysis of KRAS point mutations using polymerase chain reaction, 
ligase detection reaction and electrophoresis (Dharmasiri et al. 2011). A new approach for 
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enhanced capture of CTCs while minimizing the non-specific binding of leukocytes 
employed the use of alternating dual-protein micro-patterning technique to pattern regions 
coated with anti-EpCAM and E-selectin alternatively. This capture method followed by an 
elution step to remove bound leukocytes resulted in increased sensitivity and yields (Launiere
et al. 2012). Another dual marker based CTC capture was reported by Thege et al. for 
prostate cancer using antibodies against EpCAM and cancer-specific mucin 1 (MUC1) 
immobilized on a single chip (Thege et al. 2014). Microfluidic devices separately modified 
with EpCAM and CD49f antibodies for rare cell capture followed by the ability to culture the 
captured cells in a bio-similar hydrogel to propagate 3-dimensional spheroid colonies that can 
be used to study treatment responses and disease advancement have also been reported 
(Bichsel et al. 2012).
Microdevices engineered with three dimensional structures such as an array of silicon 
nanopillars coated with anti-EpCAM antibodies for enhancing the interactions between the 
channel surfaces and the cellular structures for capturing rare cells with increased sensitivity 
and specificity have also been fabricated (Wang, Wang, et al. 2009). This silicon nanopillar 
based device was further modified by introducing another functional component that allows 
chaotic mixing in the microchannels to increase cell capture efficiency on the nanopillar 
arrays. This chaotic mixing was generated by using chevron shaped micropatterning in the 
channels. EpCAM expressing breast cancer cell lines, MCF-7 and clinical samples from 
prostate cancer patients were used to validate the utility of the device (Wang, Liu, et al.
2011). An integrated two dimensional approach based on cell size and affinity to bound 
antibodies for CTC capture was developed by Liu et al for the first time. A deterministic 
lateral displacement array consisting of mirrored triangular microposts for size based 
separation of CTCs from blood cells followed by enrichment using anti-EpCAM antibodies 
to isolate breast cancer cells spiked in whole blood samples showed 90% capture yield and 
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more that 50% capture purity at a concentration of 100 cells per millilitre (Liu, Zhang, et al.
2013). To enhance the sensitivity of biomolecules/cell detection various nanomaterials have 
been used. Microchannels arrayed with transparent quartz nanowires immobilized with anti-
EpCAM antibodies was integrated with laser scanning cytometry that allows capture and 
subsequent characterization of rare cells in situ. This approach can help in rapid 
characterization and protein profiling of each cell captured on-chip that can aid in 
stratification of cell populations and also the patients for better therapeutic planning (Lee et 
al. 2012). Zhang et al. reported a similar approach using titanium oxide nanofibre substrate 
modified with anti-EpCAM antibodies to capture colorectal and gastric cancer cells (Zhang, 
Deng, et al. 2012). Among other nanomaterials graphene oxide has gained increased attention 
in the last few years for use in biosensors, drug delivery and also as nanocomposites because 
of the ease of preparation, controllable sheet sizes, easy surface modifications, drug loading 
and delivery properties and its optical properties such as photoluminescence in visible and 
infrared regions, fluorescence quenching ability (Chung et al. 2013; Eda, Fanchini & 
Chhowalla 2008; Sun et al. 2008; Wang, Li, et al. 2011). Yoon et al. recently reported a 
nano-graphene oxide based approach for capture, isolation and characterization of rare cells 
from metastatic breast, lung and pancreatic cancer patients with high sensitivity. This study 
used a PDMS based device having a silicon substrate with patterned gold structures (flower 
shaped) on which graphene oxide sheets-functionalized with EpCAM antibodies were 
adsorbed (Yoon et al. 2013). Use of nano-graphene oxide as a carrier for fluorescently tagged 
antisense oligonucleotides for detection of intracellular survivin mRNA levels in each 
prostate cancer cell captured on a microchannels immobilized with prostate stem cell antigen 
(PSCA) antibodies has also been reported (Li, Shan, et al. 2013).
Kirby et al. developed a PDMS based anti-prostate specific membrane antigen (PMSA) 
antibody coated device with a 3 dimensional geometry (termed as geometrically enhanced 
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differential immunocapture-GEDI) that allows capture of CTCs from blood samples of 
castrate-resistant prostate cancer (CRPC) patients while minimizing the non-specific capture 
of blood cells. More than 50 CTCs were captured from 1 ml of blood from CRPC patients 
compared to almost negligible number in healthy volunteers. This device showed increased 
capture efficiency and purity in comparison to the commercially available CellSearch system. 
Other utilities of the GEDI device include the ability to detect specific mutations and 
evaluation of on-chip taxane treatment on captured cells (Gleghorn et al. 2010; Kirby et al.
2012).  Microchannels functionalized with Herceptin, a humanized monoclonal antibody 
against HER2 (human epidermal growth factor) receptors for capturing breast cancer cells 
SK-BR-3 was reported by Thierry et al. with approximately 80% capture efficiency (Thierry
et al. 2010). Capture of breast cancer cells belonging to different subtypes for subsequent in 
situ protein expression analysis on a microfluidic device using hybrid nanoparticles 
composed of quantum dots, antibodies and biotinylated DNA. The antibodies (EpCAM, 
EGFR, HER2) in the hybrid nanoparticles bind to specific markers on the cancer cells while 
the interactions between the biotinylated DNA and the streptavidin coated channel surface 
cause the capture of cells which are subsequently identified by the fluorescence emitted by 
the quantum dots (Lee, Cho, et al. 2013). Another study reported the use of epithelial 
membrane antigen (EMA) and epithelial growth factor receptor (EGFR) for capturing breast 
cancer cells on a PDMS based microfluidic device (Du et al. 2007). Identification of cervical 
FDQFHU FHOOV RQ D PLFURIOXLGLFV GHYLFH FRDWHG ZLWK Į-integrin antibodies has also been 
reported although with a low capture purity (Du et al. 2006).
1.3.3.B. Magnetic cell separation
Use of commercially available magnetic beads or nanoparticles for rare cell isolation has 
been a common practice. Cell specific antibodies are coated on the surface of magnetic beads 
and then allowed to interact with a mixture of cells. The beads bind to cells expressing the 
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marker of interest which can be separated from the rest of the cells by using a strong 
magnetic field (Radisic, Iyer & Murthy 2006; Thiel, Scheffold & Radbruch 1998). The first 
and the only CTC capture system to be approved by Food and Drug Administration (FDA) is 
CellSearch which has been available for clinicians since 2004 (Harris et al. 2013). This 
macroscale system enables immunomagnetic based isolation of CTCs from blood samples of 
metastatic breast, prostate and colon cancer patients by using magnetic beads coated with
anti-EpCAM antibodies (de Bono et al. 2008; Zborowski & Chalmers 2011). Other EpCAM 
based immunomagnetic devices for CTC capture include MagSweeper (Talasaz et al. 2009),
Cell Enrichment and Extraction (CEE) channel (Nora Dickson et al. 2011). An integrated 
system using magnetic bead based separation of rare cells in a microfluidic device was 
reported in 2004. Separation of T cells spiked in whole blood samples was performed on a Y-
shaped micro-device immobilized with magnetic beads coated with anti-Human CD3 
antibodies using an external magnet. The captured cells were then washed out by removing 
the external magnetic field for PCR analysis (Furdui & Harrison 2004). Inglis and David et 
al. presented a cell separation device using microfabricated ferromagnetic stripes to capture 
cells tagged with magnetic beads under continuous flow conditions. CD45 labelled 
microbeads were used to capture leukocytes on the magnetic stripes whereas the non-specific 
cells in the whole blood samples followed the fluid flow and subsequently eluted out. (Inglis
et al. 2004; Inglis et al. 2006). A novel cell sorting system using antibody coated 
superparamagnetic beads immobilized on a microchannel device which is placed on a series 
of magnetic traps engineered by microcontact printing to perform sorting of more than one 
cell type from a mixture, was called as “Ephesia” (Saliba et al. 2010). A recent study by 
Plouffe et al. presented the use of a magnetophoresis system using anti-EpCAM and anti-
CD133 antibodies coated on magnetic beads for capture of breast cancer cells, hematopoietic 
stem cells and endothelial progenitor cells from whole blood samples separately. It was 
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reported that this device was capable of cell separation with high purity, efficiency and 
simultaneous separation and enumeration of two cell types from whole blood (Plouffe et al.
2012). (Plouffe, Lewis & Murthy 2011).  Kang et al. developed a microfluidics based 
magnetic cell separation system for isolation of CTCs that can be maintained in a viable state 
for subsequent culture and analysis. This PDMS based device showed capture of rare 
circulating cells from blood obtained from mammary tumor bearing mice using magnetic 
beads (<3μm diameter) coated with anti EpCAM antibodies. This chip based device offered 
high efficiency and specificity which was confirmed by staining the captured cell for the 
presence of pan-cytokeratin and SV40 large T antigen (specific for the transgenic mice model 
used) and for the absence of CD45-PerCP. (Kang et al. 2012). A negative enrichment 
approach was utilized to separate CTCs from blood cells (Chen et al. 2011) using magnetic 
beads coated with antibodies specific to leukocytes flowing in channels with deterministic 
lateral displacement that allows size based separation (Karabacak et al. 2014). A combination 
of magnetized nickel micropillars engineered on the microchannel surfaces and 
superparamagnetic beads functionalised with wheat germ agglutinin was used to capture 
human lung cancer cells (Liu, Guo, et al. 2007).  An 80% nickel and 20% iron plated 
magnetic substrate with magnetic beads coated with anti-PSMA and anti-CD10 antibodies 
was used to capture prostate cancer cells (Estes et al. 2009). A 3-dimensional system 
integrating immunomagnetic based cell capture, sample transportation on-chip and DNA 
amplification for gene expression analysis of captured cells was designed by Lien et al.
Magnetic beads coated with anti-EpCAM antibodies were used to capture ovarian and lung 
cancer cells from whole blood samples from health donors using an external magnetic field 
followed by on-chip DNA amplification for detecting expression levels of CD24 and HE4 
genes in ovarian cancer cells and expression of TSC1, SORD, TKT, and ALDOA genes in 
lung cancer cells (Lien et al. 2010). Capture and subsequent growth of breast cancer cells 
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MCF-7 from a mixture containing Jurkat cells using a microchannel device with pre-
assembled arrays of magnetic beads (using an external magnet) coated with 5D10 antibodies 
and fibronectin was described by Sivagnanam et al (Sivagnanam et al. 2010).
1.3.3.C. Aptamer based cell separation
Lack of specific biomarkers for each cancer model and the limited availability of molecular 
probes for recognising cell surface receptors has constrained the researchers for 
understanding the molecular basis of cancer. Development of detection probes for cell 
surface markers can be of tremendous help in cancer diagnosis and therapeutics. Aptamers, a 
new class of nucleic acids, have shown true potential for molecular recognition and targeting 
(Tang et al. 2007). Aptamers are single stranded DNA, RNA or modified oligonucleotide 
sequences that show target specificity and recognition to various molecules ranging from 
proteins, cell surface antigens, biomolecules such as ATP and also cells and cell membranes 
(Famulok, Mayer & Blind 2000; Shangguan et al. 2006). The aptamers are engineered in 
such a way that they form tertiary structures which lock perfectly with the target molecule. 
These aptamers can be prepared by directed evolution techniques also called as in vitro 
evolution, this involves preparation of large libraries of  random DNA or RNA molecules 
from which the sequence specific to target ligands are selected based on competitive binding 
followed by enrichment and amplification. This process is called as systemic evolution of 
ligands by exponential enrichment (SELEX) (Breaker 2004). The advantages of using 
aptamers include features such as low molecular weight, high binding affinity and specificity, 
ease of synthesis and modifications, low toxicity, increased thermal stability and tissue 
penetrating ability (Shangguan, Meng, et al. 2008). Recent approaches involving selection of 
aptamers for specific cancer cells referred to as cell-SELEX is a promising field for cancer 
diagnosis and biomarker identification. Cell-specific aptamers have been reported for 
leukaemia cells (Shangguan, Cao, et al. 2008; Shangguan et al. 2006), lymphoma cells (Tang
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et al. 2007), small-cell lung cancer cells, (Chen, Medley, et al. 2008; Kunii et al. 2011),
glioblastoma cells (Daniels et al. 2003), liver cancer (Shangguan, Meng, et al. 2008), breast 
cancer cells expressing HER2 (Kang et al. 2009).
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Table 1.2. List of cancer associated DNA and RNA aptamers
S.No Aptamer Sequence Target
(Localization)
Cell line Function Reference
DNA Aptamers
1 MUC1 GCAGTTGATCCTTTGGATACC
CTGG
Mucin
(Cell surface)
OVCAR-3 (ovarian cancer 
cells), A549 ( human lung
cancer cells), pancreatic, 
prostate, MCF-7 (breast 
cancer cells); HepG2 (human 
liver cancer cells)
Cancer cell imaging; 
Therapy
(Chang et al. 2014;
Liu et al. 2012; Tan
et al. 2011; Yu, Hu,
et al. 2011; Zhao,
Ma, et al. 2013)
2 S1.3/S2.2 GGGAGACAAGAATAAACGCT
CAAGCAGTTGATCCTTTGGAT
ACCCTGGTTCGACAGGAGGCT
CACAACAGGC
Mucin
(Cell surface)
MCF-7 (human breast cancer 
cell line)
Cancer therapy (Baouendi et al.
2012; Bruno 2010)
3 5TR-1 GGGAGACAAGAATAAACGCT
CAAGAAGTGAAAATGACAGA
ACACAACATTCGACAGGAGG
CTCACAACAGGC
Mucin
(Cell surface)
MCF-7 (human breast cancer 
cell line)
Cancer therapy (Bruno 2010)
4 SGC8 ATCTAACTGCTGCGCCGCCGG
GAAAATACTGTACGGTTAGA-
(CH2)6-NH2
Protein tyrosine 
kinase 7 (PTK7)
(Cell surface)
CCRF-CEM, (T-cell 
leukaemia cell line)
Cell imaging; diagnosis; 
cell sorting; targeted 
therapeutic delivery; 
biomarker identification
(Chang, Donovan 
& Tan 2013; Lu et 
al. 2014; Zhang, 
Sheng & Fan 2014;
Zhu et al. 2013)
5 C8FL Modified SGC8 aptamer with two 
PEG spacers instead of nucleo-tides 
A23–T30, and LNA at both ends
Protein tyrosine 
kinase 7 (PTK7)
(Cell surface)
CCRF-CEM, (T-cell 
leukaemia cell line)
Cancer cell detection (Shangguan, Tang,
et al. 2007)
6 SGA16 TTTAAAATACCAGCTTATTCA
ATTAGTCACACTTAGAGTTCT
AGCTGCTGCGCCGCCGGGAA
AATACTGTACGGATAGATAGT
Protein tyrosine 
kinase 7 (PTK7)
(Cell surface)
CCRF-CEM, (T-cell 
leukaemia cell line)
Cancer diagnosis (Li et al. 2009;
Shangguan, Tang,
et al. 2007)
                                                                                                                                                                                                                                            Chapter 1 
49 
 
AAGTGCAATCT
7 SYL3C
SYL1
SYL2
SYL3
SYL4
CACTACAGAGGTTGCGTCTGT
CCCACGTTGTCATGGGGGGTT
GGCCTG
AGCGTCGAATACCACTACAGT
TTGGCTCTGGGGGATGTGGAG
GGGGGTATGGGTGGGAGTCA
ATGGAGCTCGTGGTCAG
AGCGTCGAATACCACTACAG
AGCTCGGGGTTTTTTGGGGTT
TTTTGGGGTTTTGGTGGGGCT
AATGGAGCTCGTGGTCAG
AGCGTCGAATACCACTACAG
AGGTTGCGTCTGTCCCACGTT
GTCATGGGGGGTTGGCCTGCT
AATGGAGCTCGTGGTCAG
AGCGTCGAATACCACTACAG
AGCTCCGGGGTTTTTGGGGGT
TTTTCTGGGGTTTTTTGGGGCT
AATGGAGCTCGTGGTCAG
EpCAM
(Cell surface)
MDA-MB-231 (breast 
carcinoma cell line); Kato III 
(human gastric cancer cell 
line); HT-29 (colorectal 
adenocarcinoma cell line); 
T47D (ductal breast 
epithelial cell line)
Cell sorting (Song et al. 2013)
8 TDO5 AACACCGGGAGGATAGTTCG
GTGGCTGTTCAGGGTCTCCTC
CCGGTG-(CH2)6-NH2
IgG receptors
(Cell surface)
Ramos cells (B-cell 
lymphoma cell line) 
Cancer cell imaging; 
diagnosis; Cell sorting; 
targeted therapeutic 
delivery
(Fan et al. ; Lu et 
al. 2014; Ray & 
White 2010; Wu et 
al. 2010)
9 A1 GGTTGCATGCCGTGGGGAGG
GGGGTGGGTTTTATAGCGTAC
TCAG(CH2)6-NH2
Unknown A549 cells (adenocarcinomic 
human alveolar basal 
epithelial cells) 
Targeted drug delivery (Lu et al. 2014)
10 AS1411 TTGGTGGTGGTGGTTGTGGTG
GTGGTGG
Nucleolin
(Cell surface 
C6 (rat glioma cells), HeLa 
(human cervical cancer 
Cancer cell imaging; 
targeted therapeutic 
(Aravind et al.
2012; Hwang et al.
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and nucleolus) cells), Hep-G2 (human liver 
cancer cells), Caco-2 (human 
colorectal cancer cells), U-
87MG (human glioblastoma 
cells), F11 (mouse 
neuroblastoma cells), C6 (rat 
glioma cells), CT-26 (mouse 
colon cancer cells)
delivery 2010; Kim et al.
2012; Latorre et al.
2014; Lee, Kang, et 
al. 2010)
11 GMT4, 
GMT8
TGACGAGCCCAAGTTACCTTG
GTGATGGTTTTTGGTGGTAAC
GGGGGCGGGTGAGTAGAATC
TCCGCTGCCTACA
Unknown CCRF-CEM, (T lymphoblast 
cell line); U87, (primary 
glioblastoma cell line)
Cancer cell detection (Bayrac et al. 2011)
12 CSC1 ACCTTGGCTGTCGTGTTGTAG
GTGGTTTGCTGCGGTGGGCTC
AAGAAGAAAGCGCAAAGGTC
AGTGGTCAGAGCGT
Unknown DU145 (Prostate cancer cell 
line)
Photothermal therapy (Wang, Sefah, et al.
2013)
13 CSC13 ACCTTGGCTGTCGTGTTGTGG
GGTGTCGTATCTTTCGTGTCTT
ATTATTTTCTAGGGGAGGTCA
GTGGTCAGAGCGT
Unknown Prostate cancer stem cells Photothermal therapy (Wang, Sefah, et al.
2013)
14 KDED
2a-3
TGCCCGCGAAAACTGCTATTA
CGTGTGAGAGGAAAGATCAC
GCGGGTTCGTGGACACGGTTT
TTTTTTTT
Unknown DLD-1 (human colorectal 
adenocarcinoma  cell line)
Cancer cell imaging (Sheng et al. 2012)
15 KCHA1
0
ATCCAGAGTGACGCAGCAGG
GGAGGCGAGAGCGCACAATA
ACGATGGTTGGGACCCAACTG
TTTGGACACGGTGGCTTAGTT
TTTTTTTTT
Unknown HCT 116 (colorectal cancer 
cell line)
Cancer cell imaging (Sheng et al. 2012)
16 R13 TCTCTAGTTATTGAGTTTTCTT
TTATGGGTGGGTGGGGGGTTT
TT
Unknown A549 (lung cancer cell line) Photodynamic therapy (Liu et al. 2014)
17 S6 TGGATGGGGAGATCCGTTGA
GTAAGCGGGCGTGTCTCTCTG
CCGCCTTGCTATGGGG
Unknown SK-BR-3 (breast cancer cells 
expressing HER-2)
Cancer cell detection and 
imaging
(Kang et al. 2009)
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18 GBI-10 GGCTGTTGTGAGCCTCCTCCC
AGAGGGAAGACTTTAGGTTC
GGTTCACGTCCCGCTTATTCT
TACTCCC
Tenascin-C
(Extracellular 
matrix)
U251( human gliobalstoma 
cell line) 
Cancer cell detection (Daniels et al.
2003)
19 A-1 TAACTCAATAAGCTAGGTGGG
TGGGGGACACTACCCGGGGG
GTGGTTGGGT
Unknown HepG2, a(human liver cancer 
cell line)
Cancer cell detection (Ninomiya et al.
2013)
20 ADE1
ADE2
EJ2
EJ4
EJ5
EJ7
AGTGGTCGAACTACACATCCT
TGAACTGCGGAATTATCTAC
GAGCCCTATCTCACACCGCAC
CCGCAAACTATCCTACAT
AGTGGTCGAACTACACATCCT
TGAACTGCGGAATTATCTAC
GAAGACGAGCGGCGAGTTTA
TTACGCTTGGAAACAACCCC
TACGGGCTGGATCCACTGTTA
CGGCGTGTATCCGCTATCAA
GAAGACGAGCGGCGAGTGTT
ATTACGCTTGGAAACAACCCC
Unknown H23(lung adenocarcinoma 
cell line)
Cancer cell sorting (Jiménez et al.
2012)
21 HCA12, 
HCC03, 
HCH07, 
HCH01
Unknown NCI-H69 (small cell lung 
cancer cell line)
Cancer cell sorting (Chen, Medley, et 
al. 2008)
RNA Aptamers
1 A10 GGGAGGACGAUGCGGAUCAG
CCAUGUUUACGUCACUCCUU
GUCAAUCCUCAUCGGC
Prostate-specific 
membrane 
antigen (PSMA)
(Cell surface)
LNCaP (human prostate 
cancer cell line)
Cancer cell imaging; 
Diagnosis; Therapy; cell 
sorting
(Bagalkot et al.
2006; Bandekar et 
al. 2014; Farokhzad
et al. 2006;
McNamara et al.
2006; Min et al.
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2011)
2 A9 GGGAGGACGAUGCGGACCGA
AAAAGACCUGACUUCUAUAC
UAAGUCUACGUUCCCAGA
Prostate-specific 
membrane 
antigen (PSMA)
(Cell surface)
LNCaP,(human prostate 
cancer cell line)
Cancer therapy; cell 
sorting
(Chu et al. 2006)
3 Xpsm-
A9
GGGAGGACGAUGCGGACCGA
AAAAGACCUGACUUCUAUAC
UAAGUCUACGUUCCCAGACG
ACUCGCCCGA
Prostate-specific 
membrane 
antigen (PSMA)
(Cell surface)
LNCaP (human prostate 
cancer cell line)
Cell surface protein 
anaysis
(Farokhzad, Karp 
& Langer 2006;
Lupold et al. 2002)
4 Ep-DT3-
DY647
GCGACUGGUUCCCGGUCG EpCAM
(Cell surface)
MCF-7, breast cancer cell 
line; SW480, a colon 
adenocarcinoma cell line; 
MDA-MB-23, a breast 
carcinoma cell line; Kato III, 
a human gastric cancer cell 
line; HT-29, a colorectal 
adenocarcinoma cell line; 
T47D, a ductal breast 
epithelial cell line.
Cancer cell imaging (Shigdar et al.
2011)
5 CD4 
aptamer
AAGUGACGUCCUGAUCGAUU
GUGCAUUCGGUGUGACGAUC
U
CD4
(Cell surface)
Jurkat (T-cell leukaemia cell 
line)
Cell sorting (Guo et al. 2005;
Zhang et al. 2010)
6 PSMA 
aptamer
ACCAAGACCUGACUUCUAAC
UAAGUCUACGUUCC
Prostate-specific 
membrane 
antigen (PSMA)
(Cell surface)
LNCaP (prostate cancer cell 
line)
Cell imaging (Dharmasiri et al.
2009)
7 EGFR 
aptamer
GGCGCUCCGACCUUAGUCUC
UGUGCCGCUAUAAUGCACGG
AUUUAAUCGCCGUAGAAAAG
CAUGUCAAAGCCGGAACCGU
GUAGCACAGCAGAGAAUAAA
Epidermal 
growth factor 
receptor (EGFR)
(Cell surface)
human glioblastoma cell line Cancer cell isolation (Wan et al. 2010)
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UGCCCGCCAUGACCAG
8 J18 GGCGCUCCGACCUUAGUCUC
UGCAAGAUAAACCGUGCUAU
UGACCACCCUCAACACACUU
AUUUAAUGUAUUGAACGGAC
CUACGAACCGUGUAGCACAG
CAGA
Epidermal 
growth factor 
receptor (EGFR)
(Cell surface)
A-431 (human epidermoid 
carcinoma cell line)
Targeted delivery (Li et al. 2009; Li
et al. 2010; Master 
& Sen Gupta 2012)
9 A30 GGGAAUUCCGCGUGUGCCAG
CGAAAGUUGCGUAUGGGUCA
CAUCGCAGGCACAUGUCAUC
UGGGCGGUCCGUUCGGGAUC
CUC
Human EGFR 
related 3 (Her3)
MCF-7 (human breast cancer 
cell line)
Cell surface protein 
analysis; cell sorting; 
therapy
(Chi-hong et al.
2003; Li et al.
2009)
10 TTA1 GGAGGACGCUCGCCGUAAUG
GAUGUUUUGCUCCUG
Tenascin-C
(Extracellular 
matrix)
Breast, glioblastoma, lung 
and colon cancer 
Cancer therapy (Hicke et al. 2001;
Hicke et al. 2006;
Schmidt et al.
2004; Zhou & 
Rossi 2011)
11 E9P2-2 GGGAGGACGAUGCGGUGCCC
ACUAUGCGUGCCGAAAAACA
UUUCCCCCUCUACCCCAGAC
GACUCGCGCGA
Tenascin-C
(Extracellular 
matrix)
U251 (human glioblastoma 
cell line)
Cell sorting (Li et al. 2009;
Meyer, Scheper & 
Walter 2013)
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Use of antibodies as ligands for capturing rare cells on microfluidics is limited only to those 
few known markers that are specifically expressed in each cancer type for which high-affinity 
antibodies are available. To overcome this obstacle, use of aptamers that can be synthesized 
for any cell type has been exploited to capture rare cells in microfluidic devices. The ease of 
immobilization on a variety of substrates, their thermal stability, and high specificity to target 
molecules has made aptamers attractive targets for biosensors and microfluidics based CTC 
capture studies (Breaker 2004; Phillips et al. 2008). The first study reporting the use of 
aptamers for enrichment of CTCs in a microfluidic device was carried out by Phillips et al.
DNA aptamers sgc8 was coated on the microchannels of a PDMS based chip to capture T 
cells from an acute lymphoblastic leukaemia cell line. Effect of various parameters such as 
flow rates, aptamer concentration and cell density on cell capture was evaluated. The 
sensitivity and specificity obtained using aptamers was as good as using antibodies without 
the need for pre-treatment of cells (Phillips et al. 2008). This study was further extended for 
multiplexed cancer cell detection on a single chip using three different DNA aptamers 
namely Sgc8, TD05 and Sgd5 each specific to a leukaemia cell line. A PDMS based S-
shaped channel was used for multiplexed capture of different cancer cells in different areas of 
the channel by immobilizing specific aptamers at specific regions. The results showed that 
this device was able to sort cells with 96% purity while maintaining the viability of the 
captured cells (Xu et al. 2009). Sheng et al. developed a microfluidic device consisting of 
several micropillars coated with DNA aptamers to efficiently capture cancer cells from 
unprocessed whole blood samples. Isolation of colorectal cancer cells DLD-1 and HCT 116 
spiked in whole blood samples by using specific DNA aptamers KDED2a-3 and KCHA10 
respectively with >90% capture efficiency with >80% purity and high sensitivity was seen 
(Sheng et al. 2012). Capture and enumeration of prostate cancer cells spiked in whole blood 
samples using prostate specific membrane antigen (PSMA) specific aptamers coated on a 
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high-throughput microsampling unit (HTMSU) has been reported. This study showed 
efficient capture of cancer cells from the large background of blood cells even at low cell 
concentrations (Dharmasiri et al. 2009). Use of gold nanoparticles conjugated with DNA 
aptamers sgc8 for efficient capture of leukaemia cells was reported by Sheng et al. Capture 
efficiency increased from 49% to 92% by using gold nanoparticle-aptamer conjugates in 
comparison to aptamers alone. This approach was further validated in a flat channel with 
herringbone structures that cause microvortexing within the channels to improve interactions 
between cells and channel surface (Sheng et al. 2013). Zhu et al. designed a microfluidic 
device that allows temperature mediated release of captured cells for subsequent culture and 
analysis. This approach involved specific capture of leukaemia cells on a sgc-8 modified 
PDMS based device followed by efficient release of cells while maintaining their viability 
using integrated heaters and temperature sensors (Zhu et al. 2012). Anti-EGFR RNA 
aptamers have been used for efficient isolation of human glioblastoma cells and genetically 
modified murine glioma cells overexpressing EGFR (Wan et al. 2010). This study was 
further extended for increasing surface roughness of the PDMS chip by nano-texturing. A 2-
fold increase in capture efficiency was seen as a result of efficient functionalization of 
aptamers on the substrate (Wan et al. 2012). Effect of surface roughness on capture efficiency 
was also evaluated by Wang et al. Comparison of capture efficiencies of RAMOS cells on 
surfaces with TD05 aptamers immobilized on gold nanoparticle layers with varying 
roughness and with TD05 aptamers linked to the gold particle layers via a spacer 
poly(oligo(ethylene glycol)methacrylate) in serum-free and serum-containing media was 
carried out (Wang, Zhou, et al. 2013).
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1.4. Significance of the study
Oral squamous cell carcinoma (OSCC) was rated the fifteenth most malignant cancer in the 
world in 2011. However it is one of the top three malignancies in areas including Central and 
Eastern Europe, South Asian countries, and Melanesia. Approximately 263,900 new cases of 
oral cancer were reported in 2008 which accounted for 128,000 deaths globally. Increased 
mortality rates is attributed to poor prognosis, most of the patients die within 5 years due to 
tumor recurrence at the primary site, metastasis or field cancerization. Currently available 
diagnostic methods for oral cancer such as toluidine blue staining, oral brush biopsies, light 
based detection methods are subjective and error prone. Owing to the lack of accurate 
detection tools, oral cancer is usually diagnosed only at an advanced stage that not only leads 
to increased morbidity rates but also causes severe loss of function, deformity and depression 
after surgery or treatment. Although several groups around the world have reported potential 
diagnostic markers in saliva, serum and tumor tissues of oral cancer patients, none of them 
have reached clinical utility. 
With recent developments in omics technologies such as genomics, transcriptomics, 
proteomics, metabolomics the search for early stage diagnostic, predictive, prognostic 
markers for cancer using clinical samples (tumor tissue, body fluids) is achievable. 
Proteomics has emerged as a chief support in the diagnostic field since the completion of the 
Human genome project. Molecular processes underlying the transformation of normal cells to 
neoplastic cells are driven by proteins, therefore understanding the critical changes occurring 
at the protein level would be more beneficial than genomic markers. Several protein markers 
including PSA, CEA, CA125 to name a few, have found clinical application for monitoring 
and diagnosis of various cancers. Availability of such markers for early diagnosis of oral 
cancer that can be monitored non-invasively would enormously benefit the individuals at 
risk.
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Therefore it was hypothesized that comparing the proteomic profiles of tumor and healthy 
surrounding tissues obtained from oral cancer patients to identify differentially expressed 
markers would greatly benefit the quest for ideal oral cancer biomarkers. Use of molecular 
or immunoassays to further validate these candidate markers in tumor tissue samples so
that they can be used as surrogate tumor markers in biofluids such as saliva and plasma, 
ultimately aiding the development of non-invasive diagnostic assays.
The search for a panel of well-studied, clinically-validated, non-invasive markers for oral 
cancer that can help in early diagnosis or better clinical judgment is still ongoing. It is 
important that there be rapid advancements in personalized point-of-care diagnostics to 
reduce mortality rates caused by cancer. The development of a high-throughput, automated 
and an in-expensive screening method for cancer has been a major focus for many 
researchers since the recent advancements in the field of micro-fluidics and micro-
fabrications referred to as lab-on-a-chip. Microfluidics allows manipulation of fluids and 
biological molecules such as DNA, RNA, proteins or cells at microliter volumes in a 
specifically designed micrometre area. The small-scale design of a microfluidic device 
similar to that of cells and blood vessels helps mimic a tumor microenvironment that can be 
used for studying growth, invasive potential and response to various treatment strategies of 
cancer cells. Microfluidics enables analysis of biomarkers and bio-molecules in complex 
biological fluids such as blood, saliva and urine thus allowing non-invasive assays for cancer 
diagnosis with minimum sample requirements. Several reports have also indicated that 
microfluidic devices can be used to incorporate the various ‘omics’ tools into one platform 
that will help identify and categorize potential biomarkers for cancer. 
Therefore, microfluidics offers a great hope as a validating platform for identifying the 
specificity and sensitivity of the existing markers to each cancer type with limited use of 
samples, reagents and time. 
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The growth in microfluidics have also led to development of newer diagnostic aids and 
therapeutic targeting for cancer with the prime focus being the capture and analysis of 
circulating tumor cells (CTCs) from the peripheral blood samples of patients. This strategy 
holds great potential not only for identifying prognostic, predictive markers but also for 
minimizing the requirement for invasively obtained tumor biopsies. CTCs can either be used 
independently as biomarkers for prognosis, appropriate treatment selection and monitoring or 
as a basis for identifying existing and emerging biomarkers. Despite all the focus and 
improvements surrounding CTCs there is currently only one FDA approved CTC detection 
assay called CellSearch that was released in 2004. The microfluidic technologies have now 
been used extensively for CTC capture and analysis. Of the several methods that have been 
reported for CTC capture including CellSearch, immunoaffinity based isolation has been the 
mostly commonly used approach for cell capture. Other isolation methods include immuno-
magnetic based, size/density based filtration and dielectrophoresis. 
Therefore there is a need for developing a validation system that allows capture and 
analysis of CTCs as a source of established or emerging markers from non-invasively 
obtained patient samples at minimal volumes. There is a need for development of simple 
easy-to-fabricate microfluidic devices that besides allowing high capture sensitivity and 
specificity also enable on-chip characterization of captured cells and subsequent release 
and culture of cells in vitro for further analysis. To that end, microfluidics devices were 
designed that would capture specific cells from a cell mixture based on immune-affinity. 
Human epithelial colorectal adenocarcinoma cells (Caco-2) was used as a model system 
for validating the immune-specific capture and efficiency of the designed chips containing 
anti-EpCAM (epithelial cell adhesion molecule) antibodies immobilized on their 
microchannel surfaces as the capturing agents. 
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The complexity and heterogeneity of CTCs originated from different cancer types or within 
the CTCs from the same cancer type and also between different individuals is a major 
challenge that minimizes the possibility of development of a single CTC capture device for 
efficient capture of CTCs in all cancer types. A better understanding of the molecular 
markers specific to CTCs originated from a specific cancer site in a definite group of 
population is necessary for developing efficient CTC capture devices. With the availability of 
large number of clinical samples drug resistance, self-renewability and tumorigenicity of 
CTCs showing cancer stem cell (CSCs) properties can also be detected. On-chip isolation of 
CSCs followed by subsequent characterization for various markers and in vitro culture of 
these cells can help develop better treatment strategies and to stratify patient populations 
based on their marker expression for developing effective anti-cancer treatments.
To this end, the cancer cells captured using immobilized anti-EpCAM antibodies on the 
microfluidic devices designed for this study were further evaluated for their ability to 
characterize the CSC marker expression. The ability of these microfluidic devices to allow 
on-chip characterization of captured cells for specific markers will ultimately aid in 
validating the pool of identified candidate cancer markers for their specificity to each 
cancer type and their clinical applicability. Further application of these devices was 
analysed by releasing captured cells for subsequent in vitro culture and analysis.  
With optimized flow rates, cell densities and antibody concentrations the microfluidic devices 
can specifically capture rare cells from a cell mixture. However to further enhance the 
sensitivity of these devices; there is a need for a more robust platform that not only minimizes 
non-specific cross reactivity but also allows reproducible homogenous crosslinking of the 
capturing agent on-chip without the need for engineering complex structures. It is also of 
vital importance to develop a microfluidic platform that is robust and allows reusability 
without the need for modifying the microchannel surfaces after each run. Such a device that 
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does not require critical storage and transport conditions will allow its applicability in remote 
areas without the need for sophisticated facilities. Use of aptamers as a more robust platform 
for CTC capture than antibodies is because of their increased thermal stability, resistance to 
degradation, ease of synthesis and strong binding to modified glass surfaces. Microfluidic 
devices modified with aptamers therefore offers a great potential in developing CTC capture 
devices that can be easily stored, transported and can be used for repeated analysis of several 
samples on the same device with consistent capture efficiency and specificity. Use of 
aptamers for this purpose has received added focus in the recent years. Aptamers are 
chemically synthesized single stranded DNA or RNA probes that are known to have affinities 
to small molecules, proteins or cells comparable to that of antibodies. The additional 
advantage of using aptamers as capturing agents besides their specificities is that they are 
highly stable and they can be site-specifically labelled, modified and immobilized onto 
various surfaces. Moreover because aptamers can be chemically synthesized there is less 
heterogeneity and reduced batch to batch variation. Resistance to degradation by nucleases 
can be obtained by modifying the aptamers with locked nucleic acids (LNA).
To this end, EpCAM LNA aptamers and nucleolin LNA aptamers were used to modify the 
microchannel surfaces of the chips to compare the capture sensitivities of the antibody 
based approach. The same chip designs that were used in the antibody based experiments 
to capture Caco-2 cells from a cell mixture. Reusability and reproducibility of the aptamer 
modified chips after selective capture and controlled release of cells was also evaluated. 
Capture sensitivity and specificity of the aptamer modified devices for capturing rare cells 
from blood samples spiked with small number of cancer cells and also from blood samples 
obtained of head and neck cancer patients was analysed.
These results would not only prove that the microfluidic based rare cell detection approaches 
used in this study can be of remarkable assistance in clinical decision making and planning 
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treatment strategies for patients but can also be used as a validation tool for the existing 
potential markers for oral cancer that have not yet reached clinical utility.
1.5. Aims and objectives
Identification of potential protein markers for oral cancer is a prerequisite for decreasing the 
mortality rates and improve outcome. Lack of clinically usable markers for oral cancer 
detection and the lack of a suitable platform for validating the existing pool of identified 
markers are the two major areas that need immediate attention. Microfluidics has 
revolutionized the field of biomarker identification and rare cell capture techniques with 
minimal use of sample and time at reduced costs. Therefore a well-designed microfluidic 
device that can specifically and efficiently capture rare cells to be used as biomarkers or as a 
source for identified biomarkers and also acts as a platform for validating the established 
markers would be highly beneficial. To achieve the above stated objective the following aims 
were identified in this study.
1. Identification of potential biomarkers in oral squamous cell carcinoma from tumor 
tissues using proteomics and immunoassays
To achieve this, whole proteome analysis of tumor tissue in comparison with healthy adjacent 
tissues obtained from oral cancer patients (stage III and IV) was performed using 2-
dimensional gel electrophoresis. Differentially expressed protein spots were identified after 
silver staining using PD Quest software. Matrix assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry was used to identify the protein after in-gel trypsin 
digestion of the spot of interest. MASCOT search was performed to identify the proteins 
from databases based on the molecular weights of the individual peptides produced as a result 
of trypsin digestion of each protein spot. Identification and validation of differentially 
expressed proteins in OSCC was also performed using sandwich ELISA.
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2. Use of microfluidic devices with anti EpCAM antibody modified microchannel surfaces 
for efficient capture of cancer cells followed by on-chip characterization and subsequent in 
vitro culture
To achieve this, three different Polydimethylsiloxane (PDMS) based microfluidic chips were 
designed. The PDMS chips were reversibly attached to Poly-L-Lysine coated glass slides. 
The microchannels surfaces were modified with immobilized anti-EpCAM antibodies by 
passive adsorption. PHD Ultra 4400 Syringe pump was used for optimizing flow rates and 
injecting cell solutions and buffers into the chips. Caco-2 cells were used for evaluating 
capture efficiencies and capture purities from a cell mixture. Confocal microscopy was used 
for detection of important surface markers on the captured cells on-chip and to show that 
further analysis of captured cells on-chip was possible. 
3. Use of microfluidic devices with LNA aptamer modified microchannel surfaces for 
efficient capture of CTCs with increased sensitivity and reusability 
To achieve this, previously mentioned PDMS chips were reversibly attached on Silylated 
glass slides. The channel surfaces were modified with EpCAM LNA aptamers and Nucleolin 
LNA aptamers through amine-aldehyde crosslinking. Based on the optimized flow rates and 
cell densities from the antibody based experiments, this approach was used to evaluate 
improved efficiency and sensitivity. Reusability of the chips after successful capture was 
evaluated using trypsin to release captured cells. The ability of these devices to specifically 
capture small number of cancer cells from blood samples of head and neck cancer patients 
was also evaluated. 
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2. IDENTIFICATION OF DIFFERENTIALLY EXPRESSED PROTEINS IN ORAL 
SQUAMOUS CELL CARCINOMA
2.1. Introduction
Oral cancer is a subtype of head and neck cancer which is the sixth most common 
malignancy worldwide. Approximately 48% of head and neck cancers occur in the oral 
cavity, 90% of which are squamous cell carcinomas (Tanaka, Tanaka & Tanaka 2011).
Occurrence of precancerous lesions such as erythroplakia, leukoplakia or oral lichen planus
in the oral cavity can sometimes lead to the development of oral squamous cell carcinoma 
(OSCC) (Massano et al. 2006). For the advancement of OSCC from mild dysplasia to 
premalignant lesions and finally to carcinoma a multistep model of carcinogenesis has been 
proposed. Approximately 300,000 oral cancer cases have been reported annually. Cancers 
arising in the tongue account for 40% of cancers of the oral cavity (Tanaka, Tanaka & 
Tanaka 2011). Other sites include buccal mucosa, floor of the mouth, gingiva, palate, tonsils 
and oropharynx (Farah et al. 2012). The prevalence of OSCC shows significant geographical 
variation. Highest prevalence of OSCC is seen in South Asian countries including India, 
Pakistan Bangladesh and Sri Lanka, Melanesia and Eastern Europe (Warnakulasuriya 2010).
Major risk factors leading to the highest incidence of OSCC in south Asian countries are 
extensive betel quid chewing and tobacco smoking. Other risk factors include infection with 
human papillomavirus (HPV), alcohol consumption and malnutrition (Meurman 2010;
Warnakulasuriya 2010). Early detection tools are essential not only to reduce the high 
morbidity rates but also to reduce the severe loss of function; deformity and depression 
caused after surgery and treatment. Biomarkers have evolved as important diagnostic, 
prognostic and therapeutic tools for cancer management. Availability of such biomarkers can 
be of tremendous help in early diagnosis of oral cancer.
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A large number of potential protein markers have been identified for various cancers. Most 
commonly used gel based methods for protein analysis is the 2-dimensional gel 
electrophoresis (2-DE) which separates proteins from a crude mixture on the basis of their 
iso-electric points and their molecular weights. A modified version of this method differential 
in-gel electrophoresis (DIGE) was developed to reduce the run-to-run variations by labelling
two protein samples with different fluorescent dyes and running them simultaneously on a 
single 2-DE gel. These gel based methods are not only laborious and time consuming but also 
limit analysis of low abundance proteins, high molecular weight proteins and hydrophobic 
molecules (Rabilloud et al. 2010). Recent developments in mass spectrometry has brought 
about rapid advancement in the field of proteomics, which allow fast, easy and reliable 
detection of proteins in tissues or body fluids. Peptide mass fingerprinting (PMF) can be used 
for protein identification with the help of mass spectrometry techniques like matrix assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) (Kocevar, Hudler & Komel 2013;
Thiede et al. 2005). The surface- enhanced laser desorption ionization-time-of-flight-MS 
(SELDI–TOF–MS) allows protein identification and purification in a single instrument and 
has been widely used in biomarker discovery for cancer (Seibert, Ebert & Buschmann 2005).
Although several protein markers have been reported to be differentially expressed in 
oral cancer tissue specimens, none of them have reached clinical utility for efficient 
diagnosis. This could partially be attributed to the heterogeneity in the protein profiles of 
cancer of different sub-locations in the oral cavity. Proteomic tools such as 2-DE and 
MALDI-TOF/TOF were used to identify potential markers in tongue cancer tissue samples. 
Over 30 protein were identified to be overexpressed in tongue cancer samples in comparison 
to the healthy tissue, of these the significant markers were cytokeratin 6 and 13, beta 
globulin, alpha-2-actin and heat shock proteins 70kDa and 90kDa (Thiel et al. 2011). A 
group of 52 differentially expressed proteins were identified in OSCC tissue samples using 
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similar techniques in another study. Eight of these proteins including S100 family proteins, 
peroxiredoxin-4, RACK1, calcium binding protein P22 were reported for the first time in 
OSCC tissues. It was seen that increased RACK1 expression was associated with the 
advanced stages of cancer, metastasis to lymph nodes and cancer relapse (Wang, Jiang, et al.
2008).  Proteomic techniques such as isobaric tag relative and absolute quantitation (iTRAQ) 
labelling and liquid chromatography-mass spectrometry (LC-MS/MS) have also been 
reported for head and neck squamous cell carcinoma. S100A7/Psoriasin was identified as 
being overexpressed in HNSCC and oral premalignant lesions. (Tripathi et al. 2010).
Another group employed the use of laser capture microdissection (LCM) to select out 
a small number of homogeneous cells from head and neck squamous cell carcinomas and 
normal tissue samples for proteomic analysis. LCM can be used to isolate a group of cells 
representative of the tumor and thereby avoid the intrinsic heterogeneity seen in most human 
cancers and also prevent contamination with host cells such as fibroblasts. Protein separation 
from these cells was carried out using reverse-phase liquid chromatography (RPLC), so that 
there will be complete recovery of proteins from small samples and minimize contamination 
from sample handling. This study showed that the reduced expression of certain cytokeratins 
in SCC which correlates with the general loss of differentiation. Cytokeratins 13 and 19 were 
seen to be expressed in low levels in the tumor cells than in the normal cells. Lower 
expression levels of cytokertain 13 were further reconfirmed by expression analysis on 
archival tissues. This finding was further strengthened by another independent research group 
who showed the existence of keratin 13 mRNA in non-cancerous samples, but not in the 
tumor samples suggesting its possible role in development of cancer in HNSCC. The proteins 
that were found to be up-regulated were the Heat shock proteins (HSPs). Presence of HSP70
and HSP90 was seen in the tumor cells but not the controls (Baker et al. 2005). Several other 
studies also report upregulation of HSP70 in tumors cells and its role in inhibiting apoptosis 
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inducing factor and Bag-1. Proteins that are usually expressed in very low levels (such as 
Wnt-6, Wnt-14) have also been identified in this study which indicates the high sensitivity of 
the experimental approach used here. Several groups have studied the role of EpCAM in 
cancer development. Adult squamous epithelial cells lack EpCAM expression, however it has 
been reported that anew expression of EpCAM occurs in cells undergoing malignant 
transformations, for instance as seen in most squamous cell carcinomas of head and neck, 
colorectal, breast, lung and hepatic carcinomas (Munz et al. 2004; Went et al. 2006b).
Yanamoto et al carried out EpCAM expression analysis in primary tongue cancer samples 
using immunohistochemical analysis. It was seen that 62.5% of the tongue cancer samples 
had elevated levels of EpCAM whereas expression levels in normal epithelium were almost 
undetectable. This overexpression in cancer samples correlated with the size of the tumor, 
nodal metastasis, differentiation and metastatic potential. EpCAM levels were also studies in 
four human tongue cancer cell lines by using semi-quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR). It was reported that higher EpCAM levels correlated 
with increased invasive potential of tongue cancer; also the use of EpCAM for tongue cancer 
gene therapy has been elucidated in this study (Yanamoto et al. 2007).
Extensive research has also been performed for identification of protein markers in biofluids 
such as saliva, serum and plasma to develop non-invasive diagnostic assays for oral cancer. 
Any molecular changes in surrounding cells are likely to be reflected in saliva. Therefore 
salivary proteomics holds immense potential for oral cancer diagnostics. (Liu & Duan 2012;
Zhang, Sun, et al. 2013). Identification of several salivary markers such as transferrin (Jou et 
al. 2010); S100 calcium binding protein, S100A9 (Dowling et al. 2008; Hu et al. 2008); p53-
antibodies (Tavassoli et al. 1998); catalase (Hu et al. 2008); zinc finger proteins (Jou et al.
2011); enolase 1 (Katakura et al. 2013) have be reported. Mining of plasma/serum proteomes 
for identification of differentially expressed markers for oral cancer diagnosis has also been 
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described. Some of these include Haptoglobin Į-2 chain (Chen, Su, et al. 2008); Squamous 
cell carcinoma antigen 1 (Huang et al. 2006); Fibrinogen Į FKDLQ IUDJPHQW (Cheng et al.
2005); Cyfra 21-1 (Zhong et al. 2007).
The advancement in biomarker discovery in oral cancer has been slow. Although several 
putative biomarkers have been identified in OSCC, none of them have clinical utility so far. 
Many of these markers are not specific to OSCC and have been reported to be present in 
other cancers as well. Absence of an organized attempt to advance biomarker discovery from 
development to validation and clinical application, is the cause for the nonexistence of 
relevant biomarkers for oral cancer. High morbidity rate of oral cancer patients is because 
most patients are diagnosed at a very late stage, suggesting an immediate need for sensitive 
biomarkers to improve early detection of oral cancers. There is also a need for clinical 
validations in large sample sets to be able to use these markers in a clinical setting. Salivary 
proteomics is a promising platform not only to identify markers for early diagnosis of OSCC 
but also to develop a non-invasive diagnostic procedure. In this chapter, proteomics tools 
such as 2-DE and MALDI-TOF/TOF along with immunoassays have been employed to 
identify differentially expressed proteins in advanced stage OSCC tissues (stage III and IV). 
The whole proteome profiles obtained from tumor tissues was compared with that of normal 
surrounding tissues to identify overexpressed proteins using mass spectrometry. The presence 
of the identified proteins in early stage OSCC samples as well as in biofluids such as saliva 
and plasma can further be validated to develop non-invasive early stage diagnostic assays.
2.2. Aim
Identification of differentially expressed proteins in oral squamous cell carcinoma (OSCC) 
tissues using proteomics tools such as 2-dimentional gel electrophoresis (2-DE) and matrix 
assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) as well as 
immunoassays such as sandwich enzyme linked immunosorbent assay (ELISA). 
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2.3. Materials and methods
2.3.1. Clinical sample collection
Surgically resected primary oral squamous cell carcinoma and normal surrounding tissues 
were collected from patients undergoing surgery at Cancer Center Welfare Home & Research 
Organization, Kolkata, India. The samples were immediately flash frozen in liquid nitrogen 
before storing them in -80°C freezer until further use.  The approval to conduct this study was 
obtained from the individual ethics committees. Prior to sample collection written consents 
were taken from patients after briefing them about the purpose of the study. The tissue 
samples were collected from patients with advanced stage of cancer (stage III and IV). The 
staging was done based on TNM (tumor, nodal, metastatic) classification given by 
International agency for research on cancer (IARC) screening group, World health 
organization. Details of the samples collected are enlisted below. The following were the 
inclusion criteria for sample collection in this study.
1. Patient information about sex, age, and histories of cigarette smoking, betel quid chewing, 
and medical illness were filled out in the patient questionnaire prior to sample collection.
2. All of the OSCC patients enrolled in this study were diagnosed recently and had not 
received any prior treatment in the form of chemotherapy, radiotherapy, surgery, or 
alternative remedies before sample collection.
3. None of the subjects had a history of prior malignancy, immunodeficiency, autoimmune 
disorders, hepatitis, or HIV infection.  
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Table 2.1. Clinical data of samples included for 2-DE
Characteristics Sample No.
1. Gender
Male 11
Female 9
2. Age group
25-35 5
36-50 5
51-65 10
3. Postoperative Stage
III 12
IV 8
4. Tumor location
Buccal Mucosa 12
Tongue 7
Mandibular alveolus 1
OSCC is classified as stage III or IV when there is nodal or distant metastasis.
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Table 2.2. Clinical data of samples included for ELISA
Characteristics Sample No.
1. Gender
Male 15
Female 10
2. Age group
20-35 12
36-50 5
51-65 8
3. Postoperative Stage
III 7
IV 18
4. Tumor location
Buccal Mucosa 11
Tongue 11
Inner lip 3
OSCC is classified as stage III or IV when there is nodal or distant metastasis.
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2.3.2. Sample preparation for proteomic analysis
2.3.2.A. Total protein extraction:
Pre-weighed frozen tissue samples were taken separately in 1.5ml tubes. Extraction from 30-
50 mg of sample requires 1ml of lysis buffer (7M Urea, 2M Thiourea, 4% CHAPS, 100mM 
DTT, ImM EDTA, PIC, bromophenol blue). The frozen tissue samples were ground with a 
mortar and pestle in liquid nitrogen. The ground sample was immediately suspended in lysis 
buffer in 1.5ml centrifuge tube, which was vortexed gently for 1 hour at 4°C. The sample was 
then centrifuged at 15000rpm for 15-20 min to pellet the cell debris. The supernatant was 
stored at -80°C until further usage (Wu et al. 2005).
2.3.2.B. Acetone precipitation:
The entire precipitation process was carried out on ice. Ice-cold acetone with 20mM DTT and 
the protein samples were taken in 4:1 ratio. The mixture was incubated at -20°C overnight 
after vortexing the mixture well. The samples were then centrifuged at 15,000rpm fir 15 min 
at 4°C. The protein pellet was collected and air dried prior to dissolving in a rehydration 
buffer containing 7M Urea, 2M Thiourea, 2% CHAPS, 20mM DTT, 0.2% Biolyte 3-10
ampholyte (Dowling et al. 2007; Wu et al. 2005).
2.3.2.C. Protein Estimation:
Bradford assay was used to estimate protein concentration in each sample. Bovine Serum 
Albumin (Sigma-Aldrich) was used as protein standards here. Five different dilutions of the 
protein standards from 0.125mg/ml to 2mg/ml were prepared in duplicates. Five serial 
dilutions of the samples (tissue lysates) were prepared in duplicates. The standard curve of 
the protein standard absorbance was plotted against their respective concentrations. The 
absorbance of the unknown protein sample was plotted in the graph to determine the 
concentration (Kruger 1994).
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2.3.3. 2D-Gel Electrophoresis (2-DE)
2.3.3.A. Iso Electric Focusing (IEF)
a. Rehydration and sample loading
The samples diluted with rehydration buffers were applied to the rehydration tray. The first 
dimensional IEF was performed on a 17-cm, pH 3-10 linear immobilized pH gradient (IPG) 
gel strip (Bio-Rad) at 20 °C using a Protein IEF Cell (Bio-Rad). Once the cover sheet of the 
IEF strip was peeled, it was laid gel face down onto the sample. The strip was left to absorb 
the sample for 15-30 min before being overlaid with 2ml of mineral oil. The rehydration tray 
was left on a level bench overnight (11-16 hr) along with loading of the protein sample in the 
IPG strips.
b. Focusing of the protein samples
On a clean IEF focusing tray paper wicks were taken using forceps and placed at each 
electrode and were saturated with 8μl of nanopure water. The IEF strip was taken from the 
rehydration tray using forceps and the tip was blotted on a filter paper by holding the strip 
vertically to drain off the mineral oil. The strip was then placed gel face down in the focusing 
tray (in the channel with electrode paper wick saturated with nanopure water). The strip is 
covered with 2ml mineral oil. The focusing tray was placed in the PROTEAN IEF cell at 
20ºC, with a current of 50 μA per strip was used. Focussing conditions used:
i. Pre-focusing at 200V for 3hr (paper wicks changed hourly)
ii. 2000V for 2hr (Ramp-Linear)
iii. 2000 V for 40,000V-hr (Ramp-Rapid)
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c. Equilibration of IEF strips
After IEF, the gel strip was equilibrated with 2ml equilibration buffer 1 (containing 6M Urea, 
2% SDS, 0.375M Tris-HCl (pH 8.8), 20% glycerol, and 2% (w/v) DTT) for 15mins. After 
15min the equilibration buffer 1 was removed using a 1ml pipette and equal volume of  
equilibration buffer II (6M Urea, 2% SDS, 0.375M Tris-HCl (pH 8.8), 20% glycerol, and 
2.5% (w/v) Iodoacetamide) was added. DTT reduces the sulfhydryl groups and 
iodoacetamide alkylates the reduced sulfhydryl groups.
2.3.3.B. Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-PAGE) 
The second dimensional SDS-PAGE gel was carried out in a 1mm thick 12% acrylamide gel. 
The IEF strips were briefly dipped in the running buffer (1xTris-Glycine). Once the SDS-
PAGE gel was polymerized it was covered with overlay agarose followed by gently sliding 
the IEF strip onto the SDS-PAGE gel. After the agarose solidified the gel was mounted onto 
the electrophoresis tank and filled with 1xTris-Glycine running buffer. Power was applied to 
start electrophoresis at 200 volts. The progress of the electrophoretic run is monitored by 
checking the migration of bromophenol blue tracking dye (Boguth et al. 2000).
2.3.4. Silver Staining and Image Analysis
After 2-DE, the gels were suspended in fixing solution (10% acetic acid, 40% methanol, 
50% MilliQ water) for one hour. This was followed by repeated washes with MilliQ water for 
two hours to remove traces of acetic acid from the fixing solution. The gels were then briefly 
sensitized for staining with hypo solution (0.02% sodium thiosulphate) for one minute 
followed by washing with MilliQ water twice for 30 seconds each. The gels were then 
incubated with ice cold staining solution (0.1% silver nitrate with 0.02% formaldehyde) for 
20 minutes followed by three washes with MilliQ water for one minute each. The gels were 
then developed using the developer solution (3% sodium carbonate, 0.05% formaldehyde) 
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until the protein spots are visible. The stop solution (5% acetic acid) was used to terminate 
the developing process. The gels were then stored in 1% acetic acid solution at 4°C until 
further use. The gels were thoroughly washed with MilliQ water thrice before mass 
spectrometric analysis. Image analysis of the stained gels was performed using PD Quest 
Advanced 8.0 software to identify differentially expressed proteins (Chevallet, Luche & 
Rabilloud 2006; Yan et al. 2000).
2.3.5. In-Gel Tryptic digestion
Protein spots of interest were cut out from the stained polyacrylamide gel, made into smaller 
pieces and then taken into a 0.5 ml centrifuge tube. The gel pieces were washed with 1ml MQ 
water while vortexing for 15min. De-staining was performed with 30mM potassium 
ferricyanide solution (K3Fe(CN)6). The gel pieces were washed 4-5 times for 15 min with 
1ml of MilliQ water, until gel was transparent and had no background colour. Freshly 
prepared 20 mM Dithiothreitol (DTT) solution was added to cover the gel pieces, and 
incubated for 45 minutes at room temperature. DTT solution was then replaced with freshly 
prepared 55 mM Iodoacetamide and incubated for 45 min at room temperature in the dark. 
DTT helps in reducing the disulfide bonds in the proteins whereas Iodoacetamide helps in 
alkylating the thiol groups to prevent re-oxidation of proteins. This method helps in 
linearizing the proteins to expose all cleavage sites for better trypsin digestion. The solution 
was removed completely and the gel was dehydrated in 200μl of 100% acetonitrile (ACN)
for 10 min. The gel pieces were rehydrated with 20μl of 12.5ng/μl Trypsin. The tubes were 
placed on ice until the trypsin is completely absorbed by the gel pieces. 25mM ammonium 
bicarbonate was added so that the gel pieces were completely immersed and incubated in 
water bath for 3 hours at 37°C. After the incubation the sample was spun down by 
centrifugation (10000 rpm for 30sec). To recover the peptides from the gel pieces after the 
digestion, 2 extractions with 6% Trifluroacetic acid (TFA)/50% ACN were performed. For 
                                                                                                                                                  Chapter 2
76 
 
the first extraction, 100μl of 6% TFA/50% ACN was added and vortexed for 20min. 
Supernatants were saved in 0.5 ml micro centrifuge tubes. High TFA concentrations are used 
to reduce sample loss. The recovered peptides were concentrated in the Concentrator. The 
concentrated peptides were immediately spotted on the Opti TOF MALDI plate (Terry, 
Umstot & Desiderio 2004).
2.3.6. Peptide Mass Fingerprinting
Protein identification was carried out using MALDI-TOF/TOF. The peptides obtained after 
tryptic digestion of proteins from each gel spot are spotted on the maldi plate along with the 
matrix alpha-cyano-4-hydroxycinnamic acid (CHCA). The plate was then loaded to analyse
the peptides in the MS Reflector mode. The masses of the individual peptides obtained from 
each spot were entered in MASCOT search engine to identify the corresponding protein
(Gobom et al. 2000).
2.3.7. Immunoassays
Enzyme linked immunosorbent assay (ELISA) was performed to determine expression levels 
of heat shock 70kDa protein (HSP70), Epidermal growth factor receptor (EGFR), Epithelial 
cell adhesion molecule (EpCAM) and survivin in 20 OSCC tissue and match surrounding 
tissue lysates. To optimize the working concentrations for antibodies and cell lysates a
checkerboard titration study with varying concentrations of antibody (coated on ELISA plate) 
and tissue lysates was performed. The samples were analysed in triplicates.
2.3.7.A. Sandwich ELISA
Primary antibodies against EpCAM, HSP70, survivin and EGFR were appropriately diluted
(2, 4, 6, 8, 10 μg per ml) in 1X phosphate buffered saline (PBS), added into 96 well plates 
and incubated overnight at 4°C. The plates were then washed thrice with wash buffer (0.05% 
Tween 20 in 1XPBS). Blocking with 1% bovine serum albumin (BSA) in PBS was done for 
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2 hours at 37°C. The plates were then washed with washing buffer thrice. Tissue lysates 
diluted appropriately (0.5, 1 μg per ml) in 1XPBS were added and incubated for 2 hours at 
37°C. The wells were washed thrice before incubating with the primary antibody diluted with 
1XPBS (1:100) for 1 hour at 37°C. The wells were washed again followed by incubation with 
horse radish peroxidase (HRP) conjugated secondary antibody (1:1000 dilution in 1XPBS) at 
37°C for 30 minutes. The wells were washed before adding TMB substrate and incubated for 
10 minutes at 37°C. After colour development stop solution (12mol/l) was added to the wells 
and absorbance was taken at 450 nm (Leite et al. 2008). The diagnostic sensitivity and 
specificity was determined as follows. (Kanwar & Vinayak 1992)
Sensitivity = 
୔୭ୱ୧୲୧୴ୣ ୰ୣୱ୳୪୲ୱ
୒୳୫ୠୣ୰ ୭୤ ୲୰୳ୣ ୮୭ୱ୧୲୧୴ୣା୤ୟ୪ୱୣ ୬ୣ୥ୟ୲୧୴ୣ ୰ୣୱ୳୪୲ୱ x 100
Specificity = 
୒ୣ୥ୟ୲୧୴ୣ ୰ୣୱ୳୪୲ୱ
୒୳୫ୠୣ୰ ୭୤ ୲୰୳ୣ ୬ୣ୥ୟ୲୧୴ୣା୤ୟ୪ୱୣ ୮୭ୱ୧୲୧୴ୣ ୰ୣୱ୳୪୲ୱ x 100
2.3.7.B. Microfluidics based sandwich ELISA
Sandwich ELISA was performed on a microfluidic device. The microfluidic device design 
and fabrication protocols are discussed in page 121and Figure 3.1. Poly-L-lysine slides were 
pre-coated with antibodies against survivin, EpCAM and EGFR at a concentration of 10 μg 
per ml. Three of the capture chambers of the microfluidic device were coated with each of the 
above mentioned antibodies whereas the fourth chamber was used as blank. The 
microchannel surfaces were blocked with 1% BSA in PBS was done for 1 hour at 37°C 
before introducing cell lysates. The cell lysates at a concentration of 1 μg per ml were flowed 
through until the chambers were completely covered with the lysates and incubated for 2 
hours at 37°C. This was followed by washing with wash buffer thrice before dismounting the 
microfluidic device. The following steps are same as described in section 2.3.7.A. 
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Figure 2.1. Design and dimensions of the microfluidic device used for performing 
ELISA. 
The microfluidic device consists of 4 capture chambers each leading to an independent outlet 
chamber. Each of these chambers was independently coated with antibodies against EpCAM, 
survivin and EGFR. The fourth chamber was used as blank. The device fabrication 
procedures are described in detail in section 3.3.1 (page 128).
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2.4. Results
2.4.1. Proteomic profiling of OSCC and normal tissues by 2-DE
To determine the proteins that are differentially expressed in OSCC tissues, comparative 
proteomic analysis of advanced stage OSCC and matched normal adjacent tissues was 
performed using 2-DE. Protein expression profiling was performed individually for a total of 
20 tumors and matched normal surrounding tissues obtained from oral cancer patients. The 2-
DE maps were visualized by silver staining which showed approximately 550 protein spots 
for each tissue type (Figure 2.2). The protein spots were analysed using PD Quest Advanced 
8.0 software. For the gel image comparisons, spot generation conditions such as small spot, 
faint spot and large spot details were assigned. The overall density on the gel image was used 
to normalize each spot volume so as to reduce the effects of experimental factors on spot size 
and intensity. Protein spots that were overexpressed by >2- fold in both tumor and normal 
samples were analysed.  A master gel was first created by selecting spots that were present in 
both samples. Quantitative analysis was performed by matching the normal sample with 
tumor. The in-built statistical analysis with Student’s t-test in the PD Quest software was 
used to identify statistically significant (p<0.05) over expressed proteins in the tumor 
samples. Differences in spot intensities >2.0 fold were analysed for PMF. Twenty 
significantly upregulated proteins in tumor samples were identified (Figure 2.4, Figure 2.5).
To eliminate any run-run variations each sample was run on 2-D-GE twice. 2-DE and PMF 
have been carried out for individual samples based to confirm the results obtained from the 
pooled samples.
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Figure 2.2. Representative 2-dimensional gel electrophoresis maps of oral squamous cell 
carcinoma and paired adjacent normal tissue.
Protein samples were first separated on 17cm immobilized pH gradient (IPG) 3-10 linear 
strips based on their isoelectric points (pI) followed by separation based on their molecular 
weights (kDa) in the second dimension. The amount of proteins loaded on each IPG strip was 
approximately 200μg. Gels were silver stained after electrophoresis. Representative images 
for three pairs of OSCC and matched normal-adjacent tissues obtained from patients with 
advanced stage OSCC (stage III and IV).
                                                                                                                                                  Chapter 2
82 
 
Figure 2.3. Fold change analysis with PD Quest Advanced 8.0 software.
Quantity graph report compares the differences in protein spot intensities in both the gels.  
The ratio of the differences in the spot intensities can be used to determine the fold change 
values. Protein spots identified to have >2 fold expression were selected for peptide mass 
fingerprinting (PMF) on MALDI-TOF/TOF. The list of proteins that were identified is 
tabulated below.
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Figure 2.4. Representative image showing protein profile of an OSCC tissue sample. 
Highlighted spots represent the twenty proteins that showed upregulation consistently in most 
of the OSCC tissues in comparison to normal tissues.  
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2.4.2. Protein identification
Following image analysis for the identification of spots of interest, the protein spots were 
excised from the gel for in-gel tryptic digestion. This was followed by peptide mass 
fingerprinting (PMF) with MALDI-TOF. Database matching with MASCOT was performed
to identify proteins based on the molecular weights of the individual peptides obtained from 
each protein spot after digestion. Peptide masses belonging to the matrix, trypsin or 
contaminants such as keratin and also those peaks that had a very low intensity were 
excluded during the search. The theoretical molecular weights and pI values of the identified 
proteins were verified with the experimental values based on the molecular weight markers 
on the gel to further confirm the obtained results. Figure 2.4 shows the differential expression 
of the identified proteins in tumor samples as compared to that of normal surrounding tissues. 
The list of the identified proteins is summarized in Table 2.3.
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Figure 2.5. Protein expression patterns in tumor and normal tissues. 
Representative images of silver stained gels showing the upregulation of the twenty identified 
proteins in OSCC tissue samples. 
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Figure 2.6. Peptide mass fingerprinting of protein spot 2.
Mass spectrum (A) obtained for spot (2) corresponding to Heat shock 70 kDa protein in the 
2-DE map from OSCC tissue and the MASCOT search results (B) showing the score and 
total matches. 
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Table 2.3. Differentially expressed proteins identified from MALDI-TOF analysis.
Spot 
ID
Protein Identified Accession 
number
Molecular 
weight (da)
pI Fold 
difference
Frequency
1 Catenin beta-1 P35222 85366 5.53 +3.7 17
2 Heat shock 70kDa 
protein 1A/1B
P08107 69921 5.49 +4.3 16
3 Zinc finger protein 
398
Q8TD17 71311 6.19 +2.8 16
4 Keratin, type I 
cytoskeletal 14
P02533 51562 5.09 +3.5 18
5 Keratin, type II 
cytoskeletal 7
P08729 51386 5.5 +2.5 14
6 Angiopoietin 1 Q15389 57513 6.3 +2.1 15
7 Epidermal growth 
factor receptor 
precursor
P00533-2 44664 6.68 +2.0 11
8 Keratin, type 1 
cytoskeletal 19
P08727 44106 4.94 +7.5 19
9 Kallikrein-1 P06870 26406 4.62 +2.0 13
10 Elongation factor 1-
beta
P24534 24633 4.51 +2.6 9
11 Heat shock 27 kDa 
protein
P04792 22768 5.98 +6.8 18
12 Glutathione S-
transferase theta-2B
P0CG30 27376 6.00 +6.7 8
13 Ribonuclease T2 O00584 27142 6.21 +4.2 7
14 Beta-crystallin B2 P43320 23249 6.54 +2.1 7
15 Superoxide dismutase 
[Mn]
P04179 22204 6.87 +4.8 16
16 Ras-related protein 
Rab-2B
Q8WUD1 24214 7.69 +2.2 9
17 Stathmin P16949 17171 5.77 +3.4 13
18 Heat shock protein 
beta-6
O14558 17136 5.96 +2.3 9
19 Galectin-1 P09382 14585 5.34 +6.4 14
20 Protein S100-A9 P06702 13111 5.71 +2.7 15
21 Serotransferrin P02787 75196 6.7 -3.8 15
22 Cachectin P01375 17353 6.99 -5.4 13
23 Keratin, type I 
cytoskeletal 13
P13646 49588 4.90 -4.2 16
Proteins represented in bold are those that showed significant upregulation and higher 
frequency of expression.
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2.4.3. Sandwich ELISA
Two proteins identified to be significantly overexpressed in OSCC tissue lysates through 
proteomics were further validated using sandwich ELISA. The expression patterns of HSP70
and EGFR were analysed in another set of 20 tumor and matched surrounding tissue lysates
to validate the 2-DE data. Apart from the two proteins mentioned, ELISA was also performed 
for EpCAM and survivin. 
2.4.3.A. Checkerboard titrations for optimizing antibody dilutions
A checkerboard titration was performed to determine the working concentration of antibodies 
for each of the four proteins and also of the cell lysates (tumor and normal). The titrations 
were performed with five pairs of tumor and matched surrounding tissue lysates. Five 
dilutions of antibodies were made ranging from 2 to 10 μg per ml. Two serial dilutions of the 
tissue lysates were prepared. The concentration range where the tumor samples showed the 
highest OD while the normal samples showed the lowest OD was chosen for subsequent 
ELISA analysis with 20 pairs of tumor and matched surrounding tissues (Figure 2.7 to 2.14).
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Figure 2.7. Checkerboard titration for anti-EpCAM antibodies and OSCC tumor tissue 
lysates.
Each of the five tumor tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-EpCAM antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.8. Checkerboard titration for anti-EpCAM antibodies and normal tissue 
lysates. 
Each of the five normal tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-EpCAM antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.9. Checkerboard titration for anti-survivin antibodies and OSCC tumor tissue 
lysates. 
Each of the five tumor tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-survivin antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nmfor each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.10. Checkerboard titration for anti-survivin antibodies and normal tissue 
lysates. 
Each of the five normal tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-survivin antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.11. Checkerboard titration for anti-HSP-70 antibodies and OSCC tumor tissue 
lysates. 
Each of the five tumor tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-HSP70 antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.12. Checkerboard titration for anti-HSP70 antibodies and normal tissue 
lysates. 
Each of the five normal tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-HSP70 antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.13. Checkerboard titration for anti-EGFR antibodies and OSCC tumor tissue 
lysates. 
Each of the five tumor tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-EGFR antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450 nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Figure 2.14. Checkerboard titration for anti-EGFR antibodies and normal tissue 
lysates. 
Each of the five normal tissue lysates were serially diluted and concentrations of 0.5 and 1 μg 
per ml were used to titrate against anti-EGFR antibodies diluted at a concentration ranging 
from 2 to 10 μg per ml. The histogram is plotted with the OD obtained at 450 nm for each 
sample at different antibody concentrations. Error bars represent standard deviation obtained 
from three repeats. 
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Table 2.4. Working optimal concentrations of antibody and tissue lysates identified from 
checkerboard titrations
Protein Marker Antibody concentration Tissue lysate concentration
1. EpCAM 10 μg per ml 0.5 μg per ml
2. Survivin 8 μg per ml 1 μg per ml
3. HSP70 8 μg per ml 0.5 μg per ml
4. EGFR 10 μg per ml 1 μg per ml
 
The concentrations of antibodies and tissue lysates mentioned in table 2.4 were used for the 
subsequent sandwich ELISA assays 
2.4.3.B. Protein marker expression analysis with sandwich ELISA
Sandwich ELISA was then performed for 20 pairs of tumor and matched surrounding tissue 
lysates with the above mentioned antibody and lysate concentrations. Validation of four 
protein markers including EpCAM, survivin, HSP70 and EGFR was performed in 20 OSCC 
tumor and matched surrounding tissue lysates. All samples were run in triplicates. All tumor 
samples showed upregulated levels of these proteins, although a wide variation was seen 
from sample to sample. Significant upregulation of survivin was seen in 17 OSCC tumor 
samples (fold change >5) DVFRPSDUHGWRWKDWRIQRUPDOVDPSOHVS6LPLODUO\!IROG
increase in EpCAM expression levels was seen in 14 out of the 20 tumor samples analysed. 
Although 12 tumor samples showed a >2 fold increase in HSP70 expression levels, only 5 of 
those showed >5 fold increase. Similar results were seen with EGFR expression in tumor 
samples, where 6 of the 20 samples showed >5 fold increase in expression levels. These 
results are similar to those obtained with proteomic analysis.
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Table 2.5. Determination of diagnostic sensitivity and specificity of OSCC tumor 
samples in comparison with normal surrounding tissues.
Determination of diagnostic sensitivity and specificity for each of the four markers namely 
EpCAM, survivin, HSP70 and EGFR was done using the formulae mentioned in section 
2.3.7.A. The values enlisted in table 2.5 represent diagnostic sensitivity and specificity in 
OSCC tumor samples in comparison to that of normal surrounding tissues.
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Figure 2.15. EpCAM expression analysis in 20 pairs of OSCC and matched normal tissues.
Comparative analysis of EpCAM expression in 20 pairs of tumor and matched normal tissue lysates is represented here.  The results are 
represented as mean ±SEM obtained from three repeats run in triplicates. Statistical significance was evaluated with Student’s t-test. p value 
ZHUHFRQVLGHUHGVLJQLILFDQWRXWRIVDPSOHVVKRZHGS
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Figure 2.16. Survivin expression analysis in 20 pairs of OSCC and matched normal tissues.
Comparative analysis of survivin expression in 20 pairs of tumor and matched normal tissue lysates is represented here.  The results are 
represented as mean ±SEM obtained from three repeats run in triplicates. Statistical significance was evaluated with Student’s t-test. p value 
ZHUHFRQVLGHUHGVLJQLILFDQWRXWRIVDPSOHVVKRZHGS
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Figure 2.17. HSP70 expression analysis in 20 pairs of OSCC and matched normal tissues. 
Comparative analysis of HSP70 expression in 20 pairs of tumor and matched normal tissue lysates is represented here.  The results are 
represented as mean ±SEM obtained from three repeats run in triplicates. Statistical significance was evaluated with Student’s t-test. p value 
 ZHUHFRQVLGHUHGVLJQLILFDQWRXWRIVDPSOHVVKRZHGS5.
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Figure 2.18. EGFR expression analysis in 20 pairs of OSCC and matched normal tissues. 
Comparative analysis of EGFR expression in 20 pairs of tumor and matched normal tissue lysates is represented here.  The results are 
represented as mean ±SEM obtained from three repeats run in triplicates. Statistical significance was evaluated with Student’s t-test. p value 
ZHUHFRQVLGHUHGVLJQLILFDQWRXWRIVDPSOHVVKRZHGS
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Figure 2.19. Fold change variation in expression levels of EpCAM, survivin, HSP70, and EGFR in 20 OSCC tumor samples compared to 
that of normal samples. 
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Figure 2.20. Comparative representation of the four candidate markers in 20 pairs of 
OSCC tumor and matched normal surrounding tissues.  
The results are represented as mean ±SEM obtained from three replicates. Statistical 
significance was evaluated with Student’s t-WHVWSYDOXHZHUHFRQVLGHUHGVLJQLILFDQW
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2.4.3.C. Microfluidics based ELISA
The ability of a microfluidic device to efficiently detect biomarkers in clinical samples while 
utilizing small sample and reagent volumes was evaluated. Estimation of survivin, EpCAM 
and EGFR was performed in OSCC tumor tissue lysates on a single microfluidic device 
simultaneously.  It was seen that the microfluidic device successfully detected the presence of 
the protein markers from 4 fold decreased tissue lysate volumes as compared to that of the 
conventional 96 well microtiter plate assays. A similar trend in the OD values was seen with 
microfluidics based ELISA and the conventional ELISA methods. The results suggest that 
microfluidics holds immense potential as a validation tool for evaluating the clinical 
applicability of the vast number of candidate proteins available. The microfluidic device used 
here allows detection of upto 4 different markers simultaneously. Microfluidics based assays 
require small sample volumes, therefore offering a more feasible alternative for validating 
protein markers from clinical samples obtained in small amounts from inaccessible areas.
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Figure 2.21. Comparative expression analysis of protein markers using microfluidics 
based and conventional 96 well microtiter plate ELISA assays. 
Comparative analysis of survivin, EpCAM and EGFR expression in an OSCC tissue lysate 
using a microfluidic based and a 96 well microliter plate ELISA  method.  The results are 
represented as mean ±SEM obtained from three replicates.
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2.5. Discussion
Cancer affecting tongue, gingiva, palate, floor of the mouth, tonsils or oropharynx is referred 
to as oral cancer. Oral cancers are predominantly squamous cell carcinomas as it arises from 
the mucosal epithelial lining in the oral cavity. Oral cancer is the eighth most common 
malignancy in males worldwide. It ranks thirteenth among the various malignancies affecting 
females. Of critical importance in reducing oral cancer related mortality is the early detection 
of oral premalignant lesions. Approximately 50% of the patients die within five years 
(Warnakulasuriya 2009b). However the 5-year survival rate is much lower at 15% when 
cancer cells infiltrate the lymph nodes. Most of the oral cancer cases are diagnosed only at an 
advanced stage leading to increased mortality rates (Gómez et al. 2010). Therefore it is of 
utmost importance that any unusual discolorations or lesions occurring in the oral cavity be 
identified at early stages. Although not all precancerous lesions undergo malignant 
transformation, it is crucial to detect these at early stages to prevent cancer progression. 
Compared to the others, erythroplakia has the highest probability of progressing into a 
malignant lesion. Several diagnostics tools such as toluidine blue staining, oral brush 
biopsies, light based detection methods, tissue fluorescence imaging have been developed for 
oral cancer, but most of these methods are subjective and error-prone (Farah et al. 2012;
Mehrotra & Gupta 2011). The survival rates for oral cancer have been rather low inspite of 
the developments in detection and management of oral cancer.
Current treatment strategies for cancer can be regarded as a “one-size-fits-all” system, which 
is used regardless of the heterogeneity that exists between different patients with tumor at the 
same site. Therapy for cancer patients is usually planned based on tumor location, staging and 
recurrence. However there is a need for identifying specific quantifiable markers that can 
help decide the appropriate therapeutic regimens to be used for each patient based on the 
marker expression. Biomarkers can include DNA, mRNA, proteins, metabolites, circulating 
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tumor cells or cellular processes such as programmed cell death, angiogenesis and 
proliferation (Kulasingam & Diamandis 2008; Simon & Wang 2006). Biomarker 
identification will not only benefit early diagnosis of cancer but can also aid in identifying 
individuals at a high risk of developing cancer. Identification of such markers will also enable 
tumor staging, better clinical decision making and development of targeted anti-cancer 
therapeutics,  (Dalton & Friend 2006).
Proteomic assays have been a chief support in the diagnostic field for several decades now, 
the reason being very direct. Interpreting the critical changes at the gene level alone is not 
enough to understand the process of cancer progression, due to the intricacy of the 
mammalian systems, Hence, expression analysis at the protein level is essential. mRNA 
abundances do not often correlate with the amount of the functional proteins existing in the 
cell (Kocevar, Hudler & Komel 2013; Lu et al. 2007). The identified proteins represent a 
biological endpoint and therefore indicate any abnormal activity that may occur during 
transformation of a normal cell into a neoplastic cell. Protein biomarkers present in tissue and 
blood may therefore play an important role in early detection, monitoring and treatment of 
cancer. Examples of a few biomarkers which are clinically relevant include PAP Smears, PSA 
(Prostate-specific antigen), and CA125 (Cancer Antigen 125) (Srinivas et al. 2002); 
Srivastava and Srivastava (2005). The most commonly used methods for protein marker 
identification include use of gel based methods such as 2-dimensional gel electrophoresis (2-
DE) followed by mass spectrometric analysis. This is usually followed by peptide mass 
fingerprinting (PMF) using mass spectrometry for protein identification (Kocevar, Hudler & 
Komel 2013; Rabilloud et al. 2010).
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The present study focusses on identifying differentially expressed protein in oral squamous 
cell carcinoma (OSCC) tissue samples in comparison with the normal oral tissues with the 
use of 2-DE and MALDI-TOF/TOF. It would be highly beneficial to be able to characterize a 
wide range of proteins with variable isoelectric points on a single gel that shows an improved 
resolution in separating proteins with similar characteristics. For this purpose, 17cm IPG 
strips were used, that allow separation of proteins with iso-electric points ranging between pH 
3-10. Use of a 17cm gels although needs careful handling and consumes higher reagent 
volumes, allows enhanced protein resolution. An ideal 2-DE map staining technique is one 
that facilitates visualization of low abundant proteins with high sensitivity and also allows 
compatibility with the subsequent mass spectrometric analysis. To meet these requirements, 
the 2-DE maps generated with the use of 17cm 1PG 3-10 linear strips and a 12% SDS-PAGE 
gel were visualized with silver staining. Traditionally used method for staining 2-DE gels is 
Coomassie brilliant blue staining. The detection limit offered by this method is restricted at 
10ng of protein. Silver staining on the other hand allows sensitive detection at 1ng protein 
levels (White et al. 2004). Therefore to enhance the detectability of low abundant proteins all 
the gels were visualized with silver staining. Proteomic profiling was performed for 20 pairs 
of tumor and matched normal oral tissues obtained from patients diagnosed with advanced 
stage (stage III and IV) oral cancer. Around 20 proteins were identified to be significantly 
upregulated in the cancerous tissues.  These include cytoskeletal proteins such as keratin 14, 
7 and 19, 70 and 27 kDa heat shock proteins, EGFR, catenin-beta 1, stathmin, galectin-1,
angiopoietin-1, superoxide-dismutase, and kallikrein-1. The validation of HSP70 and EGFR 
was performed with sandwich ELISA, which showed similar results. The possible role of 
these proteins in carcinogenesis and tumor progression has been discussed below. 
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One of the earliest studies to demonstrate the role of beta-catenin in colon cancer 
advancement was reported by Rubinfeld et al in 1993. Beta-catenin was identified to form a 
gene product with adenomatous polyposis gene (APC) which is one of the earliest targets for 
genetic alterations in colorectal cancer progression. This study reported the identification of 
beta catenin as an APC associated protein with immunoprecipitation. Beta-catenin is known 
to play an essential role in cell-cell adhesion via binding with the cytoplasmic domain of E-
cadherin. The association of E-cadherin, beta-catenin and APC suggests the correlation 
between tumor initiation and cell adhesion (Rubinfeld et al. 1993; Su, Vogelstein & Kinzler 
1993). The role of APC in regulating the intracellular levels of beta-catenin as a tumor 
suppressor activity has also been demonstrated in colorectal cancer cell lines (Munemitsu et 
al. 1995). Accumulation of beta-catenin occurs as a result of a mutant APC gene which leads 
to activation of transcription factors belonging to T-cell factor and lymphoid enhancer 
binding protein (TCF/LEF) family. The oncogenic activity of beta-catenin is dependent on its
localization. Its presence on the cell membrane causes the loss of its cell adhesion property, 
whereas its nuclear translocation allows enhanced transcription of various oncogenes
(González-Moles et al. 2014; Laxmidevi et al. 2010). Loss of surface expression of beta-
catenin has been reported in several cancers including oral dysplasia and colon 
adenocarcinomas (Bánkfalvi et al. 2002; Hao et al. 1997; Williams et al. 1998).
Translocation of beta-catenin to the nucleus is associated with increased dysplasia,
malignancy and poor prognosis in oral squamous cell carcinoma (Chaw et al. 2012; Lee, 
Hung, et al. 2010). Increased beta-catenin and ras mediated transcription of cyclin D1 
strongly promotes cell proliferation in colon cancer (Tetsu & McCormick 1999). Role of 
beta-catenin in promoting the over expression of matrix mettaloproteinase-7 was reported by 
Brabletz et al. Matrix metalloproteinases (MMPs) allow degradation of basal membrane and 
extracellular matrix for malignant transformation of tumors and ultimately leading to 
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metastasis. Evidences stating the role of MMPs in maintaining a microenvironment that 
permits growth and proliferation of primary and metastatic tumors has also been reported 
(Chambers & Matrisian 1997). Over expression of MMP-7 is seen in a majority of colorectal 
carcinomas (Brabletz et al. 1999). Localization of higher levels of beta-catenin have also 
been reported at the invasive front of colorectal tissue samples (Brabletz et al. 1998).
Activation of functional beta-catenin occurs via WNT signaling pathway. Degradation of 
beta-catenin and down regulation of beta-catenin target genes occurs in the absence of active 
WNT signaling. However, accumulation of beta-catenin and activation of transcription 
factors occur as a result of WNT signaling (Fodde & Brabletz 2007; Moon et al. 2004).
Overexpression of endothelin-1 a growth factor produced by a majority of cancer cells, has 
also been reported to be regulated by beta-catenin in colon cancer (Kim et al. 2004). Besides 
colorectal cancer, overexpression of beta-catenin has also been observed in hepatocellular 
and prostate cancer (Chen, Shukeir, et al. 2004; Wong, Fan & Ng 2001).
Cytokeratins (CK) are intermediate filament proteins that are major components 
constituting the cytoskeleton of epithelial cells. These proteins are classified into type I and II 
based on their acidic or basic properties (Moll et al. 1982; Stigbrand 2001). Overexpression 
and release of full length CK19 by viable epithelial tumor cells was demonstrated by Alix-
Panabieres et al (Alix-Panabières et al. 2009). Ding et al described the correlation of 
overexpressed CK19 with increased metastatic potential of hepatocellular carcinoma and its 
potential use as a therapeutic target (Ding et al. 2004). The detection of CK19 mRNA and 
mammaglobin A mRNA expressing cells from peripheral blood samples of breast cancer 
patients showed poor disease free survival (Ignatiadis et al. 2008; Stathopoulou et al. 2002;
Xenidis et al. 2006). Recent investigations of the saliva Cyfra21-1 levels in oral squamous 
cell carcinoma patients and healthy individuals by Zhong and co-workers revealed that OSCC 
subjects had elevated levels of this protein in comparison to healthy individuals (Zhong et al.
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2007). Cyfra 21-1 a 40kDa protein, is a soluble fragment of CK19 which is expressed on 
most epithelial tissues (Linder 2007; Sawant, Zingde & Vaidya 2008). It has been reported 
that soluble fragments of cytokeratins are secreted into the circulation by degenerating tumor 
cells. Quantification of such cytokeratin fragments which are released from rapidly dividing 
cells or that undergoing programmed cell death can be used as potential biomarkers for 
diagnosing cancers of the epithelial origin (Wieskopf et al. 1995). Higher levels of serum 
Cyfra 21-1 correlated with decreased survival rates in non-small cell lung cancer (Doweck et 
al. 1995). Zhong et al deduced from the follow-up data of each patient that the pre-operative 
saliva Cyfra 21-1 levels in patients who suffered from tumor relapse at a future stage were 
higher than those in the patients who did not have a relapse (Zhong et al. 2007). Similar 
results were reported by Nagler et al in 1999 where serum Cyfra 21-1 and tissue polypeptide 
specific antigen (TPS) levels were elevated in oral cancer tissue samples. TPS is a soluble
fragment of CK18. Several studies have indicated use of Cyfra 21-1 and TPS as highly 
sensitive and specific prognostic markers for head and neck cancers. Statistical analysis 
showed high specificity and sensitivity values for Cyfra 21-1 (93%, 84% respectively) and 
TPS (87%, 69% respectively), suggesting their role for disease diagnosis and therapeutic 
monitoring (Nagler et al. 2000). Potential use of Cyfra 21-1 as an independent prognostic 
marker for lung carcinoma has been demonstrated by Pujol et al (Pujol et al. 1993).
Overexpression of CK 7 and CK 19 has been reported in lung adenocarcinomas (Gharib et al.
2002; Meyerson & Carbone 2005), ovarian cancers (Wang et al. 2004; Zhu et al. 2006), head 
and neck cancer (Patel et al. 2008). Sharma et al demonstrated the differences in cytokeratin 
expression in metastatic lung and colon cancer biopsies. Immunohistochemical analysis 
showed that the colon cancer samples were negative for CK7 expression while the lung 
cancer biopsies stained positive for CK7 and CK20 (Sharma et al. 1998).
                                                                                                                                                 Chapter 2
115 
 
Heat shock proteins (HSPs), discovered in 1962, are highly conserved proteins which 
are expressed as a result of stress induced inside the cell (Ritossa 1962). HSPs possess 
cytoprotective ability and functions as molecular chaperones during protein aggregation for 
other proteins, thus restoring homeostasis inside the cell. According to their molecular sizes, 
mammalian HSPs are divided into five different families: HSP27, HSP60, HSP70, HSP90 
and HSP100. Few members of each family are regulated either inductively or constitutively 
and are also either ATP-dependent or ATP-independent (Qian et al. 2006). Out of five HSPs 
family, HSP70 and HSP27 are universal chaperones and their expression is strongly regulated 
by stresses such as heat, irradiation and chemotherapy during cancer treatment (Garrido et al.
2001). HSP27 and HSP70 are known to play a role in apoptotic pathway due to its 
cytoprotective ability. Thus these proteins are prime targets for cancer therapy. In cancer the 
overexpression of HSPs facilitate cancer cell proliferation, metastasis and escape of apoptosis 
(Sarto, Binz & Mocarelli 2000).
HSP27 is the smallest member of the HSP family and is actively involved in 
metastasis, drug resistance, and decrease in patient survival in various cancers as a result of 
its overexpression (Bauer et al. 2012; Chen et al. 2012; Straume et al. 2012). When 
compared to normal cells, higher levels of HSP70 and HSP27 was observed in cancers like 
cholangiocarcinoma, pancreatic cancer (Aghdassi et al. 2007; Ribeil et al. 2006).
Overexpression of HSP27 was also observed in various other cancers like endometrial 
cancer, breast cancer, ovarian cancer and gastric cancer where the expression is correlated to 
the advanced stage of the tumors (Jäättelä 1999; Ribeil et al. 2006; Ryu et al. 2003). Similar 
to HSP27, HSP70 also overexpresses in endometrial cancer, gastric cancer, renal cell tumors, 
ovarian cancer, colorectal cancer, bladder cancer, pancreatic cancer, and osteosarcoma (Gress
et al. 1994; Hu et al. 2001; Isomoto et al. 2003; Kanazawa et al. 2003; Nanbu et al. 1997;
Santarosa et al. 1997; Syrigos et al. 2003). HSP27 expression in cancer is inhibited by 
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various antisense oligonucleotides and one such molecule is OGX-427 which enhanced the 
response to chemotherapy and radiotherapy in head and neck squamous cell carcinoma 
(Hadchity et al. 2009). Use of antisense oligomer against HSP70 which reduced HSP70 
expression in tumor cells resulted in inhibition of cell proliferation and induction of apoptosis 
suggesting its role in tumor progression (Wei et al. 1995). Unlike HSP27, inhibitors of 
HSP70 has not been developed mainly because of its high induction during suppression of 
HSP90 (Chang et al. 2006). Few strategies developed for counteracting HSP70 surge are 
silencing of HSP70 (Powers, Clarke & Workman 2008) and use of inhibitors like VER-
155008 (Massey et al. 2010) and ADD70 (Schmitt et al. 2006). A combinational therapy 
involving inhibitors against HSP27 and HSP70 show promising results in breast cancer 
(Krause et al. 2004). A potential role of HSP70 and HSP90 in activating matrix 
metalloproteinase-2 (MMP-2) that promotes cell migration and contributes to increased 
invasive potential of breast cancer has been described (Sims, McCready & Jay 2011).
Several DNA binding proteins which are constituted of numerous copies of zinc 
binding structural motifs are referred to as zinc finger proteins. These structural motifs are 
primarily made up of different types of cysteine-cysteine or cysteine-histidine residues 
(Brown 2005). Since the early detection of transcription factor IIIA (TFIIIA) in Xenopus,
several zinc binding motifs have been identified and categorized as zinc finger proteins (Berg 
1993; Miller, McLachlan & Klug 1985). In addition to their role as DNA, RNA-binding 
proteins they also allow protein-protein interactions. Most commonly occurring DNA binding 
zinc finger motifs are composed of Cys2-His2 repeats. These proteins function as 
transcription factors that bind to specific DNA sequences (Ladomery & Dellaire 2002; Laity, 
Lee & Wright 2001). Several studies have reported the engineering of novel zinc finger 
proteins that can specifically bind to target sites on the genome to aid gene therapy (Choo & 
Isalan 2000). The zinc finger protein identified to be upregulated in OSCC samples in the 
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current study is ZNF398/ZER6 which contains 9 Cys2-His2 residues and is a transcription 
activator. A correlation between ZER6 expression and estrogen receptor-alpha expressing 
breast cancer cells has been put forth by Stabach et al (Conroy et al. 2002; Stabach, 
Thiyagarajan & Weigel 2005). Besides its role in breast cancer, ZER6 has not been identified 
as a potential tumor marker elsewhere. 
Angiopoietin-1 is a vascular growth factor that plays a major role in vascular 
development and angiogenesis. The receptor for angiopoietin-1 is TEK receptor tyrosine 
kinase which is expressed on most endothelial cells in humans. The significance of this 
protein during embryonic angiogenesis has been well elucidated (Fiedler et al. 2003; Suri et 
al. 1996). Isolation of angiopoietin-1 as a ligand for TIE2, a receptor-like tyrosine kinase was 
reported by Davis et al., in 1996 (Davis et al. 1996). Role of angiopoietin-1 in protecting 
matured vascular system from plasma leakage has been described (Thurston et al. 2000).
Colon cancer cell lines stably transfected with angiopoietin-2 showed larger tumors with 
higher angiogenesis and proliferation compared to those transfected with angiopoietin-1.
However it is of importance to note that angiopoietin-1 expressing cells showed higher 
angiogenesis and proliferation compared to that of the cells transfected with vector alone 
(Ahmad et al. 2001). In vivo studies with transfected human cervical cancer cells expressing 
high levels of angiopoietin-1 showed inhibition of apoptosis and improved angiogenesis in 
the tumor while increasing the plasticity of the blood vessels in the tumor (Shim et al. 2002).
Higher expression levels of angiopoietin-1 in human gastric cancer tissues as wells as cell 
lines was described by Wang et al (Wang et al. 2005). Overexpression of angiopoietin-1 has 
also been reported in human glioblastoma tumor cells (Stratmann, Risau & Plate 1998), rat 
glioblastoma models (Machein et al. 2004), non-small cell lung carcinoma (Takahama et al.
1999).
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Epidermal growth factor receptor (EGFR) is one of the four members of the ErbB 
family of receptor tyrosine kinases. All ErbBs are constituted of an extra cellular ligand 
binding domain which binds to EGF related growth factors, a transmembrane domain and an 
intracellular cytoplasmic tyrosine kinase domain.  The distribution of ErbBs has been 
reported in epithelial, mesenchymal and neuronal tissues (Adamson & Rees 1981; Olayioye
et al. 2000).  Upon ligand binding with ErbBs hetero- or homodimers are formed which 
further activates the signal transduction cascade by auto-phosphorylation of specific tyrosine 
molecules that ultimately aid cell proliferation and malignant growth (Salomon et al. 1995).
Overexpression of EGFR has been reported in various malignancies including those of head 
and neck, breast, prostate, lung and ovary (Normanno et al. 2006; Salomon et al. 1995). A 
higher expression level of EGFR expression has been correlated with poor prognosis and has 
therefore gained importance as a potential therapeutic target (Huang & Harari 1999;
Nicholson, Gee & Harper 2001). Among the various strategies developed to block these 
receptors, Herceptin a humanized monoclonal antibody against ErbB2 is the most commonly 
used for the treatment of breast cancer. (Baselga et al. 1996; Yarden & Sliwkowski 2001).
Human kallikreins (HKs) are a group of serine proteases present in the plasma and a 
wide range of tissues. It has been well elucidated that proteolysis and degradation of 
extracellular matrix is a key player contributing to the increased invasiveness of cancer. 
Proteolytic initiation by the involvement of urokinase plasminogen activator (uPA) leading to 
activation of various matrix metalloproteinases (MMPs) has been the most commonly studied 
mechanism for ECM degradation in cancer (Paliouras, Borgono & Diamandis 2007; Werb 
1997). Kallikreins have gained importance for their involvement in cancer progression in the 
recent years. Clinically used tissue kallikreins include hK3, also referred to as prostate-
specific antigen (PSA) which is used as a marker for prostate cancer. Involvement of hKs in 
activation of the Proteolytic pathway involving uPA and MMPs has also been elucidated. The 
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possible role of hK1 in promoting tumor growth and survival by degradation of insulin-like 
growth factor binding proteins which leads to increased cell proliferation and inhibition of 
apoptosis due to the availability of free insulin-like growth factor-1 has also been described 
(Borgoño & Diamandis 2004). Several studies have also reported the pro-angiogenic 
properties of hK1 (Dominek et al. 2010; Spinetti et al. 2011). Among all the hKs, hK1 shows 
kininogenase activity and is actively involved in the kinin-kallikrein system which is a major 
contributor for disease related processes such as inflammation, cancer progression and 
pancreatitis (Yousef & Diamandis 2001). High levels of hK1 expression are seen in salivary 
glands, pancreas and kidneys (Clements et al. 2004; Diamandis et al. 2000).
S100 calcium binding proteins have been reported to be associated with various cellular 
operations including cell cycle progression, differentiation and also in malignant 
transformation of the cell (Dowling et al. 2008). Comprehensive research has been carried 
out on proteins belong to the S100 family to understand their association with cancer 
progression and invasion. S100A9 is known to be vitally expressed on cells such as 
neutrophils, granulocytes and endothelial cells (Cross et al. 2005). Report on the role of 
S100A9 contributing for the metastatic potential of gastric cancer cells and also the 
localization of S100A9 positive cells along the invasive front of colorectal cancer have also 
been published. These studies also reported upregulated levels of S100A8 and formation of a 
complex with S100A9 to form calprotectin (Yui, Nakatani & Mikami 2003). However, 
another study reported the downregulation of S100A9 protein in laryngeal squamous cell 
carcinomas (Sewell, Yuan & Robertson 2007). These reports are indicative of the role of 
S100 calcium binding proteins as potential biomarkers for cancer. A better knowledge about 
its functions and specificity for different types of cancers can help us analyze its use for 
therapeutic interventions. Superoxide dismutases (SOD) are enzymes that function as 
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antioxidant defense systems by catalyzing the dismutation of superoxide free radicals in all 
oxygen rich environments. Three types of SODs have been identified in mammals, which 
include two isoforms containing copper and zinc that are either cytoplasmic (CuZn-SOD or 
SOD1) or extracellular (EC-SOD or SOD3) and another isoform containing manganese (Mn-
SOD or SOD2) which is present in the mitochondria (Keller et al. 1991; Wan, Devalaraja & 
St. Clair 1994). Oxidative stress caused by elevated levels of such reactive oxygen species 
(ROS) triggers various disease conditions such as cancer, neurodegeneration, diabetes, 
vascular diseases and inflammation (Feig, Reid & Loeb 1994; Jenner 2003; Klaunig et al.
1998; Li & Zhou 2011; Madamanchi, Vendrov & Runge 2005). Role of Mn-SOD in 
promoting cancer progression has been elucidated by St. Clair et al. (St Clair et al. 1994).
Upregulation of Mn-SOD has been reported in prostate cancer (Zhong et al. 2004),
esophageal (Qi et al. 2005), buccal (Chen, He, et al. 2004)and oral squamous cell carcinoma 
(Lo et al. 2007).
Galectins are a group of carbohydrate binding protein belonging to the family of 
lectins. The proteins belonging to the galectin family show high binding affinity to beta-
galactosidase and a conserved carbohydrate binding domain (Barondes et al. 1994).
Galectins contribute to various cellular processes such as regulation of cell transformation, 
splicing of pre-mRNA, cell cycle regulation and apoptosis (Camby et al. 2006; Liu, Patterson 
& Wang 2002). Elevated levels of galectin-1 have been reported in head and neck cancers, 
(Chiang et al. 2008; Saussez et al. 2008b), thyroid tumors (Xu, El-Naggar & Lotan 1995),
colorectal cancer (Sanjuan et al. 1997) and breast cancer (Jung et al. 2007). Stathmin plays a 
crucial role in mitosis by regulating the microtubule dynamics. There is a definite correlation 
between stathmin levels and cellular proliferation. Studies with leukaemic cell lines showed 
that the levels of stathmin fell drastically when the cells stop proliferating or undergo 
terminal differentiation (Feuerstein & Cooper 1983). Stathmin levels significantly increased 
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when these cells were treated with mitogenic agents (Hanash et al. 1988). Similar results 
were also seen in solid tumors such as breast and ovarian cancer, where high stathmin levels 
correlated with tumors with higher proliferative potentials (Rubin & Atweh 2004).
Biomarker discovery has seen several advancements in the recent years. With 
developments in the field of proteomics such as mass spectrometry and two-dimensional gel 
electrophoresis, researchers have been able to perform proteome-wide expression profiling to 
identify disease specific protein signatures (Shangguan, Cao, et al. 2008). Despite these 
developments, proteomic technologies have not been able to completely characterize 
membrane proteins which contribute to upto 30% of the total genome. Various factors 
contributing to this are the heterogeneity, the hydrophobicity and the low abundance levels of 
membrane proteins (Tan, Tan & Chung 2008). Membrane proteins are critical in maintaining 
cellular homeostasis through their involvement in cell signalling, cell to cell interactions and 
transport of metabolites. They have also been identified as potential targets for drug delivery 
and therapeutic targeting in many disease conditions including cancer (Mermelekas & 
Zoidakis 2014; Wu & Yates 2003). Some of the examples of surface membrane proteins that 
have helped in developing effective anti-cancer treatments include the identification of 
epidermal growth factor receptor, HER2 in breast cancer cells (Tai, Mahato & Cheng 2010)
and epidermal growth factor receptor, EGFR in non-small-cell lung cancer patients (Hensing
et al. 2014). A better understanding of surface markers specific to a particular cancer is 
required to develop appropriate detection, diagnostic or therapeutic strategies (Shin et al.
2003). The availability of a very few clinically validated biomarkers for specific cancers 
indicates that there is a need for the development of novel molecular probes that can be used 
to study membrane proteins to differentiate one cell population from another (Tang et al.
2007).
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One of the most widely studied membrane protein is epithelial cell adhesion molecule 
(EpCAM). EpCAM is a transmembrane glycoprotein that was originally identified as a 
biomarker for colorectal cancers using antibodies in 1979 (Herlyn et al. 1979). Although 
EpCAM is expressed by most normal epithelial cells (Winter et al. 2003), reports have also 
shown the over expression of EpCAM in several carcinomas (Went et al. 2006a; Went et al.
2004a). Expression of EpCAM has also been reported in cancer stem cells which are a small 
group of tumor cells which show self-renewability and tumor initiating properties (van der 
Gun et al. 2010; Visvader & Lindeman 2008). The proteomic analysis in this study did not 
report the overexpression of EpCAM in OSCC tumor samples. To verify EpCAM expression 
patterns in OSCC, immunoassays were performed using sandwich ELISA method and the 
results demonstrated that more than 90% of OSCC tumor tissues (n=20) showed upregulated 
levels of EpCAM. Similarly, expression analysis of survivin was performed using sandwich 
ELISA. Survivin, a member of inhibitor of apoptosis gene family plays an important role in 
resisting cell death and enhancing cell proliferation. Accumulating work on this marker has 
shown the expression of survivin in most human cancers, its prominent role in imposing a 
stem cell like phenotype on cancer cells and its association with poor disease outcome and 
reduced survival rates (Altieri 2013; Di Stefano et al. 2010; Kim et al. 2003). Greater than 
five fold upregulation of survivin was seen in 17 out of the 20 OSCC tissues analysed. These 
results demonstrate the limitations of the standard proteomic tools for whole proteome 
profiling.  
Despite the availability of an enormous pool of potential biomarkers for oral cancer 
detection and diagnosis, a clinically acceptable marker in a large population is still lacking. 
This can be partly attributed to the lack of well-designed validation studies because of the 
unavailability of large sample volumes. Development of oral cancer diagnostics using saliva 
and serum samples from patients is underway. Use of biofluids to identify surrogate tumor 
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markers can help develop non-invasive diagnostic assays for cancer screening. Availability of 
such markers that can estimate the risk of cancer progression from pre-malignant lesion, help 
in cancer staging, or predict treatment responses would be of tremendous benefit in cancer 
management. For this to become reality there is a need for an efficient validation system that 
can be used to evaluate the clinical applicability of the existing pool of potential markers 
while using very small sample volumes. Microfluidics holds remarkable potential for 
developing validation platforms that can specifically monitor protein markers of interest with 
high sensitivity. Use of microfluidics for detection of proteins in solution (tissue lysates, body 
fluids) or as cell surface markers would be an ideal platform for validating the identified 
protein markers in large sample sets and also for identifying novel disease specific markers. 
The results obtained with a microfluidics based ELISA method showed efficient detection of 
three protein markers simultaneously in a single run. The obtained results showed similar 
trend to those obtained with the conventional 96 well microtiter plate suggesting its 
applicability as a validation tool. The following chapters will discuss the development and 
use of microfluidic devices for detection of cancer based on cell surface biomarkers.
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3. ISOLATION AND CHARACTERIZATION OF CANCER CELLS ON 
MICROFLUIDIC DEVICES FUNCTIONALIZED WITH ANTIBODIES
3.1. Introduction
Cancer has been the prime focus of medical and scientific research due to its high incidence 
and its incurability for several decades now. Global cancer statistics showed approximately 
12.7 million cancer cases and 7.6 million cancer related deaths in 2008 with breast cancer as 
a leading cause of mortality in females and lung cancer in males (Jemal et al. 2011). There is 
an immediate need for a point-of-care device that can take advantage of the existing 
candidate markers to develop a quick, simple, easily measureable, robust non-invasive 
diagnostic assay that can ultimately aid in developing personalized treatment strategies 
(Zhang & Nagrath 2013). Microfluidics has increasingly been used for cancer diagnostics 
because of its ability to analyse biomarkers and bio-molecules in complex biological fluids 
such as blood, saliva and urine in vitro using low sample and reagent volumes with integrated 
separation, identification, detection and analysis platforms for the development of sensitive 
non-invasive assays (Sorger 2008). The small-scale design of a microfluidic device similar to 
that of cells and blood vessels helps mimic a tumor microenvironment that can be used for 
studying growth, invasive potential and response to various treatment strategies of cancer 
cells (Ying & Wang 2013).
It has been well established that small number of tumor cells disseminate from tumorous 
tissues and enter the circulating system causing distant metastasis. Ciculating tumor cells 
(CTCs) can be shed as early as during the formation of the primary tumor which then get 
blood-borne and can cause micrometastases that may remain hidden for a very long time or 
even after the thorough surgical removal of the primary tumor (Alix-Panabières & Pantel 
2013). Role of CTCs in disease diagnosis, prognosis, monitoring of the therapeutic efficacy, 
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clinical decision making and for evaluating the metastatic spread of cancer is immense, hence 
attracting tremendous focus in the last decade (Alix-Panabières & Pantel 2014; Gröbe et al.
2014). Detection and enumeration of CTCs from peripheral blood non-invasively referred to 
as “liquid biopsy” for molecular characterization has been the forefront of cancer research in 
the recent years. Role of CTCs as biomarkers has been well elucidated in several cancer types 
including breast cancer (Ramirez et al. 2014), gastric cancer (Galletti et al. 2014), prostate 
cancer (Friedlander et al. 2014), oral cancer (Gröbe et al. 2014), colorectal cancer (Raimondi
et al. 2014), lung cancer (Krebs et al. 2011), ovarian cancer (Poveda et al. 2011) and 
melanomas (Kiyohara et al. 2014),
Several methods have been used for isolation of CTCs and rare cells (around 1 to 100 CTCs 
per ml of blood) based on the physical properties such as shape, size and deformability; 
dielectrophoretic signatures of cell membranes, immunospecific surface markers or magnetic 
nanoparticle based immunoaffinity. The most commonly used platform for isolating CTCs is 
based on antigen-antibody interactions. EpCAM (epithelial cell adhesion molecule) is the 
most frequently used marker for separation of CTCs because of its frequent expression on 
most human carcinomas (Went et al. 2004b). The first and the only CTC capture system to be 
approved by FDA is CellSearch which has been available for clinicians since 2004 (Harris et 
al. 2013). This macroscale system enables immunomagnetic based isolation of CTCs from 
blood samples of metastatic breast, prostate and colon cancer patients by using magnetic 
beads coated with anti-EpCAM antibodies (de Bono et al. 2008; Zborowski & Chalmers 
2011). Other EpCAM based immunomagnetic devices for CTC capture include MagSweeper 
(Talasaz et al. 2009), Cell Enrichment and Extraction (CEE) channel (Nora Dickson et al.
2011).
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Numerous studies across the globe have shown efficient capture of CTCs using anti-EpCAM 
antibodies immobilized on microfluidic devices. The first ‘CTC-Chip’ consisting of several 
micropillars coated with EpCAM antibodies was reported by Nagrath et al. that efficiently 
captured CTCs from unprocessed whole blood samples from metastatic lung, prostate, breast, 
pancreatic and colon cancer, early stage prostate cancer patients.(Nagrath et al. 2007; Stott, 
Lee, et al. 2010) and also from blood samples of non-small-cell lung cancer patients 
(Maheswaran et al. 2008). Other devices using EpCAM dependent cell capture include  the 
herringbone-chip consisting of herringbone pattern based micromixers for capture of prostate 
cancer cells from whole blood samples (Stott, Hsu, et al. 2010), a microfluidics device with a 
series of microchannels to separate breast cancer cells, MCF-7 (Adams et al. 2008) and 
colorectal cancer cells (Dharmasiri et al. 2011) from whole blood samples followed by a 
label free on-chip enumeration of single cells. A new approach for enhanced capture of CTCs 
while minimizing the non-specific binding of leukocytes employed the use of alternating 
dual-protein micro-patterning technique to pattern regions coated with anti-EpCAM and E-
selectin alternatively. This capture method followed by an elution step to remove bound 
leukocytes resulted in increased sensitivity and yields (Launiere et al. 2012). Another dual 
marker based CTC capture was reported by Thege et al. for prostate cancer using antibodies 
against EpCAM and cancer-specific mucin 1 (MUC1) immobilized on a single chip (Thege et 
al. 2014). Microfluidic devices separately modified with EpCAM and CD49f antibodies for 
rare cell capture followed by the ability to culture the captured cells in a bio-similar hydrogel 
to propagate 3-dimensional spheroid colonies that can be used to study treatment responses 
and disease advancement have also been reported (Bichsel et al. 2012).
Microdevices engineered with three dimensional (3D) structures such as an array of silicon 
nanopillars coated with anti-EpCAM antibodies for enhancing the interactions between the 
channel surfaces and the cellular structures for capturing rare cells with increased sensitivity 
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and specificity have also been fabricated. EpCAM expressing breast cancer cell lines, MCF-7
and clinical samples from prostate cancer patients were used to validate the utility of the 
device (Wang, Liu, et al. 2011). An integrated two dimensional approach based on cell size 
and affinity to bound antibodies for CTC capture was developed by Liu et al for the first 
time. To enhance the sensitivity of biomolecules/cell detection various nanomaterials have 
been used. Microchannels arrayed with transparent quartz nanowires immobilized with anti-
EpCAM antibodies, titanium oxide nanofibre substrate modified with anti-EpCAM 
antibodies have been developed that allows capture and subsequent characterization of rare 
cells in situ (Lee et al. 2012; Zhang, Deng, et al. 2012). Yoon et al. recently reported a nano-
graphene oxide based approach for capture, isolation and characterization of rare cells from 
metastatic breast, lung and pancreatic cancer patients with high sensitivity. This study used a 
poly dimethylsiloxane (PDMS) based device having a silicon substrate with patterned gold 
structures (flower shaped) on which graphene oxide sheets-functionalized with EpCAM 
antibodies were adsorbed (Yoon et al. 2013). Use of nano-graphene oxide as a carrier for 
fluorescently tagged antisense oligonucleotides for detection of intracellular survivin mRNA 
levels in each prostate cancer cell captured on a microchannels immobilized with prostate 
stem cell antigen (PSCA) antibodies has also been reported (Li, Shan, et al. 2013).
An ideal CTC capture device would be one that enables efficient capture of rare cells from a 
mixture containing vast background of non-specific cells while maintaining the purity on a 
simple microfluidic device without the need for engineering complex 3-dimensional 
structures with an efficient yet easily reproducible antibody coating method. Such a device 
besides being reasonably easy to fabricate should also allow downstream applicability of the 
captured cells like on-chip protein expression profiling while maintaining the viability of 
captured cells to allow the release and subsequent in vitro culture of these cells to 
characterise the molecular and cellular function of the cells. This would allow researchers to 
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study treatment responses and behaviour under various culture conditions to develop better 
therapeutic strategies.
3.2. Aims
The aim of this study was to compare the efficiency of three microfluidic devices designed 
with simple flat channels and chambers immobilized with anti-EpCAM antibodies to capture 
cancer cells. Furthermore, their ability to perform on-chip characterization of captured cells 
and to assess the capability of these devices to maintain the cells in viable conditions for 
subsequent release and in vitro analysis was determined.
3.3. Materials and Methods
3.3.1. Device fabrication
The microfluidic chips used in this study were comprised of polydimethylsiloxane (PDMS) 
devices reversibly bonded on to microscope glass slides. Fabrication of all PDMS devices 
was performed at Melbourne Centre for Nanofabrication, Melbourne, Victoria. Commercially 
available poly-L-Lysine coated glass slides were used. Standard lithography and DRIE 
etching methods were used for PDMS device fabrication. The detailed protocol for the same 
is given below. 
i. Pre-cleaning:
Silicon wafers (diameter:4 inch; thickness: 500μm) were dipped in piranha solution (30% 
H2O2) for 15 minutes followed by rinsing with deionized water for 10 minutes and blow 
drying with nitrogen.
ii. Lithography:
The silicon wafers were first coated with hexamethyldisilazane (HMDS) to enhance 
photoresist adhesion by spinning at 3000 rpm for 30 seconds and then allowed to rest for a 
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minute at room temperature. This was followed by spin coating with AZ4652 photoresist 
with a 4μm thick layer at 3000 rpm for 30 seconds. The wafers were then soft baked at 100C 
for a minute and then allowed to re-hydrate at room temperature for 15 minutes. They were 
then exposed using a contact mask aligner at 180mJ/cm2, developed in 4:1 (Water:AZ400K) 
developer for one minute and rinsed with deionized water.
iii. Deep reactive-ion etching (DRIE etching)
Pre-cleaning was performed with de-scum in DRIE tool for 10 seconds. Bosch processing to 
etch target depth of 100 μm was the carried out. Visual inspection and depth verification was 
performed via stylus profiler. 
iv. Post-etch clean:
Silicon master wafers were stripped in oxygen plasma and re-cleaned with piranha as above. 
v. PDMS device fabrication:
Master molds were activated with oxygen plasma for 1min at 500mTorr in a Harrick plasma 
unit. Molds were immediately transferred to a vacuum desiccator with 20μl (tridecafluoro-
1,1,2,2-tetrahydrooctyl)-1-trichlorosilane and brought to vacuum (300-500mTorr) for 1hr. 
Silanized molds were then transferred to a casting dish where 10:1 PDMS (Sylgard 184) was 
poured to a depth of approximately 0.75-1cm. Casting tray was degassed for 1hour under 
vacuum before being transferred to a surface levelled oven at 80C for 2hrs. Devices were 
extracted from master mold by manual dicing with a straight edge and scalpel. 
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Figure 3.1. Design and dimensions of the microfluidic devices. 
Chip 1 is a flat-channel device consisting of four parallel 40mm long channels for cell 
capture converging into a single outlet reservoir, whereas chip 2 and 3 consist of four cell 
capture chambers, each leading to a separate outlet reservoir. The four microchannels in chip 
1 were connected at the inlet and the outlet to ensure uniform flow in each channel. All the 
devices used in this study were made of polydimethylsiloxane (PDMS). The inlet and outlet 
holes on the PDMS devices were punched after fabrication. These PDMS devices were 
reversibly bound onto silylated glass slides.
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3.3.2. Surface modification with anti-EpCAM antibodies
The PDMS devices were bonded on to poly-L-lysine slides. The microchannels were first 
flowed with PBS to wet the surfaces for subsequent procedures. The microchannels were then 
modified with antibodies via passive adsorption by flowing anti-EpCAM antibody C-10 (sc-
25308, Santa Cruz biotechnology) solution (50 μg per ml) at a flow rate of 10μl per minute 
by connecting the inlet with a syringe pump. The microchannels were incubated with the 
antibody solution overnight at 4°C in a humidified chamber. The surfaces were rinsed with 
phosphate buffered saline (PBS) twice to remove any unbound antibodies. The washes were 
performed at a flow rate 15μl per minute. To prevent non-specific binding of cells on the 
microchannel surfaces 3% bovine serum albumin (BSA) solution with 0.1% Tween-20 was 
flowed through the channels and incubated at room temperature for 1 hour. The channels 
were finally washed with PBS thrice to remove BSA and traces of Tween-20.
3.3.3. Evaluation of surface roughness with Atomic Force Microscopy (AFM)
An Asylum Research Cypher Atomic Force Microscopy (AFM) was used, in tapping mode, 
to study the surface roughness of the antibody coated slide surfaces. Anti-EpCAM antibody 
coated glass slides were tested for an increase in surface roughness as compared to that of 
non-coated slides to evaluate the efficiency of antibody coating. Comparison of surface
roughness was performed with AFM. Argyle Light, Asylum Research, Santa Barbara, CA, 
was used for data analysis.
3.3.4. Cell culture and culture conditions
The cell lines used in this study namely human colon adenocarcinoma cells (Caco-2), human 
hepatocellular carcinoma cells (HepG2), human mammary adenocarcinoma cells (MCF7), 
human prostate carcinoma cells (DU145), human intestinal epithelial cells (FHs 74 Int), and 
human prostate epithelial cells (RWPE-1) were obtained from American type culture 
collection (ATCC), Manassas, VA, USA. Eagle’s Minimum Essential Medium (EMEM) used 
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for the culture of Caco-2, MCF7, HepG2 and DU145; Hybri-Care medium for FHs 74 Int 
cells and Keratinocyte Serum Free Medium supplemented with epidermal growth factor for 
RWPE-1 cells was obtained from Gibco, Australia. The media for the other cell lines was 
supplemented with 10% fetal bovine serum purchased from Bovogen, Australia, and 
antimycotic-antibiotic or penicillin/streptomycin purchased from Gibco, Australia. Human 
cardiomyocytes grown in Celprogen cell culture complete medium with serum were obtained 
from Celprogen, California, USA. The cells were cultured at 37°C with 5% CO2. Media 
changes were done every 3 days and the cells were subcultured with 0.25% trypsin/EDTA 
(obtained from Gibco, Australia) upon reaching a confluency of 80-90%. 
3.3.5. Cell capture assays
Immediately before performing the cell capture experiments, the cells were trypsinized and 
resuspended in fresh serum free media. Cell viability was evaluated prior to running the 
experiment with trypan blue exclusion assay. The cells were mixed with an equal volume of 
trypan blue stain and counted on haemocytometer for evaluating cell viability. Cell 
suspensions showing >95% cell viability were used for subsequent analysis. The cells were 
diluted to the required concentration in serum free media before introducing into the 
microfluidic devices. Serum free media spiked with cancer cells at concentrations ranging 
from 103 to 107cells per ml were flowed through the anti-EpCAM antibody modified 
microchannels at a flow rate of 15μl per minute to evaluate capture efficiency based on cell 
concentrations and device design. The cell suspensions were introduced into the devices 
using a syringe pump (PHD Ultra 4400 series, Harvard apparatus) connected at the inlet of 
the devices with a 1 ml syringe via polymer tubing. This was followed with washes with PBS 
to remove any unbound cells. The total number of cells captured in the microchannels and the 
total number of unbound cells collected at the outlet reservoirs were counted at the end of 
each run to determine the capture yield. Cells captured on Chip 2 and 3 were stained with 
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4,6-diamidino-2-phenylindole (DAPI) (nuclear staining) after unmounting the PDMS device 
from the glass slide for cell counting using confocal microscopy whereas the total number of 
cells captured on Chip 1 was determined by counting the number of unbound cells collected 
at the outlet reservoirs.   
3.3.6. Cell staining with methylene blue
Cells were stained with 1% methylene blue solution to enable real time evaluation of capture 
specificity. Freshly trypsinized cells were incubated for 15 minutes at 37°C in 1% methylene 
blue solution prepared in serum free media. The stained cells were pelleted by centrifugation 
at 1500rpm for 5 minutes. The pellet was rinsed in PBS thrice before resuspending in serum 
free media. Methylene blue stained cells were then mixed with unstained cancer cells at 
predetermined concentrations to evaluate capture specificity in real time. The cell mixture 
containing target cells (unstained cancer cells) and control cells (stained non-cancerous cells) 
were flowed through the devices at flow rates ranging from 5 to 30μl per minute to determine 
the optimal flow conditions for obtaining high capture efficiency with a high capture purity.
3.3.7. Propidium iodide staining
Freshly trypsinized cells were stained with 1% methylene blue. Propidium iodide (PI) 
staining was performed to evaluate if methylene blue staining caused cell death. Cell 
suspension containing 1X104 cells per ml in PBS were mixed with 1mg per ml PI and 
incubated at 4°C for 30 minutes. The cells were then analysed using Flow cytometry (BD 
FACSDiva software).
3.3.8. Cell recovery and viability post-capture
All experiments were performed using freshly trypsinized cells with >95% cell viability 
(using trypan blue exclusion assay). After the cell suspensions were flowed through the 
microfluidic devices the captured cells were released using 0.25% trypsin-EDTA at 37°C 
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flowed at 20μl per minute and collected at the outlet reservoirs. The released cells were 
stained with trypan blue and counted on haemocytometer to determine cell viability. 
3.3.9. On-chip characterization for stem cell markers
After performing the cell capture experiments followed by washing with PBS to remove 
unbound cells, the captured cells were analysed for stem cell marker expression using 
immunofluorescence. This involved fixing the captured cells with 4% paraformaldehyde 
solution (PF) for 20 minutes at room temperature. The channels were then washed with PBS 
thrice followed by cell permeabilization with 0.1% Triton X-100 for 5 minutes. Washes with 
PBS were done to remove any traces of Triton X-100. Blocking solution composed of 3% 
BSA was then introduced and incubated for 30 minutes at 37°C to minimise non-specific 
binding of antibodies. The channels were washed with PBS. The PDMS device was then 
carefully dismounted from the glass slide to allow staining of cells captured in each capture 
chamber (of chip 2 and 3) with a specific antibody. The cells were incubated with the primary 
antibodies (against survivin, CD133 and EpCAM) for 1 hour at 37°C. The cells were then 
washed gently with PBS followed by incubation with the appropriate secondary antibody for 
1 hour. The cells were washed again with PBS before adding the mounting media containing 
DAPI followed by sealing with a cover slip. Immunofluorescence was analysed using Leica 
SP5 confocal microscope. The details of the primary antibodies and secondary antibodies 
used are enlisted below.
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Table 3.1. List of primary and secondary antibodies used for confocal microscopy
Marker Primary Antibody Secondary Antibody
Survivin  Dilution used: 1:1000
 Species origin: Mouse monoclonal
 Antigen origin: Human
Anti-mouse IgG-FITC
 Diluton: 1:200
CD133  Dilution used: 1:100
 Species origin: Goat polyclonal
 Antigen origin: Human
Anti-goat IgG-FITC
 Diluton: 1:200
EpCAM  Dilution used: 1:100
 Species origin: Mouse monoclonal
 Antigen origin: Human
 Fluorescein (FITC) conjugated
-
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3.3.10. Sorting of cancer cells based on cancer stem cell marker expression
Freshly trypsinized cancer cells were flowed through sorting columns contained magnetic 
beads specific to CD133, CD44 and EpCAM. These columns were obtained from MACS 
Miltenyl Biotec, Australia. Magnetic separation on the MACS column was performed using 
anti-biotin magnetic beads to separate cells labelled with biotin-conjugated antibodies against 
the above mentioned markers. The sorted cells were cultured for 24 hours before performing 
cell capture experiments.  
3.4. Results
3.4.1. Successful immobilization of anti-EpCAM antibodies on poly-L-Lysine glass 
slides
Freshly coated poly-L-lysine slides with 50 μg per ml anti-EpCAM antibody solution were 
analysed for surface roughness in comparison with uncoated slides. AFM results showed a 
>10 fold increase in surface roughness upon antibody binding. This can be attributed to the 
larger size of the antibodies. These results demonstrate the successful immobilization of 
antibodies on poly-L-Lysine glass slides that can further be used for capture of specific cell 
types.  
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Figure 3.2. Surface roughness analysis using Atomic force microscopy (AFM).
Representative images showing increase in surface roughness upon antibody immobilization..
Image shows the surface roughness of a poly-L-lysine slide (left) and anti-EpCAM antibody 
coated (right) slide. The experiment was repeated twice.
Non-coated Anti-EpCAM antibody coated
Roughness = 0.415 nm Roughness = 11.47 nm
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3.4.2. Efficient capture of cancer cells on antibody immobilized surfaces
Capture efficiency studies for the three microfluidic devices functionalized with anti-EpCAM 
antibodies were performed using a human colorectal adenocarcinoma cell line (Caco-2) and a 
human hepatocellular carcinoma cell line (HepG2) both of which are high EpCAM 
expressing cells. Serum free media spiked with cancer cells at concentrations ranging from 
103 to 107cells per ml were flowed through the chip devices at a flow rate of 15μl per minute 
to identify the cell concentration at which there is highest capture yield (which varies based 
on the chip design) that can be used in subsequent studies. The total number of cells captured 
in the microchannels and the total number of unbound cells collected at the outlet reservoirs 
were counted at the end of each run to determine the capture yield. Cells captured on Chip 2 
and 3 were stained with DAPI (nuclear staining) after unmounting the PDMS device from the 
glass slide for cell counting whereas the total number of cells captured on Chip 1 was 
determined by counting the total number of unbound cells.  Chip 1 owing to the increased 
surface area of its microchannels showed efficient capture of cells (>95%) at all cell 
concentrations for both cell lines, whereas Chips 2 and 3 showed relatively improved capture 
efficiency at a concentration of 103cells per ml (>50% for HepG2 cells and >40% for Caco-2
cells). Hence for all subsequent studies with Chip 1, cells at a concentration of 105cells per ml
were used and for Chip 2 and 3 cells suspensions with 103 cells per ml were used. A higher 
concentration of cells (105cells per ml) were used for studies with Chip 1 to allow better 
availability of cells for further on-chip studies of captured cells that would not have been 
possible with fewer cells spread over  the large surface area.
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Figure 3.3. Capture efficiency for Caco-2 cells at varying concentrations on chip 1 
functionalized with anti-EpCAM antibodies.
Representative bright field images of Caco-2 cells captured on chip 1 flowed at 
concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v respectively). Images for 
each run were taken at the same area of the device. The experiments were repeated thrice. 
i
viv
iiiii
                                                                                                                                                 Chapter 3
141 
 
Figure 3.4. Capture efficiency for Caco-2 cells at varying concentrations on chip 2 
functionalized with anti-EpCAM antibodies. 
Representative confocal microscopy images of Caco-2 cells (stained with DAPI) captured on 
chip 2 flowed at concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v 
respectively). Images are representative of the total number of cells captured in each capture 
chamber. The experiments were repeated thrice.
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Figure 3.5. Capture efficiency for Caco-2 cells at varying concentrations on chip 3 
functionalized with anti-EpCAM antibodies. 
Representative confocal microscopy images of Caco-2 cells (stained with DAPI) captured on 
chip 3 flowed at concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v 
respectively). Images are representative of the total number of cells captured in each capture 
chamber. The experiments were repeated thrice.
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Figure 3.6. Capture efficiency at varying cell concentrations of Caco-2 cells on anti-
EpCAM antibody immobilized surfaces. 
Comparison of capture efficiencies at varying concentrations of Caco-2 cells spiked in serum 
free media. Capture efficiency for chip 1 was determined based on the total number of 
unbound cells collected at the outlet. ImageJ software was used to calculate the total number 
of cells captured on chip 2 and 3. Error bars represent the standard deviation obtained from 
three repeats.
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Figure 3.7. Capture efficiency for HepG2 cells at varying concentrations on chip 1 
functionalized with anti-EpCAM antibodies. 
Representative bright field images of HepG2 cells captured on chip 1 flowed at 
concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v respectively). Images for 
each run were taken at the same area of the device. The experiments were repeated thrice.
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Figure 3.8. Capture efficiency for HepG2 cells at varying concentrations on chip 2 
functionalized with anti-EpCAM antibodies. 
Representative confocal microscopy images of HepG2 cells (stained with DAPI) captured on 
chip 2 flowed at concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v 
respectively). Images are representative of the total number of cells captured in each capture 
chamber. The experiments were repeated thrice.
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Figure 3.9. Capture efficiency for HepG2 cells at varying concentrations on chip 3 
functionalized with anti-EpCAM antibodies. 
Representative confocal microscopy images of HepG2 cells (stained with DAPI) captured on 
chip 3 flowed at concentrations 107, 106, 105, 104 and 103 cells per ml (images i to v 
respectively). Images are representative of the total number of cells captured in each capture 
chamber. The experiments were repeated thrice.
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Figure 3.10. Capture efficiency at varying cell concentrations of HepG2 cells on anti-
EpCAM antibody immobilized surfaces.
Comparison of capture efficiencies at varying concentrations of HepG2 cells spiked in serum 
free media. Capture efficiency for chip 1 was determined based on the total number of 
unbound cells collected at the outlet. ImageJ software was used to calculate the total number 
of cells captured on chip 2 and 3. Error bars represent the standard deviation obtained from 
three repeats.
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3.4.3. High capture sensitivity on anti-EpCAM antibody coated surfaces of chip 1
To further evaluate the capture yield of the three microfluidic devices at low cell 
concentrations, the media was spiked with Caco-2 and HepG2 cells at concentrations of 10, 
50 and 100 cells per ml. Capture yield was determined at flow rates of 15μl per minute by 
counting total number of bound and unbound cells. Chip 1 showed similar capture 
efficiencies for both cell lines at 100 and 50 cells per ml (>95%), whereas HepG2 cells at a 
concentration of 10 cells per ml showed relatively enhanced efficiency of 90% compared to 
the 70% capture efficiency of Caco-2 cells at the same concentration. Chip 2 and 3 on the 
other hand showed reduced efficiency in capturing cells because of the reduced size of the 
antibody functionalized area. Both Chip 2 and 3 showed better capture of HepG2 cells in 
comparison to Caco-2 cells at all cell concentrations suggesting higher EpCAM expression 
levels in HepG2 cells in contrast to Caco-2 cells.  
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Figure 3.11. Evaluation of cell recovery for cancer cells spiked into serum free media at 
low concentrations. 
Comparative analysis of capture sensitivity on anti-EpCAM antibody functionalized surfaces 
of chip 1, 2 and 3 with Caco-2 (A) and HepG2 (B) cells. Capture efficiency for chip 1 was 
determined based on the total number of unbound cells collected at the outlet. ImageJ 
software was used to calculate the total number of cells captured on chip 2 and 3. Error bars 
represent the standard deviation obtained from three repeats.
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3.4.4. Enhanced capture specificity (purity) and sensitivity (efficiency) at a flow rate of 
10 μl per minute
To further evaluate the efficiency in capturing target cells (with high EpCAM expression) 
from a mixture containing both target and control cells (low or no EpCAM expression), cell 
suspensions were prepared in serum free media containing equal concentrations of target 
Caco-2 cells and control FHs 74 Int cells (human intestinal epithelial cells). The FHs 74 Int 
cells were pre-stained with 1% methylene blue before mixing with un-stained Caco-2 cells to 
visualize capture purity and sensitivity on-chip in real time. To evaluate the effects of flow 
rate in yielding improved capture efficiency while maintaining the capture purity the cell 
suspension was flowed through the microfluidic devices at a flow rates ranging from 5μl per 
minute to 30μl per minute. To investigate the specificity of Caco-2 cell capture on antibody 
functionalized surfaces, the cell suspension was also flowed through capture 
chambers/channels without the anti-EpCAM antibody modification. Significant differences 
could be seen in cell capture between the antibody coated and non-coated chambers/channels, 
as cell capture was visually apparent in antibody coated slides whereas there was negligible 
amount of cell capture in the uncoated slides. 
It was evident from the results that the capture purity increased with higher flow rates as there 
was little contact time between cells and slide surfaces to allow non-specific binding of cells, 
however the capture efficiency was greatly reduced at higher flow rates as a result of 
decreased interaction of target cell surface markers with the immobilized antibodies. 
Similarly, increased capture efficiency with higher non-specific binding of control cells was 
seen at lower flow rates. It was seen that capture sensitivity and specificity was ideal at a flow 
rate of 10μl per minute for all chip devices. Chip 1 showed a capture efficiency of 96% while 
maintaining the purity of captured cells at >85%, while both Chip 2 and 3 showed a capture 
efficiency of 75% at the flow rate of 10μl per minute. Chip 2 however, showed a better purity 
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percentage at the same flow rate as compared to chip 3. Therefore a flow rate of 10μl per 
minute for all the chip devices was used for the subsequent studies. 
To further validate the sensitivity of this method to capture target cells at increasing 
concentrations of control cells, cell suspensions were prepared in serum free media 
containing a constant number of Caco-2 cells and increasing concentrations of methylene 
blue stained FHs 74 Int cells flowed at 10μl per minute. Chip 1 showed 80% capture purity 
with a cell suspension containing 10x FHs 74 Int cells to that of Caco-2 and a purity of 74% 
at 100x FHs 74 Int cell concentrations. Chip 2 and 3 showed a capture purity of >70% at 10x 
concentration of FHs 74 Int cells where as a reduced capture purity (between 55-60%) was 
seen with cell mixtures containing 100x concentration of FHs 74 Int cells compared to that of 
Caco-2 cells. Between chip 2 and 3, it was seen that capture efficiency and purity percentages 
of chip 2 was relatively higher compared to that of chip 3. These results demonstrate the 
ability of chip 1 to sensitively detect small number of target cells from a vast background of 
non-specific bystander cells. 
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Figure 3.12. Cell capture specificity in anti-EpCAM antibody coated micro-chambers. 
Representative confocal microscopy images of Caco-2 cells captured on anti-EpCAM 
antibodies coated chambers (above) and non-coated chambers (below) of Chips 1 and 2,
stained with DAPI (blue) and FITC-labelled anti-EpCAM antibodies (green). All the captured 
cells in the antibody coated chambers showed expression of EpCAM (green) while the non-
coated chambers had little or no captured cells suggesting the specificity of the capture 
method used. The experiments were repeated thrice.
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Figure 3.13. Evaluation of capture purity and efficiency on Chip 1. 
Figures (i) to (iv) are representative bright field images of the cell capture efficiency of Caco-
2 cells alone at a concentration of 105 cells per ml at flow rates 5, 10, 20 and 30 μl per minute 
respectively. Figures (v) to (viii) are representative bright field images of Caco-2 cell 
(unstained) captured from a mixture containing Caco-2 (105 cells per ml) and FHs 74 Int 
(blue) cells (105 cells per ml) at flow rates 5, 10, 20 and 30 μl per minute respectively. Image 
(ix) is representative of unbound FHs 74 Int cells collected at the outlet reservoir while 
performing the flow studies at 10 μl per minute. Image (x) represents FHs 74 Int cells stained 
with 1% methylene blue before mixing with Caco-2 cells. The histogram represents the 
capture purity and efficiency at four different flow rates. Error bars represent the standard 
deviation obtained from three repeats.
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Figure 3.14. Evaluation of capture purity and efficiency on Chip 2. 
Figures (i) to (iv) are representative bright field images of Caco-2 cells (unstained) captured 
from a mixture containing Caco-2 (105 cells per ml) and FHs 74 Int (blue) cells (105 cells per 
ml) at flow rates 5, 10, 20 and 30 μl per minute respectively. Image (v) represents FHs 74 Int 
cells stained with 1% methylene blue before mixing with Caco-2 cells. Image (vi) is 
representative of unbound FHs 74 Int cells collected at the outlet reservoir while performing 
the flow studies at 10 μl per minute. The histogram represents the capture purity and 
efficiency at four different flow rates. Error bars represent the standard deviation obtained 
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from three repeats.
Figure 3.15. Evaluation of capture purity and efficiency on Chip 3. 
Figures (i) to (iv) are representative bright field images of Caco-2 cells (unstained) captured 
from a mixture containing Caco-2 (105 cells per ml) and FHs 74 Int (blue) cells (105 cells per 
ml) at flow rates 5, 10, 20 and 30 μl per minute respectively. Image (v) represents FHs 74 Int 
cells stained with 1% methylene blue before mixing with Caco-2 cells. Image (vi) is 
representative of unbound FHs 74 Int cells collected at the outlet reservoir while performing 
the flow studies at 10 μl per minute. The histogram represents the capture purity and 
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efficiency at four different flow rates. Error bars represent the standard deviation obtained 
from three repeats.
Figure 3.16. Comparative representation of capture efficiency and purity percentages at 
different flow rates. 
Capture purity (A) is calculated as the ratio of the number of Caco-2 cells captured and the 
total number of cells captured. Error bars represent standard deviation obtained from three 
replicates. Capture efficiency (B) is the ratio of total number of target cells captured and the 
total number of target cells pumped into the device. Error bars represent standard deviation
obtained from three repeats.
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Figure 3.17. Evaluation of capture sensitivity of Caco-2 cells at increasing 
concentrations of FHs 74 Int cells. 
Cell concentrations: 1= 1x105 cells per ml. The cell suspensions were flowed through the 
microfluidic devices at a flow rate of 10 μl per minute. The error bars represent standard 
deviation obtained from three repeats.
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3.4.5. Methylene blue staining does not affect cell viability
To determine if methylene blue staining of FHs 74 Int cells resulted in cell death, methylene 
blue stained cells were treated with propidium iodide (PI) followed by flow cytometry. 
Unstained FHs 74 Int cells were used as control.  It was seen that the cell viability of 
methylene blue stained FHs 74 Int cells was almost similar to that of unstained cells and there 
was no significant difference in the number of dead cells pre and post methylene blue 
staining. This suggests that methylene blue staining can be used for labelling cells for real 
time estimation of capture purity. 
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Figure 3.18. Effect of methylene blue staining on cell viability.
Propidium iodide (PI) staining followed by flow cytometry was used to confirm non-toxic
effects of methylene blue staining on FHs 74 Int cells (A). The histogram (B) represents 
percentage cell viability of methylene blue stained and unstained FHs 74 Int cells. The error 
bars represent standard deviation obtained from the experiment repeated twice.
B
A
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3.4.6. Successful recovery of captured cells with high cell viability 
All experiments were performed using freshly trypsinized cells with >95% cell viability 
(using trypan blue exclusion assay). After the cell suspensions were flowed through the 
microfluidic devices the captured cells were released using 0.25% trypsin-EDTA at 37°C
flowed at 20μl per minute and collected at the outlet reservoirs. To be able to culture these 
cells it is necessary that the cells be viable post capture. To this end the released cells were 
stained with trypan blue and counted on haemocytometer to determine cell viability. It was 
seen that the cell viability remained >90% at all the flow rates run on Chip 1, whereas the 
cells showed a slight decrease in cell viability at higher flow rates run on Chip 2 and 3 
although still above 85%.  These results suggested that the cells can be collected for further in 
vitro culture and analysis. The released cells were collected at the outlet reservoirs 
centrifuged at 1200 rpm for 5 minutes, resuspended in fresh media containing 10% foetal 
bovine serum and plated in 96 well plates for in vitro cell culture.  
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Figure 3.19. Evaluation of cell viability post capture at various flow rates. 
Caco-2 and HepG2 cells captured on-chip after flowing cell mixture containing equal 
concentration of methylene blue stained FHs 74 Int cells (105 cells per ml for chip 1; 103 cells 
per ml for chip 2 and 3) at various flow rates were released using trypsin to determine their 
viability for subsequent cell culture. Cell viability was determined using trypan blue 
exclusion assay. Images A,B and C represent cell viability with chip 1, 2 and 3 respectively. 
The error bars represent standard deviation obtained from three repeats.
A
B
C
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3.4.7. Successful on-chip characterization of captured cells for stem cell markers
The design of chip 2 and 3 allows the characterization of captured cells for presence of 
different markers in each capture chamber using very low reagents and antibodies. Once the 
cells are captured on-chip, the PDMS device can easily be dismounted to perform 
immunostaining for various markers. Chip 2 and 3 were used to detect the presence of stem 
cell markers namely CD133 and survivin on the captured EpCAM+ Caco-2 cells. The cells 
captured in the first chamber were stained for cell surface CD133 and intracellular survivin 
expression. The cells captured in the second chamber were stained for CD44 expression 
alone; whereas the cells captured in the third chamber were used as a positive control for 
EpCAM expression and the last chamber was a negative control without the antibody coating.
It was seen that the captured EpCAM+ cells showed high expression of CD133 and survivin.
All the captured cells showed expression of EpCAM suggesting the efficiency of capture 
while the non-antibody coated chamber showed capture of negligible number of cells
signifying the specificity of capture. These results suggest that rare cells captured from a 
single sample can be used for the analysis of at least four different markers on chip 2 and 3 
with very low reagent consumption.
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Figure 3.20. Schematic representation of Chip 2 and 3 used for characterizing the 
captured cells. 
This illustration represents the use of cells captured in each capture chamber for expression 
analysis of different stem cell markers.
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Figure 3.21. On-chip characterization of EpCAM+ Caco-2 cells for CD133, CD44 and 
survivin expression. 
Representative confocal microscopy images of Caco-2 cells stained with DAPI (blue), 
TRITC (red) for survivin and FITC (green) for CD133 and CD44 expression analysis in each 
of the four capture chambers of chip 2. The error bars in the histogram represent standard 
deviation obtained from cells counted at five different areas of the chamber.
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3.4.8. Efficient cell capture based on EpCAM expression in various cell lines
To determine the EpCAM expression levels in different cancer cell lines, Chip 1 
functionalized with anti-EpCAM antibodies was used to flow through cancer cells mixed 
with equal proportions of methylene blue stained non-cancerous cells. EpCAM expression 
levels were determined in (i) human prostate cancer cell line (DU145) mixed with human 
prostate epithelial cells (RWPE-1); (ii) human breast cancer cell line (MCF-7) mixed with 
human cardiomyocytes (HCM); (iii) HepG2 cells mixed with FHs 74 Int cells; (iv) Caco-2
cells mixed with FHs74 Int cells. Capture efficiency varied with each cell line based on 
surface EpCAM expression on these cell lines. The normal cells were pre-stained with 1% 
methylene blue before mixing with un-stained Caco-2 cells to visualize non-specific on-chip 
capture of cells in real time. It was seen that DU145 and Hep-G2 cells showed higher. 
Furthermore, the capture purity was highest with MCF-7 cells mixed with human 
cardiomyocytes as the latter has very low EpCAM expression
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Figure 3.22. Cancer cell capture based on EpCAM expression in various cell lines. 
Representative bright field images of the various cancer cell lines captured on anti-EpCAM 
antibody coated surfaces of chip 1. Cancer cells (105 cells per ml) were mixed with equal 
proportions of methylene blue stained normal cells. Percentage EpCAM expression, capture 
purity and capture efficiency was determined for each of the cell mixtures.
Cell lines % Cells expressing EpCAM Efficiency % Purity %
Cancer cells Normal cells
Caco-2 : FHs 74 Int 95 11 95 89
DU145 : RWPE-1 99 13 99 87
MCF-7 : HCM 96.5 3 96.5 97
HepG2 : FHs 74 Int 97 9 97 91
Caco-2 DU145 MCF-7 HepG2
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Figure 3.23. Evaluation of specificity of cell capture.
Confocal images of cancer cells stained with DAPI (blue) and FITC labelled anti-EpCAM 
antibodies for determining specificity of cell capture. EpCAM expression levels in each of 
the four cancer cell lines were deduced based on the capture efficiency percentages obtained.
The error bars represent the standard deviation obtained from two repeats.
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3.4.9. Efficient capture of cancer stem cells on antibody modified surfaces
Cancer cells showing stem cell like properties were also flowed through antibody modified 
surfaces of chip 1 to evaluate the capture efficiency. Cancer cells (DU145, MCF-7, Caco-2) 
were first immuno-magnetically sorted based on cell surface stem cell marker (EpCAM, 
CD44 and CD133) expression. These cancer stem cells were mixed with equal proportions of 
1% methylene blue stained normal cells (RWPE-1 and FHs74 Int cells) before introducing 
into antibody coated chip 1.  Greater than 97% cell capture was seen with cancer stem cells 
on anti-EpCAM antibody modified devices. However, the capture purity fell as all epithelial 
cells express EpCAM on their cell surface, which resulted in capture of a few FHs 74 Int and 
RWPE-1 cells. The isolation and characterization of rarely occurring CTCs showing stemness 
is of enormous benefit to understand various processes such as drug resistance, metastasis 
and tumor recurrence. 
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Figure 3.24. Antibody enabled capture of cancer stem cells on chip 1.  
Cancer stem cells (105 cells per ml) mixed in equal proportion with methylene blue stained 
normal cells were flowed through anti-EpCAM antibody functionalized microchannels of 
chip 1. Percentage EpCAM expression in various cancer stem cells as well as normal cells 
was estimated based on capture efficiency. Capture purity was deduced based on the total 
number of methylene blue stained normal cells captured on chip. Error bars represent 
standard deviation obtained from two repeats.
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3.5. Discussion
A vast majority of cancer associated deaths occur due to the development of metastasis at a 
secondary site due to disseminated tumor cells from the primary site that gain access to the 
vascular system. The unavailability of readily obtainable tumor tissue/biopsy samples from 
cancer patients throughout the course of the disease progression limits the understanding of 
the molecular pathways involved in the progression of localized tumor to distant metastasis. 
CTCs have gained importance in the recent years and have been referred to as “liquid biopsy” 
for their capture and identification holds immense potential in understanding the metastatic 
process using less invasive methods and for developing relevant therapeutic strategies 
ultimately aiding in personalized medical treatments (Maheswaran & Haber 2010; Yu, Stott,
et al. 2011). Till date several assays have been reported for capture of CTCs from metastatic 
cancer patients, although only one of them namely CellSearch technology which depends on 
EpCAM based approach for CTC capture has been approved by FDA (Harris et al. 2013). In 
the recent years microfluidics has been extensively used for cancer diagnostics especially for 
CTC capture.
This study focuses on comparing the efficiency of three microfluidic devices to 
effectively capture rare cells from a cell mixture that can ultimately be used as a diagnostic 
tool for separating circulating tumor cells (CTCs) from blood samples of cancer patients. This 
study was primarily targeted to achieve the following goals, (i) to develop a simple 
microfluidic device to efficiently capture rare cells without the need to engineer complex 
microstructures; (ii) to optimize fluidic conditions for capturing cells with high purity and 
efficiency; (iii) on-chip characterisation of captured cells for protein expression to obtain 
better clinical information about disease progression and outcome and also to isolate cancer 
cells expressing stem cell markers; (iv) to recover viable captured cells for further in vitro 
culture and characterization.  
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The microfluidic devices used in this study consisted of microchannels branching out from a 
single inlet into four capture microchannels (Chip 1) or capture microchambers (Chip 2 and 
3) that ultimately converged into a single outlet reservoir (Chip 1) or independently led to 
separate outlets (Chip 2 and 3). The efficiency of these chips was evaluated without the need 
for engineering complex 3-dimensional structures within the channels for improving 
interaction between cells under flow conditions and modified channel surfaces. Several 
groups across the globe have reported CTC capture devices engineered with micropillars 
coated with antibodies (Nagrath et al. 2007; Stott, Lee, et al. 2010), herringbone structures 
that create micro-vortexing within the channels (Stott, Hsu, et al. 2010), silicon nanopillars 
coated with antibodies (Wang, Wang, et al. 2009), deterministic lateral displacement arrays 
(Liu, Zhang, et al. 2013), microchannels arrayed with nanowires functionalized with 
antibodies (Lee et al. 2012), silicon substrates with patterned gold structures immobilized 
with nano graphene oxide sheets modified with antibodies (Yoon et al. 2013). These 
microstructures limit the downstream applicability of the captured cells for culture and 
analysis and also hinder imaging process. 
This study employed the used of microfluidic devices with simple designs and easily 
achievable, highly reproducible anti-EpCAM antibody modification on bio-adhesive poly-L-
lysine coated glass slides. The PDMS devices were not bound permanently on the glass slides 
enabling their reuse on fresh antibody coated slides after each run. Capturing rare cells or 
CTCs by targeting cell surface EpCAM expression is one of the most commonly reported 
method because of its frequent expression in most human carcinomas (Went et al. 2004b).
Although there have been reports suggesting the down-regulation of EpCAM during 
epithelial to mesenchymal transition of the tumor cells that have entered the vascular system 
(Gorges et al. 2012; Raimondi et al. 2011) leading to reduced effectiveness of EpCAM 
targeted capture of CTCs, EpCAM is still one of the  most commonly used markers for 
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capturing CTCs even from early stage cancers with high efficiency (Thege et al. 2014; Yoon
et al. 2013). EpCAM has been used independently as well as in combination with other 
known markers such as mucin 1, CD49f and E-selectin for efficient capture of cells on 
microfluidic devices with or without microstructures (Bichsel et al. 2012; Launiere et al.
2012; Thege et al. 2014).
Efficiency of capture in each of these anti EpCAM antibody functionalized devices was first 
determined using human colon cancer cells (Caco-2) and human liver cancer cells (HepG2) 
spiked in serum free media at concentrations ranging from 103 to 107 cells per ml at flow 
rates of 15μl per minute under continuous flow conditions without any disturbances. 
Percentage of capture efficiency was determined based on the total number of unbound cells 
collected at the outlet reservoirs. Chip 1 showed high efficiency in cell capture of both cell 
lines at all cell concentration owing to the availability of long channels (40mm long and 1mm 
wide) coated with antibodies. The capture efficiency for Chip 2 and 3 was comparatively less 
which can be attributed to the small available size of the capture chambers. Among Chip 2 
and 3, Chip2 showed better capture efficiency for both Caco-2 and HepG2 cells suggesting 
that the elliptical shape of the capture chambers in Chip 2 allows a more enhanced 
streamlined flow within the capture chambers thereby reducing any undesirable change in 
direction of fluid flow that would in turn affect the interactions of cells with the chamber 
surfaces when compared to the circular chambers of the Chip 3. For all subsequent 
experiments a cell concentration of 105 cells per ml for Chip 1 and a concentration of 103
cells per ml for Chip 2 and 3 were used. Although it can be seen from the results that Chip 1 
showed highest capture efficiency at the cell concentration of 103 cells per ml, a slightly 
higher number of cells (105 cells per ml) was chosen for subsequent experiments to enhance 
the availability of cells spread over the large area of the microchannels for better imaging and 
visualization. It was seen in all chips that the capture efficiency of HepG2 was relatively 
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higher than that of Caco-2, suggesting a higher level of EpCAM expression in HepG2 cells. 
To further investigate the sensitivity of these devices in capturing cells at low concentrations, 
serum free media was spiked with Caco-2 and HepG2 cells at a concentration of 10, 50 and 
100 cells per ml were flowed through the devices at 15μl per minute under continuous flow 
conditions.  It was evident from the results that Chip 1 was definitely showing high 
sensitivity of cell capture even at cell concentration as low as 10 cells per ml. Approximately 
7 Caco-2 cells and 9 HepG2 cells were captured out of 10 cells flowed through Chip 1. 
Capture efficiency for both cell lines at concentrations 50 and 100 cells per ml was greater 
than 95%. Capture sensitivities for both cell lines was almost similar for both Chip 2 and 3. 
These results suggest that this method of cell capture in combination with the given 
microfluidic device designs can be a used as a simple yet beneficial tool for capture and 
identification of rare cells without the need for manufacturing complex 3 dimensional 
structures in the chip. 
The rarity of occurrence (approximately 1-100 CTCs per ml of blood), the high levels of 
heterogeneity of CTCs and the presence of a vast background of blood cells are some of the 
major challenges in developing a CTC based cancer detection assay with the limited available 
sample. (Li, Stratton, et al. 2013; Lianidou, Strati & Markou 2014). An ideal CTC 
enumeration system should allow rapid capture and isolation of CTCs besides having high 
capture efficiency (capturing all the CTCs from the available sample volume) and high 
capture purity (capturing only CTCs) while maintaining cell viability. To achieve this it is 
important to have a microfluidic system with optimized flow conditions that enables highly 
specific and efficient capture of target cells from a mixture containing non-specific cells. To 
this end a cell suspension containing human colon cancer cells and normal epithelial cells 
(Caco-2 and FHs 74Int) in equal proportions was prepared and flowed through the three 
microfluidic devices at flow rates ranging from 5 to 30μl/min. High flow rates enhance 
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capture purity and lower flow rates enhance capture efficiency, optimizing shear stress by 
varying the flow rates in the microchannels is necessary to have good capture efficiency
while maintaining the purity of the cells captured. Several fluorescent dyes (such as Vybrant 
DiI, Vybrant DiD, cell tracker)  have been used to label cells before mixing with other cell 
population for flowing through microfluidic devices that can later be imaged under a 
fluorescence microscope for evaluating capture yield and purity (Sheng et al. 2012; Sheng et 
al. 2013; Yoon et al. 2013). It is however more beneficial to be able to stain cells that can be
monitored in real time. For this purpose FHs 74 Int cells were stained with 1% Methylene 
blue prepared in serum free media to allow real time analysis of cells captured. Propidium 
iodide staining followed by flow cytometry of methylene blue stained cells was performed to 
evaluate if methylene blue causes cell death, which showed no significant fall in cell viability 
of methylene blue labelled FHs 74 Int cells as compared to unstained cells. Hence methylene 
blue staining was adopted for all subsequent experiments for visualizing the effectiveness of 
cell capture in real time using bright field microscopy. To evaluate the capture efficiency and 
purity in real time the control cells (FHs 74 Int) were pre-stained with 1% methylene blue 
before being mixed with unstained target (Caco-2) cells. The results showed that a flow rate 
of 10μl per minute was ideal for a high efficient cell capture while maintaining the purity of 
captured cells by minimizing non-specific cell binding. It was seen that at a flow rate of 10μl
per minute Chip 1 gave a capture yield of 96% while retaining the purity with >88%. Higher 
flow rates although increased capture purity as non-specifically adsorbed cells are easily 
washed away, it greatly minimized capture efficiency because of the reduced interaction time 
of the target cells with the antibody modified surfaces. A capture yield of 75% was seen in 
Chip 2 and 3 at a flow rate 10μl per minute with a purity percentage of 83 and 78 
respectively. Flow rates of 10μl per minute were used for all subsequent experiments based 
on these results. 
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As discussed earlier the presence of a vast background on nonspecific cells along with the 
CTCs in blood samples greatly hampers the effective capture of these rare cells. To mimic 
such a condition cell suspensions were prepared with a constant number of target Caco-2
cells and an increasing concentration of control FHs 74 Int cells. The cell suspensions were 
prepared with unstained Caco-2 cells mixed with 1% methylene blue stained FHs 74 Int cells 
at a concentration of 1x, 10x and 100x to that of Caco-2. These cell suspensions were flowed 
through the microfluidic devices at a flow rate of 10μl per minute to evaluate capture purity 
at increasing concentrations of non-specific cells. It was evident from the results that there 
was a gradual fall in capture purity with increasing concentration of FHs 74 Int cells. The 
purity percentage in Chip 1fell from 91 to 80 and 74 at 10x and 100x concentration of FHs74 
Int cells respectively. The capture purity in Chip 2 and 3 fell drastically at 100x concentration 
of FHs 74 Int cells from 83% to 60% and 58% respectively. It can be said that the fall in 
purity is proportional to the fall in capture yield, as higher non-specific binding reduced 
binding sites for target cells hence minimizing capture yield. 
Capture and isolation of CTCs should be followed with characterization of molecular and 
cellular functions that can be used for identifying new therapeutic targets and for better 
prognosis and clinical judgement. Characterization of CTCs can not only help in cancer 
staging but can also be used for monitoring therapies in real time by detecting the number of 
CTCs present in peripheral blood samples collected during the course of the treatment. The 
concept of cancer stem cells (CSCs) has received a lot of attention in the recent years. These 
CSCs are a small subpopulation of cells present within the tumor with properties such as self-
renewal, differentiation and tumorigenicity. Enrichment of CSCs is usually carried out by 
identifying cell surface markers such as CD44, CD133, CD29, CD9, CD24 and aldehyde 
dehydrogenase 1 which are tissue specific.  CSCs have been reported to be resistant to chemo 
and radiotherapy and are potential cause for cancer metastasis after a course of therapy and 
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surgical resection (Pantel, Brakenhoff & Brandt 2008; Yu, Z et al. 2012). It is therefore 
essential to develop microfluidic devices that can efficiently capture CTCs and characterize 
these cells for the presence of CSC markers that can be used for developing cancer treatments 
targeting CSCs. Considering this application of characterizing captured cells for surface 
marker expression, Chip 2 and 3 were designed. These chips which have four separate 
capture chambers allow analysis of different markers in each chamber post capture. The 
PDMS device can easily be dismounted from the glass slide after cell capture and can be 
processed for immunostaining with very low volumes of antibodies and reagents. The 
experiments performed using Chip 2 and 3 were done to show the capability of these chips to 
allow expression analysis of at least four different markers present either on cell surface or as 
intracellular proteins.  Three of the four capture chambers were coated with anti-EpCAM 
antibodies, whereas the last chamber was left uncoated as a negative control to evaluate non-
specific binding. Caco-2 cells mixed in equal proportions of methylene blue stained FHs 74 
Int cells were flowed through the chips at 10μl per min. After cell capture the cells were fixed 
with 4% paraformaldehyde, following which the PDMS device was unmounted from the 
slides to perform immunostaining. Cell captured in one chamber were stained for intracellular 
survivin expression (TRITC- red), cells in the second chamber were stained for cell surface 
CD133 expression (FITC- green), whereas cell captured in the third chamber were stained for 
EpCAM expression (FITC- green) as a positive control to show that only EpCAM +cells 
were captured. The results revealed that 88% of EpCAM+ Caco-2 cells expressed survivin 
and 91% expressed CD133 marker. All the cells stained for EpCAM in the third chamber 
showed 100% EpCAM expression showing the efficiency of cell capture. The uncoated 
chamber had negligible number of cells bound; this reinforces the fact that the total number 
of cells bound in the remaining antibody coated chambers is not as a result of non-specific 
binding. 
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Survivin, a member of inhibitor of apoptosis gene family plays an important role in resisting 
cell death and enhancing cell proliferation. Accumulating work on this marker has shown the 
expression of survivin in most human cancers, its prominent role in imposing a stem cell like 
phenotype on cancer cells and its association with poor disease outcome and reduced survival 
rates (Di Stefano et al. 2010; Kim et al. 2003). Despite the growing volumes of information
concerning survivin biology in cancer, there are a very few commercially available 
therapeutics targeting survivin (Altieri 2013). CD133 a transmembrane glycoprotein, on the 
other hand has been identified as a cancer stem cell marker in several human cancers 
including kidney, prostate, liver and colon carcinomas. Although the role and function of 
CD133 is still unclear it is a commonly used marker for sorting CSCs for its ability to induce 
cell division and self-renewable capacity (Todaro et al. 2010). Hence a microfluidics based 
analysis of such markers allows characterization at single cell level that can aid in 
categorizing cancer cells based on their protein expression profiles for developing effective 
targeted therapy and personalized treatment strategies. The results obtained in this study 
evidently prove the capability of these chips in performing multi-marker staining on a single 
chip device after each run. Percentage of specific stem cell markers expressed depending on 
the type of cells used can also be determined immediately after cell capture based on the 
marker of interest. Capture of prostate cancer cells based on immobilized prostate specific 
membrane antigen (PSMA) antibodies or breast cancer cells based on Her-2 expression with 
high capture yield and purity and further on-chip downstream analysis is possible.
Furthermore, these microfluidic devices were used to evaluate percentage EpCAM 
expression in various cancer cell lines based on their capture efficiency. EpCAM expression 
levels were determined in (i) human prostate cancer cell line (DU145) mixed with human 
prostate epithelial cells (RWPE-1); (ii) human breast cancer cell line (MCF-7) mixed with 
primary human cardiomyocytes (HCM); (iii) HepG2 cells mixed with FHs 74 Int cells; (iv) 
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Caco-2 cells mixed with FHs74 Int cells. DU145 cells showed the highest capture efficiency 
suggesting high expression of EpCAM, followed by HepG2, MCF7 and Caco-2 cells. These 
results were also confirmed by confocal microscopy.
Although several published reports have shown successful capture and isolation of rare tumor 
derived cells using microfluidics with high capture yield and purity, very few CTC capture 
chips have been reported that allow downstream applications of captured cells. It would be 
highly beneficial to further characterize the function of captured cells, their response to 
various therapeutic strategies and their behaviour under different culture conditions. To 
accomplish this it is necessary to be able to release viable captured cells and culture these 
cells for longer periods of time. Different methods have been proposed to release captured 
cells on chip, some of which include temperature mediated release (Zhu et al. 2012) and the 
use of 0.25% trypsin (Dharmasiri et al. 2011; Zheng, Iqbal & Wan 2013). Use of 0.25% 
trypsin at 37°C was employed in this study to release captured cells and to evaluate cell 
viability post capture. Cell viability was determined for Caco-2 and HepG2 cells at varying 
flow rates using trypan blue exclusion assay to study the effect of increasing shear stress on 
cell viability. Cell viability was determined before each run and experiments were continued 
only with cells showing >95% viability. As expected there was a slight decrease in the cell 
viability at flow rates 20 and 30 μl per minute, although less than 5%. It can be said from the 
obtained results that the flat channels and chambers in the three microfluidic devices do not 
affect cell viability drastically at all flow rates. The released cells were resuspended in fresh 
media with 10% FBS, centrifuged at 1200 rpm for 5 minutes and resuspended in fresh media 
before plating them in 96 well plates for in vitro cell culture. The cells showed cell division 
and proliferation and were maintained for 4 days. These results not only show that the 
microfluidic devices used here help maintain cell viability but also suggest that this method 
can be used to capture specific cells (such as cancer stem cells) by modifying the surfaces 
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with various antibodies and allow downstream applicability of captured cells such as cell 
culture, response to various treatment strategies, gene and protein expression profiling. With  
recent reports suggesting the dissemination of primary cancer cells to distant secondary sites 
as an early event of cancer progression (Pantel, Brakenhoff & Brandt 2008), microfluidic 
devices described here can be effective tools in isolation and characterization of these cells 
for early stage disease diagnosis and better clinical decision making. 
Although the most commonly used molecular recognition probes for cell surface markers are 
the antibodies. However factors such as (i) use of animal models for antibody production 
limiting the generation of antibodies to only those molecules that are not toxic to animals, (ii) 
limited applicability of these antibodies in therapeutic and diagnostic assays because of their 
non-human origin, (iii) laborious, time-consuming and expensive methods for production and 
purification of monoclonal antibodies, (iv) batch to batch variation in antibody-target 
interaction, (v) denaturation of antibodies at high temperatures have limited their applicability 
(Chames et al. 2009; Jayasena 1999). Although various approaches including humanization 
of antibodies (Almagro & Fransson 2008), in vitro immunization (Bradbury et al. 2011) and 
antibody engineering (Vincent & Zurini 2012) have been reported to overcome these 
limitations, there is still a need for molecular probes that are highly specific to targets while 
incurring reduced production costs without the need for in vivo conditions (Chames et al.
2009). Therefore, the applicability of aptamers as cell capture probes to developing robust 
microfluidic platforms has been investigated in the next chapter. 
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4. REUSABLE MICROFLUIDIC DEVICES FOR CAPTURE OF CIRCULATING 
TUMOR CELLS ON APTAMER FUNCTIONALIZED SURFACES
4.1. Introduction
Biomarker discovery has seen several advancements in the recent years. With developments 
in the field of proteomics such as mass spectrometry and two-dimensional gel 
electrophoresis, researchers have been able to perform proteome-wide expression profiling to 
identify disease specific protein signatures (Shangguan, Cao, et al. 2008). Despite these 
developments, proteomic technologies have not been able to completely characterize 
membrane proteins which contribute to upto 30% of the total genome. Various factors 
contributing to this are the heterogeneity, the hydrophobicity and the low abundance levels of 
membrane proteins (Tan, Tan & Chung 2008).
Aptamers as molecular recognition probes have received a great deal of attention in the last 
few years although first identified in the late twentieth century. Aptamers are single stranded 
oligonucleotides (DNA or RNA) approximately 20-100 bases long that form unique 
secondary and tertiary structures to bind with the specific targets with high specificity (Wang 
& Farokhzad 2014). The efficiency of aptamers to bind specifically with targets ranging from 
small molecules to proteins and even whole cells has been well demonstrated. (Iliuk, Hu & 
Tao 2011; Kanwar et al. 2010; Ninomiya et al. 2013; Shangguan et al. 2006). Generation of 
aptamers is through an in vitro selection procedure called as SELEX (systemic evolution of 
ligands by exponential enrichment), which involves the selection of specific aptamers from a 
large library of random DNA or RNA molecules on competitive binding with target 
molecules followed by purification and amplification (Li et al.). The aptamer-target binding 
occurs through a mechanism involving the folding of the aptamer over the target molecule 
like a lock and key (Hermann & Patel 2000). Aptamers have been used extensively in clinical 
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medicine since their revolutionary discovery by two independent groups in 1990 and 1998 
(Alexis et al. 2008; Holeman et al. 1998; Tuerk & Gold 1990).  Increased clinical and bio-
analytical applicability of aptamers is due to factors such as (i) increased stability and 
resistance to high temperatures, (ii) ease of synthesis with highly reproducible chemical 
procedures without batch to batch variations, (iii) ease of introducing 
modifications/functional groups for increasing stability (against nucleases) and also for use as 
signalling probes (fluorophores),  (iv) reduced immunogenicity and toxicity, hence an 
improved biocompatibility, (v) the ability to generate large volumes of highly specific 
aptamers to a wide range of target molecules (Song, Lee & Ban 2012). SELEX has also been 
used to select highly specific aptamers to complex molecules including entire cells, referred 
to as Cell-SELEX. This allows the selection of a panel of aptamers for specific cell types 
without the need for understanding the structure and localization of target molecules, hence 
enabling the development of molecular probes for unknown markers as well (Li et al. ;
Ninomiya et al. 2013). Aptamers have found clinical applicability in areas such as anti-
coagulants, anti-angiogenics, oncology and diabetes. They have also widely been used in pre-
clinical studies as therapeutic agents for targeted delivery of nanoparticles, small interfering 
RNA (siRNA) and also as imaging probes (Keefe, Pai & Ellington 2010; Ni, Castanares, et 
al. 2011).  The only FDA approved therapeutic nucleic acid aptamer is pegaptanib, which is 
an anti-VEGF RNA aptamer used as an anti-angiogenic agent for age related macular 
degeneration (AMD) (Kurihara et al. 2013; Zehetner et al. 2013).
Development of personalized treatment regimens for cancer patients depends on the 
detection and identification of disease specific markers that differentiate cancer cells from 
normal cells. SELEX allows selection of aptamers that are able to detect minute differences 
at molecular or cellular level (Reinemann & Strehlitz 2013).  Applicability of aptamers as 
detection probes for early diagnosis and treatment of cancer has been tremendous. The ability 
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of aptamers to efficiently recognize specific cancer cells as well as differentiate between 
different subtypes of a cancer type has been well elucidated by Zhao et al. They reported the 
selection of a panel of single stranded DNA aptamers against live adenocarcinoma cells 
A549, a non-small-cell lung cancer (NSCLC) cell line. These aptamers were able to 
competently distinguish A549 cells from other NSCLC cell lines such as HLAMP, NCI-
H460 as well as from other cancer cell lines such as Hep-G2 (hepatocellular) and MCF-7
(human breast carcinoma). These results showed that aptamers can be used to study the 
molecular heterogeneity existing between different subtypes of a cancer type as well as 
among various cancers (Zhao et al. 2009). Use of aptamers to target specific tumor markers 
for intracellular delivery of therapeutic molecules such as siRNAs, (Hussain, Tur & Barth 
2013; Yoo et al. 2014) drugs (Xing et al. 2013; Zhu et al. 2013) loaded on nano-vehicles has 
been well studied. 
4.1.1. Applications of aptamers
4.1.1.A. Aptamers as imaging probes:
Aptamers allow easy modifications with fluorophores for target cell detection and imaging. 
The small size of aptamers allows cellular permeation and their ability to target an extensive 
array of target molecules makes them very suitable as imaging probes (Wang & Farokhzad 
2014). An array of DNA aptamers were selected using Cell-SELEX method to specifically 
differentiate between T-cell leukaemia and B-cell lymphoma. Aptamer sgd5 was highly 
specific to Toledo cells (B-cell lymphoma cell line), while aptamers sgc8, sgc3, sgc4, sgd2, 
and sgd3 were specific to CCRF-CEM cells (T cell acute lymphoblastic leukaemia cell line). 
Such aptamers can be used as molecular probes for detection and identification of the type of 
neoplastic cells in blood samples of patients (Shangguan, Cao, et al. 2007; Shangguan et al.
2006). Another study reported the development of DNA aptamers TD05 that specifically 
bound to the immunoglobin heavy mu chain of the B cell antigen receptor on Ramos cells 
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(Burkitt’s lumphoma cell line) (Mallikaratchy et al. 2007; Tang et al. 2007). Aptamers 
immobilized on magnetic nanoparticles for detection of cancer cells from a complex sample 
have also been developed. A dual signal amplification platform using iron oxide 
nanoparticles along with gold nanoparticles that bind specifically to CCRF-CEM cells with 
the help of aptamers was reported by Zhang et al. This strategy showed a detection limit of 
10 cells (Zhang, Tan, et al. 2013). A similar study reporting the use of aptamer conjugated 
gold nanoparticles for detection of CCRF-CEM cells (Medley et al. 2008). An in vivo 
imaging probe using sgc-8 aptamers was developed by Shi et al. referred to as activatable 
aptamer probe (AAP). The fluorophores conjugated on these aptamer probes were quenched 
when present in a free state, whereas upon binding to target cells the probes showed 
fluorescence recovery by undergoing conformational changes. In vivo studies with these AAP 
molecules showed fluorescence enhancement at the site of tumor compared to that of non 
tumor areas (Shi et al. 2011). Use of superparamagnetic iron oxide nanoparticle-aptamer 
(A10) conjugates to target prostate specific membrane antigen (PSMA) expressed on prostate 
cancer cells has been reported for magnetic resonance imaging (Wang, Bagalkot, et al. 2008).
The aptamer A10 has also been used in conjugation with gold nanoparticles to develop a 
computed tomography platform for imaging PSMA expressing prostate cancer cells (Kim, 
Jeong & Jon 2010). Radiolabelled aptamers have also been reported for use as molecular 
probes. TTA1, an RNA aptamer that targets tenascin-C was radiolabelled for in vivo imaging 
and bio-distribution studies in brain and breast cancer xenografts. Tenascin-C is an 
extracellular matrix protein that has been reported to be expressed during tumor growth and 
angiogenesis. (Hicke et al. 2006; Winnard et al. 2008). Radiolabelled DNA aptamers 
targeting MUC1 (mucin 1), a glycoprotein that is known to be over expressed in most tumors 
of epithelial origin was used  for imaging breast cancer (Pieve, Perkins & Missailidis 2009).
Another group reported the development of a nanoparticle probe that constituted a 
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nanoparticle-aptamer conjugate that was both fluorescently and radioactively labelled for 
multimodal in vitro or in vivo imaging. The DNA aptamer used in this study is AS1411 which 
specifically targets nucleolin a nucleolar protein known to control ribosomal biogenesis and 
is overexpressed in rapidly dividing cells (Hwang et al. 2010).
4.1.1.B. Aptamers as therapeutics:
Aptamers being non-toxic and biocompatible have emerged as potential therapeutic agents 
for targeted delivery of nanoparticles, drugs and siRNAs (Kanwar, Roy & Kanwar 2011).
Aptamers targeting PSMA expressed on prostate cancer cells have been developed for 
imaging as well as for therapy (Pei, Zhang & Liu 2014). Since the developments of the two 
RNA aptamers (A9 and A10) targeting PSMA by Lupold et al in 2002, they have been 
extensively used for developing treatment strategies for prostate cancer (Lupold et al. 2002).
McNamara et al developed an aptamer-siRNA chimera for intracellular delivery of siRNA. 
The aptamer (A10) portion of the chimers binds to the PSMA expressing cells leading to 
intracellular delivery of the siRNA that inhibits cell survival genes polo-like kinase 1 (PLK1) 
and BCL2. This aptamer-siRNA chimera showed specific inhibition of tumor growth without 
effecting non-cancerous cells (McNamara et al. 2006). A truncated version of aptamer A10, 
A10-3.2 was used for intracellular delivery of pegylated polyamidoamine based tumor 
suppressor genes miR-15a and miR-16-1 to PSMA expressing LnCAP cells (prostate cancer 
cell line) (Wu et al. 2011). A novel strategy for improving treatment of high-risk localized 
prostate cancer was developed by Ni et al using A10-shRNA (short hairpin RNA) chimeras. 
This chimera increased the sensitivity of PSMA expressing cells to ionizing radiations 
without damage to surrounding non-cancerous tissue. This was achieved by selecting shRNA 
that specifically targeted DNA-activated protein kinase, catalytic polypeptide (DNAPK) 
which resulted in radiosensitization (Ni, Zhang, et al. 2011). A10 aptamers have also been 
used for therapeutic targeting of prostate cancer using aptamer-nanoparticle conjugates for 
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intracellular drug delivery. Farokhzad et al demonstrated the use of pegylated poly-lactic acid 
nanoparticles encapsulated with a florescent labelled dextran conjugated with A10 aptamers 
for prostate cancer specific cell binding and intracellular delivery of the drug model (dextran) 
to the cells. It was shown that only PSMA expressing cells efficiently took up the 
nanoparticle-aptamer conjugates while the non-PSMA expressing cells did not take up the 
conjugates (Farokhzad et al. 2004). A truncated version of aptamer A10, A10-3 was used in 
conjugation with poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles loaded with 
docetaxol for in vivo delivery of the drug to prostate cancer cells, which showed complete 
tumor regression in five out of seven xenograft nude mice (Farokhzad et al. 2006). The same 
group also compared the efficacy of platinum prodrugs in conjugation with aptamer targeted 
pegylated PLGA nanoparticles to that of free cisplatin.  This nano-formulation showed a 
higher anti-tumor efficacy at lower doses compared to that of the conventional cisplatin 
treatments (Dhar et al. 2011). A combinatorial drug delivery using A10 conjugated 
nanoparticles to deliver docetaxol and cisplatin to prostate cancer cells has also been reported 
(Kolishetti et al. 2010). Aravind et al recently demonstrated the use of pegylated PLGA-
lecithin nanoparticles functionalized with an anti-nucleolin DNA aptamer AS1411 for site 
specific delivery of an anticancer drug paclitaxel. The antitumor effect of the aptamer-
targeted nanoparticles was much higher than the non-targeted delivery in MCF-7 (breast 
cancer cell line) and GI-1 (human gliosarcoma cell line) cells (Aravind et al. 2012). Quantum 
dots-aptamer-drug conjugates for imaging and treatment of cancer were developed by Savla 
et al. Quantum dots were conjugated with a DNA aptamer MUC1 and doxorubicin for 
targeting mucin expressing A2780/AD multidrug resistant ovarian cancer cells (Savla et al.
2011).
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4.1.1.C. Aptamers as CTC capture probes:
Aptamers have also been successfully used in microfluidic devices because of the various 
benefits they offer compared to traditionally used probes such as antibodies. Aptamers are 
excellent affinity probes for microfluidic devices because of the ease of modifications with 
fluorophores, increased specificity to target molecules and their stability. Microfluidics has 
revolutionized the field of biomarker identification and rare cell capture techniques with 
minimal use of sample and time at reduced costs. One of the major applications of aptamer 
immobilized microfluidic devices is to capture circulating tumor cells (CTCs) from a mixture 
of heterogeneous (normal) cells. Detection of CTCs in blood and other biofluids allows early 
diagnosis of cancer and better treatment planning. Increased thermal stability, resistance to 
degradation, ease of synthesis and strong binding to modified glass surfaces are some of the 
reasons that prove aptamer functionalized microfluidic devices as efficient cell capture 
platforms. There is a need for a well-designed microfluidic device that can specifically and 
efficiently capture rare cells to be used as biomarkers or as a source for identified biomarkers. 
It is also of vital importance to develop a platform that is robust and allows reusability 
without the need for modifying the microchannel surfaces after each run. Such a device that 
does not require critical storage and transport conditions would be of tremendous help in a 
clinical setting. This study reports the use of LNA modified aptamers targeting EpCAM and 
nucleolin markers immobilized on silylated glass slides to efficiently capture rare cells from 
blood samples. This study also demonstrates the regeneration of the functionality of the 
aptamer modified devices after each run to enable reusability
4.1.1.D. EpCAM LNA Aptamer
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that was 
originally identified as a biomarker for colorectal cancers using antibodies in 1979 (Herlyn et 
al. 1979). Although EpCAM is expressed by most normal epithelial cells (Winter et al.
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2003), reports have also shown the over expression of EpCAM in several carcinomas (Went
et al. 2006a; Went et al. 2004a). Expression of EpCAM has also been reported in cancer stem 
cells which are a small group of tumor cells which show self-renewability and tumor 
initiating properties (van der Gun et al. 2010; Visvader & Lindeman 2008). Recent reports 
have also shown that controlled proteolysis of the intracellular domain (EpICD) of EpCAM causes its 
translocation to the nucleus which ultimately aids in cell proliferation (Maetzel et al. 2009).
Edrecolomab, an EpCAM murine monoclonal antibody was developed to induce cytotoxicity 
in EpCAM expressing cells. Several clinical trials including a phase III trial using this 
monoclonal antibody in colorectal cancer patients showed unsatisfactory inconsistent results 
(Gires & Bauerle 2010; Schmoll & Arnold 2009). The causes for the failure of edrecolomab 
in effectively treating colorectal cancer have been attributed to factors such as large size and 
increased immunogenicity (Ismail et al. 2013). Aptamers have played an important role in 
overcoming this limitation because of their small size and biocompatibility. Shigdar et al
recently reported the selection of RNA aptamers for EpCAM that can specifically target 
cancer cells and cancer stem cells expressing EpCAM. To improve in vivo applicability of 
this 73 nucleotide long aptamer, it was subjected to two rounds of truncation resulting in a 43 
(EpDT1) and a 19 (EpDT3) nucleotide long aptamers. The dissociation constant (Kd) of 
EpDT3 to Kato III cells (human gastric carcinoma cell line) was found to be 12±6.5 nM. 
Interestingly, EpDT3 showed an increase in its Kd value (from 12nM to 54.5nM) when 
labelled with Dy647 for enabling in vivo bio-distribution and imaging studies. It was shown 
that Dy647-EpDT3 specifically bound to EpCAM expressing cells such as MCF-7 (breast 
cancer), SW480 (colon cancer), T47D (breast cancer), HT-29 (colon cancer), MDA-MB-231
(breast cancer) cells besides Kato III cells. To correlate the levels of EpCAM expression on 
each of these cell lines obtained with fluorophore tagged aptamers, flow cytometry was also 
performed with the same cell lines using anti-EpCAM antibodies. It was also reported that 
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upon binding the Dy647-EpDT3 aptamer was internalized into the cells via endocytosis, 
signifying its applicability for therapy and in vivo imaging (Shigdar et al. 2011). Shigdar et al
also reported in another study the efficiency of two EpCAM RNA aptamers in the detection 
of low levels of EpCAM in formalin fixed paraffin embedded breast cancer samples in 
comparison with that of antibodies (Shigdar et al. 2013). Li et al reported the use of anti-
EpCAM RNA aptamers functionalized on pegylated-PLGA-lecithin nanoparticles loaded 
with curcumin as an efficient site-specific drug delivery system for colorectal carcinoma. 
Curcumin is a well-studied herbal compound obtained from Curcuma longa known for its 
antitumor, anti-inflammatory and antioxidant properties (Wilken et al. 2011). The curcumin 
encapsulated-aptamer functionalized nanoparticles were shown to be taken up specifically by 
EpCAM expressing HT29 cells (human colon cancer cells), while the conjugates without the 
EpCAM aptamer showed poor uptake. It was also shown that encapsulation of curcumin in 
the nanoparticles increased bioavailability hence increasing the cytotoxicity to target cells in 
comparison to free curcumin (Li et al. 2014). Selection of DNA aptamers targeting EpCAM 
has also been reported (Song et al. 2013).
4.1.1.E. Nucleolin LNA Aptamer
One of the major applications of oligonucleotides is their use in antisense or antigene studies 
as therapeutic agents  that can control specific gene expression based on sequence specific 
binding with mRNA or DNA of interest (Gleave & Monia 2005; Praseuth, Guieysse & 
Helene 1999). However there are other biological functions of oligonucleotides that are not 
entirely as a result of sequence specific binding to nucleic acids. An important example is the 
non-antisense effect of guanosine rich oligonucleotides (GROs) that form stable inter- and 
intra-molecular G-quartet structures (ĈDSLF et al. 2002; Han & Hurley 2000; Saijo et al.
1997). These G-quartets have been reported to have anti-proliferative effects on cells. These 
quadruplex oligonucleotides also enhance biostability and allow efficient cellular uptake 
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making them useful therapeutic agents. It has been well elucidated that these effects imparted 
by guanosine rich oligonucleotides are as a result of the formation of unique quadruplex 
structures and not dependent on sequence specific binding (Bates et al. 2009). The most 
advanced aptamer developed so far that has been used in human clinical trial is AS1411, 
which is a guanosine rich DNA aptamer developed as AGRO100. The discovery of 
AGRO100 was serendipitous and not a result of a strategic SELEX procedure. Bates et al in 
1999 were working on developing novel anti-cancer therapeutics using sequence specific 
triplex forming oligonucleotides to knock out genes of interest. The results showed that the 
controls used in the experiment which were G/T containing oligonucleotides with no 
complementarity to any gene, showed the highest anti-proliferative activity to DU145 
(prostate cancer), MDA-MB-231 (breast cancer), HeLa (cervical cancer) cells (Bates et al.
1999). Further modifications to these GROs were performed to analyse their properties on 
various cell lines. A 29 base long GRO, GRO29A showed anti-proliferative effects on 
DU145, MDA-MB-231, and HeLa cells while normal cells Hs27 (human diploid skin 
fibroblasts) remained unaffected by treatment with GROs. Further studies showed that cancer 
cells treated with GRO29A showed cell cycle arrest in S phase. While the RNA and protein 
synthesis was unaffected, it was seen that GRO treatment inhibited DNA synthesis and 
ultimately resulted in cell apoptosis (Xu et al. 2001). A truncated version of GRO29A which 
is 26 bases long GRO referred to as AS1411 (previously called AGRO100) has also shown 
similar effects in most cancer cell lines (Bates et al. 2009). Recent studies proved selectivity 
of this aptamer for tumor cells using breast cancer cells (MCF-7) in comparison to normal 
breast epithelial cells (MCF10A) (Soundararajan et al. 2008) and acute myelogenous 
leukaemia cells (MV4-11, KG1, HL60 AND K562) in comparison with B cells (Mongelard 
& Bouvet 2010; Shah et al. 2006). It is now well established that AS1411 aptamer 
specifically binds nucleolin. Nucleolin is essentially a nucleolar non-ribosomal protein that is 
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also expressed in nucleus and cytoplasm and on the cell surface of most cancers 
(Hovanessian et al. 2000; Srivastava & Pollard 1999). Role of nucleolin in various cellular 
processes such as DNA transcriptional regulation, pre-RNA processing, transport of rRNA 
and cell proliferation has been reported. Watanabe et al recently reported the translocation of 
intracellular nucleolin to the cell surface as a process occurring during carcinogenesis as over 
expression of nucleolin was only seen on the surface of gastric cancer cells while normal 
gastric epithelial cells showed no expression in the membrane fraction (Watanabe et al.
2009).
The LNA modified EpCAM aptamer used in this study is the 19 bases long RNA aptamer 
while the nucleolin aptamer used is the 26 bases long DNA aptamer.
4.2. Aim
The aim of this study was to evaluate the efficiency of LNA modified aptamer functionalized
microfluidic devices to competently capture rare cells in comparison to antibody coated 
devices. This study also aims at evaluating the reusability of these LNA modified aptamer 
functionalized microfluidic devices besides validating its clinical applicability with whole 
blood samples obtained from patients with head and neck cancer.
4.3. Materials and Methods
4.3.1. Device fabrication
The microfluidic chips used in this study were comprised of polydimethylsiloxane (PDMS) 
devices reversibly bonded on to microscope glass slides. Fabrication of all PDMS devices 
was performed at Melbourne Centre for Nanofabrication, Melbourne, Victoria. Commercially 
available silylated glass slides were used. Standard lithography and DRIE etching methods 
were used for PDMS device fabrication. The detailed protocol for the same is given below. 
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i. Pre-cleaning:
Silicon wafers (diameter:4 inch; thickness: 500μm) were dipped in piranha solution (30% 
H2O2) for 15 minutes followed by rinsing with deionized water for 10 minutes and blow 
drying with nitrogen.
ii. Lithography:
The silicon wafers were first coated with hexamethyldisilazane (HMDS) to enhance 
photoresist adhesion by spinning at 3000 rpm for 30 seconds and then allowed to rest for a 
minute at room temperature. This was followed by spin coating with AZ4652 photoresist 
with a 4μm thick layer at 3000 rpm for 30 seconds. The wafers were then soft baked at 100C 
for a minute and then allowed to re-hydrate at room temperature for 15 minutes. They were 
then exposed using a contact mask aligner at 180mJ/cm2, developed in 4:1 (Water:AZ400K) 
developer for one minute and rinsed with deionized water.
iii. Deep reactive-ion etching (DRIE etching)
Pre-cleaning was performed with de-scum in DRIE tool for 10 seconds. Bosch processing to 
etch target depth of 100 μm was the carried out. Visual inspection and depth verification was 
performed via stylus profiler. 
iv. Post-etch clean:
Silicon master wafers were stripped in oxygen plasma and re-cleaned with piranha as above. 
v. PDMS device fabrication:
Master molds were activated with oxygen plasma for 1min at 500mTorr in a Harrick plasma 
unit. Molds were immediately transferred to a vacuum desiccator with 20μl (tridecafluoro-
1,1,2,2-tetrahydrooctyl)-1-trichlorosilane and brought to vacuum (300-500mTorr) for 1hr. 
Silanized molds were then transferred to a casting dish where 10:1 PDMS (Sylgard 184) was 
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poured to a depth of approximately 0.75-1cm. Casting tray was degassed for 1hour under 
vacuum before being transferred to a surface levelled oven at 80C for 2hrs. Devices were 
extracted from master mold by manual dicing with a straight edge and scalpel. 
Figure 4.1. Design and dimensions of the microfluidic devices. 
Chip 1 is a flat-channel device consisting of four parallel 40mm long channels for cell 
capture converging into a single outlet reservoir, whereas chip 2 consists of four cell capture 
chambers, each leading to a separate outlet reservoir. The four microchannels in chip 1 were 
connected at the inlet and the outlet to ensure uniform flow in each channel. All the devices 
used in this study were made of polydimethylsiloxane (PDMS). The inlet and outlet holes on 
the PDMS devices were punched after fabrication. These PDMS devices were reversibly 
bound onto silylated glass slides.
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4.3.2. Surface modification with locked nucleic acid (LNA) modified aptamers
20μM LNA modified aptamers were suspended in 3X Standard saline citrate (SSC) (0.15M 
Sodium Chloride, 15mM Sodium Citrate, pH: 7) and pumped onto silylated microscope 
slides mounted with the PDMS chip. Incubation with the aptamer solution was done for 4 
hours in a humidified chamber to enable rehydration. The channels were then cleaned with 
0.2% SDS for a minute followed by washing with nuclease free water twice for a minute 
each. Washing with sodium borohydride solution (10 mg of NaBH4 dissolved in 3 ml of 
phosphate buffered saline (PBS) and 1ml of ethanol; PBS was prepared in nuclease free 
water) was performed for five minutes. The slides were submerged in water for 2 minutes at 
95°C then rapidly washed with 0.2% SDS for a minute. The slides were rinsed well in water
twice and air dried before storing them in dark at room temperature until further use (Schena
et al. 1996). The aptamers used in this study are nucleolin DNA aptamer (AS1411): 5’-
GGTGGTGGTGGTTGTGGTGGTGGTGG-3’ and EpCAM RNA aptamer (Ep-DT3): 5’-
GCGACUGGUUACCCGGUCG-3’. The regions in the aptamer sequence with the LNA 
modification are given in bold. 
4.3.3. Evaluation of surface roughness with Atomic Force Microscopy (AFM)
An Asylum Research Cypher Atomic Force Microscopy (AFM) was used, in tapping mode, 
to study the surface roughness of the aptamer coated surfaces. Silylated glass slides were 
tested for an increase in surface roughness after aptamer functionalization as compared to that 
of non-coated slides. A comparison of increase in surface roughness with aptamer (on 
silylated glass slides) and antibody (on poly-L-lysine slides) coating was carried out with 
AFM. Argyle Light, Asylum Research, Santa Barbara, CA, was used for data analysis.
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Figure 4.2. Schematic representation of aptamer immobilization on silylated glass slides. 
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The formation of a Schiff base between the aliphatic or aromatic amine (present on the 
nucleotide bases on the aptamer) and a carbonyl group (present on the silylated glass slides) 
through nucleophilic addition is the basis for aptamer immobilization. 
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Figure 4.3. Schematic representation of CTC capture on LNA aptamer functionalized surfaces.
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Figure 4.4. Schematic representation of translocation of EpCAM and nucleolin.
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4.3.4. Cell culture and culture conditions
The cell lines used in this study namely human colon adenocarcinoma cells (Caco-2), human 
hepatocellular carcinoma cells (HepG2), human mammary adenocarcinoma cells (MCF7), 
human prostate carcinoma cells (DU145), human intestinal epithelial cells (FHs 74 Int), and 
human prostate epithelial cells (RWPE-1) were obtained from American type culture 
collection (ATCC), Manassas, VA, USA. Eagle’s Minimum Essential Medium (EMEM) used 
for the culture of Caco-2, MCF7, HepG2 and DU145; Hybri-Care medium for FHs 74 Int
cells and Keratinocyte Serum Free Medium supplemented with epidermal growth factor for 
RWPE-1 cells was obtained from Gibco, Australia. The media for the other cell lines was 
supplemented with 10% fetal bovine serum purchased from Bovogen, Australia, and 
antimycotic-antibiotic or penicillin/streptomycin purchased from Gibco, Australia. Human 
cardiomyocytes grown in Celprogen cell culture complete medium with serum were obtained 
from Celprogen, California, USA. The cells were cultured at 37°C with 5% CO2. Media 
changes were done every 3 days and the cells were subcultured with 0.25% trypsin/EDTA 
(obtained from Gibco, Australia) upon reaching a confluency of 80-90%. 
4.3.5. Serum Stability analysis of LNA modified aptamer
The EpCAM and Nucleolin LNA aptamers were suspended in nuclease free water and stored 
at -20°C as stock solutions. The serum stability of each of these aptamers was determined by 
incubating 20μM aptamer solutions with PBS containing 10% fetal bovine serum for 0 to 120 
hours. These solutions were then run on 1% agarose gel at 100 V for 35 minutes and 
visualized with SYBR safe on Bio-Rad gel doc.
4.3.6. Cell capture assays
Immediately before performing the cell capture experiments, the cells were trypsinized and 
resuspended in fresh serum free media. Cell viability was evaluated prior to running the 
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experiment with trypan blue exclusion assay. The cells were mixed with an equal volume of 
trypan blue stain and counted on haemocytometer for evaluating cell viability. Cell 
suspensions showing >95% cell viability were used for subsequent analysis. The cells were 
diluted to the required concentration in serum free media before introducing into the 
microfluidic devices. Aptamer immobilized slides were blocked with 3% BSA and 0.1% 
Tween-20 (prepared in nuclease-free water) for 1 hour. Channels were washed with PBS 
(prepared in nuclease-free water) thrice. Cell suspensions with predetermined concentrations 
of cells (approximately 300μl) were injected at a flow rate of 10μl per minute. Media at the 
outlet reservoir was collected regularly in 1.5ml tubes for counting total number of unbound 
cells. The channels were washed with PBS (prepared in nuclease-free water) to remove 
unbound cells and media. The cell suspensions were introduced into the devices using a 
syringe pump (PHD Ultra 4400 series, Harvard apparatus) connected at the inlet of the 
devices with a 1 ml syringe via polymer tubing. The total number of cells captured was 
determined by counting the number of unbound cells collected at the outlet reservoirs.
4.3.7. Evaluation of reusability of LNA aptamer functionalized devices
Trypsin (approximately 150μl) at 37°C was injected at a flow rate of 20μl/min to release 
bound cells. Channels were washed with PBS (prepared in nuclease-free water) to remove 
any traces of trypsin. Once the channels were free of all bound cells and trypsin, fresh cell 
suspensions (showing >95% cell viability) were flowed through to determine the capture 
yield for each run. This process was repeated for a total of 10 times and the capture yield was 
determined after each run based on the total number of unbound cells collected at the outlet 
reservoir. The experiments were discontinued if the cell viability fell below 95%. The Chip-
bound aptamer coated slides were washed with PBS, drained of any liquid and stored in dark 
at room temperature. The same slides were reused on availability of fresh cells the following 
day.
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4.3.8. Cancer cell capture from whole blood
Blood from nude mice (balb/c nu nu) collected in an EDTA vacutainers was spiked with 
predetermined concentration of Caco-2 cells to evaluate the capture specificity. The whole 
blood samples were used within 2 hours of collection. To test the specificity of the cell 
capture method, 1ml whole blood was spiked with 1000 Caco-2 cells and flowed through 
EpCAM LNA aptamer and nucleolin LNA aptamer modified devices at a flow rate of 10 μl
per minute. Capture yield was determined after washing with PBS at a flow rate of 15 μl per 
minute.
4.3.9. Cell staining with methylene blue
Cells were stained with 1% methylene blue solution to enable real time evaluation of capture 
specificity. Freshly trypsinized cells were incubated for 15 minutes at 37°C in 1% methylene 
blue solution prepared in serum free media. The stained cells were pelleted by centrifugation 
at 1500rpm for 5 minutes. The pellet was rinsed in PBS thrice before resuspending in serum 
free media. Methylene blue stained cells were then mixed with unstained cancer cells at 
predetermined concentrations to evaluate capture specificity in real time. The cell mixture 
containing target cells (unstained cancer cells) and control cells (stained non-cancerous cells) 
were flowed through the devices at flow rates ranging from 5 to 30μl per minute to determine 
the optimal flow conditions for obtaining high capture efficiency with a high capture purity.
4.3.10. Sorting of cancer cells based on cancer stem cell marker expression
Freshly trypsinized cancer cells were flowed through sorting columns contained magnetic 
beads specific to CD133, CD44 and EpCAM. These columns were obtained from MACS 
Miltenyl Biotec. Magnetic separation on the MACS column was performed using anti-biotin 
magnetic beads to separate cells labelled with biotin-conjugated antibodies against the above 
mentioned markers. The sorted cells were cultured for 24 hours before performing cell 
capture experiments.  
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4.3.11. Cell recovery and viability post-capture
All experiments were performed using freshly trypsinized cells with >95% cell viability 
(using trypan blue exclusion assay). After the cell suspensions were flowed through the 
microfluidic devices the captured cells were released using 0.25% trypsin-EDTA at 37°C 
flowed at 20μl per minute and collected at the outlet reservoirs. The released cells were 
stained with trypan blue and counted on haemocytometer to determine cell viability. 
4.3.12. Blood sample collection
Blood samples were collected from patients with head and neck cancers (n=25) and also from 
patients with pre-cancerous lesions (n=8) after obtaining informed consents under an 
institutional review board protocol. The blood samples were collected in EDTA vacutainers 
and were processed within 4 hours of sample collection. The blood samples were collected 
from patients with advanced stage of cancer (stage III and IV). The staging was done based 
on TNM (tumor, nodal, metastatic) classification given by International agency for research 
on cancer (IARC) screening group, World health organization. Details of the samples 
collected are enlisted below.
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Table 4.1 Clinical data of samples used for isolation of CTCs
Characteristics Sample No.
1. Gender
Male 28
Female 5
2. Age group
25-35 5
36-50 14
51-65 12
66-80 2
3. Postoperative Stage
III 6
IV 19
Pre-cancerous lesions 8
4. Tumor location
Buccal Mucosa 17
Tongue 8
Gingiva 3
Hard palate 3
Floor of mouth 1
Mandibular alveolus 1
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4.3.13. CTC capture and characterization from blood samples
Freshly collected blood samples were diluted in equal proportion with PBS before being 
introduced into the microfluidic device chip 1, functionalized with EpCAM LNA aptamer. 
Approximately 1ml of whole blood was passed through the device at a flow rate of 10 μl per 
minute. The channels were then washed with PBS at 15 μl per minute to minimize 
nonspecific binding of cells. The captured cells were analysed for EpCAM expression and for 
the presence of a nucleus using immunofluorescence. This involved fixing the captured cells 
with 4% paraformaldehyde solution (PF) for 20 minutes at room temperature. The channels 
were then washed with PBS thrice. Blocking solution composed of 3% BSA was then 
introduced and incubated for 30 minutes at 37°C to minimise non-specific binding of 
antibodies. The channels were washed with PBS. The cells were incubated with the primary 
antibodies (anti EpCAM antibody) for 1 hour at 37°C. The cells were then washed gently 
with PBS followed by incubation with the appropriate secondary antibody for 1 hour. The 
cells were washed again with PBS before adding the mounting media containing DAPI 
followed by sealing with a cover slip. Immunofluorescence was analysed using Leica SP5 
confocal microscope. The details of the primary antibodies and secondary antibodies used are 
enlisted in table 3.1. The experiments were done on two separate devices simultaneously.
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4.4. Results
4.4.1. Successful immobilization of aptamers on silylated glass slides
Freshly coated silylated and poly-L-lysine slides with 20μM EpCAM LNA aptamer solution 
and 50 μg per ml anti-EpCAM antibody solution respectively were analysed for surface 
roughness in comparison with uncoated slides. AFM results showed a two fold increase in 
surface roughness upon aptamer immobilization, suggesting the successful functionalization 
of silylated surfaces with aptamers. On the other hand antibody coating on poly-L-lysine 
slides showed a >10 fold increase in surface roughness. This can be attributed to the larger 
size of the antibodies in comparison with that of the EpCAM LNA aptamer. These results 
suggest that the method used for aptamer immobilization via Schiff base formation allows 
successful binding of aptamers on the silylated glass slides. 
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Figure 4.5. Surface roughness analysis using Atomic force microscopy (AFM).
Representative images showing increase in surface roughness upon aptamer or antibody 
immobilization. Image (A) represents the surface roughness of a silylated glass slide (left) 
and an EpCAM LNA aptamer functionalized (right) silylated slide. Image (B) shows the 
surface roughness of a poly-L-lysine slide (left) and anti-EpCAM antibody coated (right) 
slide. The experiment was repeated twice.
Non-coated EpCAM LNA aptamer coated
Roughness = 1.21 nm Roughness = 2.22 nm
Non-coated Anti-EpCAM antibody coated
Roughness = 0.415 nm Roughness = 11.47 nm
A
B
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4.4.2. High serum stability of LNA modified aptamers
LNA aptamers suspended in PBS containing 10% fetal bovine serum for time periods ranging 
from 0 to 5 days were run on 1% agarose gel to determine the stability. It was seen that both 
EpCAM and nucleolin LNA aptamers were highly stable in 10% serum without any 
degradation. Nucleolin LNA aptamer was stable for upto 5 days; however EpCAM LNA 
aptamer showed slight degradation after 72 hours (Figure 4.4).
4.4.3. Specific capture of cancer cells on LNA aptamer functionalized surfaces
The performance of the microfluidic devices functionalized with locked nucleic acid (LNA) 
modified aptamers targeting EpCAM and nucleolin was first evaluated using Caco-2 cells 
(human colorectal cancer cells). The silylated glass slides were functionalized with LNA 
modified aptamers (20μM) followed by blocking with 3% bovine serum albumin (BSA) and 
0.1% Tween-20 to minimize non-specific binding of cells to glass surfaces. The channels 
were washed with phosphate-buffered saline (PBS) prior to flowing cell suspensions. Serum 
free media spiked with cancer cells at a concentration of 1000 cells per ml was flowed 
through the microfluidic devices at a flow rate of 10μl per minute to evaluate the efficiency 
of the aptamer enabled cell capture. PBS was then flowed at 15μl per minute to remove any 
unbound cells. The total number of unbound cells after each run was counted from the media 
and PBS collected at the outlet reservoirs. 
4.4.3.A. Increased cell capture efficiency on aptamer functionalized surfaces
A capture efficiency as high as 99% and 98% was obtained on EpCAM LNA aptamer and 
nucleolin LNA aptamer functionalized surfaces of chip 1. On the other hand, chip 2 showed a 
capture efficiency of 71% and 66.5% on EpCAM LNA aptamer and nucleolin LNA aptamer 
functionalized surfaces. It was also evident from the results that the capture efficiency of 
Caco-2 cells on aptamer functionalized surfaces was considerably higher than on antibody 
coated surfaces of chip 2. Capture yield of Caco-2 cells based on their surface EpCAM 
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expression was remarkably higher at 71% on aptamer functionalized devices compared to the 
46% of the antibody coated chambers of chip 2. Cell capture targeting nucleolin expression 
on chip 2 was also considerably higher at 66.5% compared to antibody based capture method. 
These results showed a 1.5 fold increase in cell capture efficiency on chip 2 and a 1 fold 
increase on chip 1 functionalized with EpCAM LNA aptamers in comparison with that of 
anti-EpCAM antibody coated surfaces. It can be inferred from these results that despite 
having the same capture areas, aptamer functionalized devices showed an improved capture 
yield than on antibody coated surfaces. 
4.4.3.B. Selective capture of cancer cells on aptamer functionalized surfaces
To confirm the specificity of cell capture, Caco-2 cells were also flowed through microfluidic 
devices without aptamer modification. Similarly FHs 74 Int cells (normal colon epithelial 
cells) were also flowed through devices with and without aptamer modification. This was 
performed to validate that the cell capture is as a result of cell surface EpCAM/nucleolin 
expression and not due to non-specific binding of cells. It was seen that neither Caco-2 nor 
FHs 74 Int cells were captured on surfaces without aptamer modification. A small percentage 
of FHs 74 Int cells were captured on EpCAM LNA aptamer modified surfaces which can be 
expected because of the epithelial origin of the cells (Armstrong & Eck 2003). These results 
confirm that aptamer functionalized device capture cells with increased specificity. 
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Figure 4.6: High serum stability of LNA modified aptamers.
Representative agarose gel images showing serum stability of LNA modified aptamers in 
PBS containing 10% fetal bovine serum. It was seen that the nucleolin LNA aptamer was 
highly stable for the entire period of the experiment which was 5 days. The EpCAM LNA 
aptamer was stable until a period of three days with slight degradation there on. The stability 
studies were performed thrice independently.
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Figure 4.7. Cancer cell capture on aptamer functionalized microfluidic devices. 
Representative bright field images of Caco-2 cells captured on EpCAM LNA aptamer and 
nucleolin LNA aptamer functionalized surfaces of chip 1 and 2. Cells captured on-chip was 
counted after washing with PBS to remove unbound cells. The experiments were repeated 
thrice.
Chip 1
Chip 2
Chip 1
Chip 2
EpCAM LNA 
Aptamer
Nucleolin LNA 
Aptamer
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Figure 4.8. Comparison of capture efficiency of Caco-2 cells on aptamer and antibody 
modified surfaces. 
Percentage capture efficiency on aptamer modified surfaces was obtained by counting the 
total number of captured cells on-chip and total number of cells collected at the outlets. The 
results are represented as mean ±SEM obtained from three repeats. Statistical significance 
was evaluated with Student’s t-test. p value 0.05 were considered significant. S LV
represented as *** when compared with cell capture efficiency on aptamer non-coated slides.
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Figure 4.9. Evaluation of capture specificity of cancer cells on EpCAM LNA aptamer 
coated and non-coated surfaces. 
Caco-2 and FHs 74 Int cell suspensions (1000 cells per ml) were flowed through aptamer 
coated and non-coated surfaces at a flow rate of 10μl per minute. The results are represented 
as mean ±SEM obtained from three repeats. Statistical significance was evaluated with 
Student’s t-WHVWSYDOXHZHUHFRQVLGHUHGVLJQLILFDQWSLVUHSUHVHQWHGDVZKHQ
compared with cell capture efficiency on aptamer non-coated slides. 
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4.4.4. Multiple reusability of aptamer functionalized devices for cancer cell capture
The ability to reuse a single microfluidic device for multiple samples without the need for 
modifying its surfaces after each run would be highly beneficial. To evaluate the reusability 
of an aptamer modified microfluidic device for repeated runs, capture efficiency of caco-2
cells was determined for ten repeats on the same device. The capture yield was maintained 
above 90% for upto six repeats on chip 1 functionalized with EpCAM LNA aptamer, which 
gradually fell to around 71% in the tenth repeat. Chip 1 functionalized with nucleolin LNA 
aptamers maintained >90% capture efficiency for four repeats. Chip 2 functionalized with 
EpCAM LNA aptamer showed >10% fall in capture efficiency by the fifth repeat, while the 
nucleolin LNA aptamer functionalized device showed similar results in the fourth repeat. 
These results showed that a single aptamer functionalized device can be repeatedly used for 
six times (in case of chip 1) and 4 times (in case of chip 2) to capture cancer cells without a 
significant fall in capWXUH\LHOGS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Figure 4.10. Reusability of chip 1 functionalized with LNA modified aptamers. 
Capture yield of 1000 Caco-2 cells flowed through EpCAM LNA aptamer and nucleolin 
LNA aptamer modified chip 1 microchannels after each run for ten repeats. The results are 
represented as mean ±SEM obtained from three repeats. Statistical significance was evaluated 
with Student’s t-WHVW S YDOXH ZHUH FRQVLGHUHG VLJQLILFDQW S LV UHSUHVHQWHG DV
*** when compared with cell capture efficiency on aptamer non-coated slides. 
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Figure 4.11. Reusability of chip 2 functionalized with LNA modified aptamers. 
Capture yield of 1000 Caco-2 cells flowed through EpCAM LNA aptamer and nucleolin 
LNA aptamer modified chip 2 microchambers after each run for ten repeats. The results are 
represented as mean ±SEM obtained from three repeats. Statistical significance was evaluated 
with Student’s t-WHVW S YDOXH ZHUH FRQVLGHUHG VLJQLILFDQW S LV UHSUHVHQWHG DV
*** when compared with cell capture efficiency on aptamer non-coated slides.   
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Figure 4.12. Comparison of the reusability of chip 1 and 2 for 10 repeats
Capture yield of 1000 Caco-2 cells flowed through EpCAM and nucleolin LNA aptamer 
functionalized chip 1 and chip 2 microchannels after each run for ten repeats. The results are 
represented as mean ±SEM obtained from three repeats. The results are represented as mean 
±SEM obtained from three repeats, *** SSS 
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4.4.5. High capture sensitivity on aptamer functionalized devices
The rarity of occurrence of circulating tumor cells (CTCs) in peripheral blood samples of 
cancer patients poses a major challenge in developing a sensitive cell capture system. Caco-2
cells spiked in serum free media at concentrations 10, 100 and 1000 cells/ml was flowed 
through aptamer functionalized devices to evaluate the sensitivity of the said method. The 
ability of aptamer modified devices to capture cancer cells present in very low numbers 
targeting EpCAM and nucleolin expression was evaluated. Chip 1 functionalized with LNA 
modified aptamers showed high capture sensitivity even with low cell numbers. The EpCAM 
LNA aptamer modified chip 1 device was able to capture upto eight cells of the ten cells that 
were flowed through, while the same device functionalized with nucleolin LNA aptamer 
captured seven cells. Similar results were also obtained when chip 1 was flowed with cell 
suspensions containing 100 cells. Both LNA modified aptamer modified devices showed 
>90% capture efficiency for cell suspensions containing 100 cells. However aptamer 
modified chip 2 showed efficient captured only 2-3 cells when flowed with cell suspensions 
containing 10 cells. Approximately 50% reduction in capture yield was seen on chip 2 with 
cell suspensions containing 100 cells compared to 1000 cells. Similar experiments were also 
performed using Hep-G2 cells (human liver cancer cells) to analyse capture sensitivity on 
chip 1 and 2 modified with LNA modified aptamers. 
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Figure 4.13. Aptamer enabled capture of Caco-2 cells on chip 1 at cell numbers ranging 
from 1000 to 10 cells. 
Representative bright field images of Caco-2 cells captured on microchannels of chip I 
functionalized with EpCAM LNA aptamer (upper panel) and nucleolin LNA aptamer (lower 
panel). Capture sensitivity of aptamer modified devices was evaluated for cell suspensions 
containing 1000 cells (A), 100 cells (B) and 10 cells (C). The experiments were repeated 
thrice.
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Figure 4.14. Aptamer enabled capture of Caco-2 cells on chip 2 at cell numbers ranging 
from 1000 to 10 cells. 
Representative bright field images of Caco-2 cells captured on microchannels of chip 2 
functionalized with EpCAM LNA aptamer (upper panel) and nucleolin LNA aptamer (lower 
panel). Capture sensitivity of aptamer modified devices was evaluated for cell suspensions 
containing 1000 cells (A), 100 cells (B) and 10 cells (C). The experiments were repeated 
thrice.
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Figure 4.15. Comparative analysis of capture sensitivity of Caco-2 cells on aptamer 
functionalized surfaces.
The ability of aptamer modified devices to efficiently capture cells present in less numbers 
was evaluated by flowing cell suspensions containing 10, 100 and 1000 cells. Capture 
efficiency percentage was obtained by counting total number of captured cells and total 
number of cells collected at the outlet reservoirs after washing with PBS. The results are 
represented as mean ±SEM obtained from three repeats. Statistical significance was evaluated 
with Student’s t-WHVW S YDOXH  ZHUH FRQVLGHUHG VLJQLILFDQW S LV UHSUHVHQWHG DV
*** when compared with cell captur`e efficiency on aptamer non-coated slides.   
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Figure 4.16. Comparative analysis of capture sensitivity of Hep-G2 cells on chip 1 
functionalized with aptamers targeting EpCAM and nucleolin. 
The ability of aptamer modified devices to efficiently capture cells present in less numbers 
was evaluated by flowing cell suspensions containing 10, 100 and 1000 cells. Capture 
efficiency percentage was obtained by counting total number of captured cells and total 
number of cells collected at the outlet reservoirs after washing with PBS. The results are 
represented as mean ±SEM obtained from three repeats. Statistical significance was evaluated 
with Student’s t-WHVW S YDOXH ZHUH FRQVLGHUHG VLJQLILFDQW S LV UHSUHVHQWHG DV
*** when compared with cell capture efficiency on aptamer non-coated slides.   
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4.4.6. Efficient capture of cancer cells spiked in whole blood on aptamer modified 
surfaces.
To simulate the ability to capture rare CTCs in peripheral blood of cancer patients, 
predetermined concentrations of Caco-2 cells (1000 cells) were spiked in whole blood 
samples obtained from BALB/C Nude mice. It is important to evaluate the sensitivity and 
specificity of a cell capture device to capture target cells present in small numbers in a 
heterogeneous cell suspension.
4.4.6.A. Efficient capture of cancer cells spiked in whole blood
It was seen that chip 1 showed 92% cell capture efficiency with EpCAM LNA aptamers, 
while nucleolin LNA aptamer functionalized chip 1 showed capture of 88% of Caco-2 cells
from blood. Chip 2 showed a capture efficiency of 65% and 61% with EpCAM and nucleolin 
LNA aptamers respectively. The results showed a slight decrease in capture efficiency of 
cancer cells spiked in whole blood compared to that in media. It was however evident that the 
aptamer modified devices specifically captured only cancer cells. Chip 1 modified with 
EpCAM LNA aptamers showed a 7% fall in capture efficiency, while the nucleolin LNA 
aptamer modified devices showed a 10% fall when compared with cell capture in media. 
Aptamer modified chip 2 devices showed approximately 6% fall in capture efficiency of 
cancer cells in blood compared to that in media. These results showed the ability of the 
aptamer functionalized devices to capture target cells specifically from a vast background of 
bystander cells. 
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Figure 4.17. Aptamer enabled capture of Caco-2 cells spiked in whole blood on chip 1. 
Representative bright field images of Caco-2 cells captured on microchannels of chip 1 
functionalized with EpCAM LNA aptamer (upper panel) and nucleolin LNA aptamer (lower 
panel). Capture specificity was evaluated for 1000 Caco-2 cells spiked in whole blood 
samples. Images (A) represent cancer cells capture introduced with blood samples. Images 
(B) represent captured cancer cells after washing with PBS. The experiments were repeated 
thrice.
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Figure 4.18. Aptamer enabled capture of Caco-2 cells spiked in whole blood on chip 2. 
Representative bright field images of Caco-2 cells captured on microchannels of chip 2 
functionalized with EpCAM LNA aptamer (upper panel) and nucleolin LNA aptamer (lower 
panel). Capture specificity was evaluated for 1000 Caco-2 cells spiked in whole blood 
samples. Images (A) represent cancer cells capture introduced with blood samples. Images 
(B) represent captured cancer cells after washing with PBS. The experiments were repeated 
thrice.
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Figure 4.19. Specific capture of cancer cells spiked in whole blood. 
Capture efficiency obtained with Caco-2 cells spiked in blood samples at a concentration of 
1000 cells per ml flowed through aptamer modified devices at 10 μl per minute. The results 
are represented as mean ±SEM obtained from three repeats. Statistical significance was 
evaluated with Student’s t-WHVW S YDOXH  ZHUH FRQVLGHUHG VLJQLILFDQW S LV
represented as *** when compared with that of the blank sample (whole blood without 
cancer cells).
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Figure 4.20. Comparative analyses of cell capture efficiency from whole blood and 
media.
Capture yield of 1000 Caco-2 cells spiked in whole blood in comparison to that in media is 
represented. Error bars represent standard deviation obtained from three repeats.
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4.4.6.B. High capture sensitivity for cancer cells spiked in whole blood
To further illustrate the clinical applicability of this cell capture method, whole blood was 
spiked with 10, 50 and 100 Caco-2 cells to mimic the rarity of occurrence of CTCs in blood 
samples of cancer patients. The same flow conditions were used as described above for 
introducing blood samples spiked with Caco-2 cells and for PBS washes. EpCAM LNA 
aptamer modified chip 1 showed capture of up to six cells of the ten Caco-2 cells that were 
flowed through the microchannels, while chip 2 effectively captured only two cells. Similar 
results were seen with nucleolin LNA aptamer modified devices. Capture efficiency of 77% 
and 80% was observed with chip 1 functionalized with EpCAM and nucleolin aptamers 
respectively when flowed with 50 Caco-2 cells per ml sample. Both aptamers showed greater 
than 80% cell capture on chip 1 flowed with blood samples spiked with 100 cells. These 
results demonstrate the immense potential of this aptamer modified device as a diagnostic 
tool in a clinical setting. 
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Figure 4.21. Aptamer enabled capture of Caco-2 cells spiked in whole blood at low 
concentrations.
Clinical applicability of chip 1 to identify cancer cells present in low numbers in whole blood 
sample was evaluated. Blood samples spiked with 10, 50 and 100 Caco-2 cells were flowed 
through aptamer modified chip 1 microchannels to evaluate capture sensitivity and 
specificity. The results are represented as mean ±SEM obtained from three repeats. Statistical 
significance was evaluated with Student’s t-WHVWSYDOXHZHUHFRQVLGHUHGVLJQLILFDQW
SLVUHSUHVHQWHGDVZKHQFRPSDUHGZLWK that of the blank sample (blood sample 
without cancer cells).
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4.4.6.C. Improved capture sensitivity on dual aptamer functionalized surfaces
Analysis of capture efficiency using microfluidic devices coated with aptamers targeting 
more than one surface marker on cancer cells was also performed. This was carried out by 
coating the microfluidic devices with both EpCAM LNA aptamer and nucleolin LNA 
aptamer. Blood samples spiked with 10, 50 and 100 Caco-2 cells were flowed through the 
dual aptamer modified devices. Capture efficiency was determined after washing with PBS 
based on the total number of cancer cells captured on-chip.  The results showed improved 
capture efficiency on both chip devices compared to that of the single aptamer coated 
devices.
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Figure 4.22. Dual aptamer enabled capture of Caco-2 cells spiked in whole blood at low 
concentrations. 
Capture efficiency with low cell concentrations spiked in whole blood sample was evaluated 
on chip 1 and 2 coated with both EpCAM LNA aptamer and Nucleolin LNA aptamer. Blood 
samples spiked with 10, 50 and 100 Caco-2 cells were flowed through dual aptamer modified 
microchannels to evaluate capture sensitivity and specificity. The results are represented as 
mean ±SEM obtained from three repeats. Statistical significance was evaluated with 
Student’s t-WHVW S YDOXH  ZHUH FRQVLGHUHG VLJQLILFDQW S LV UHSUHVHQWHG DV 
when compared with that of the blank sample (blood sample without cancer cells).
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4.4.6.D. Efficient release of cells post-capture while maintaining cell viability
Cell viability post-capture was analysed with trypan blue exclusion assay. Cell captured on 
EpCAM LNA aptamer modified devices were released using trypsin and resuspended in fresh 
media before determining cell viability. Cell viability percentage was calculated using a 
haemocytometer. The results showed that there was a very negligible decrease in cell 
viability post capture. This ability would have a tremendous applicability in identification and 
capture of rare cells that can be used for subsequent in vitro culture for understanding 
treatment responses to a variety of drugs as well as to further characterize the captured cells 
for their stemness. 
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Figure 4.23. Cell viability post-capture on EpCAM LNA aptamer functionalized devices. 
The cell lines namely Caco-2 and HepG2 were used to determine cell viability following cell 
capture on chip. Error bars represent standard deviation obtained from duplicates. Error bars 
represent standard deviation obtained from three repeats.
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4.4.7. Efficient capture of various cancer cells based on EpCAM/Nucleolin expression
To determine the EpCAM and nucleolin expression levels in different cancer cell lines, Chip 
1 functionalized with aptamers was used to flow through cancer cells mixed with equal 
proportions of methylene blue stained non-cancerous cells. Cell capture based on surface 
marker expression was performed with (i) DU145 cells (human prostate cancer cells) mixed 
with RWPE-1 cells (human prostate epithelial cells); (ii) MCF-7 cells (human breast cancer 
cells) mixed with RWPE-1 cells; (iii) HepG2 cells mixed with FHs 74 Int cells; (iv) Caco-2
cells mixed with FHs74 Int cells. Capture efficiency varied with each cell line based on 
surface EpCAM/Nucleolin expression on these cell lines. The normal cells were pre-stained 
with 1% methylene blue before mixing with un-stained Caco-2 cells to visualize non-specific 
on-chip capture of cells in real time. It was seen that DU145 and Hep-G2 cells showed higher 
EpCAM expression compared to Caco-2 and MCF-7, whereas MCF-7 showed the highest 
nucleolin expression compared to other cancer cells. A cell capture device that can capture 
cells specifically based on surface marker expression can be used to stratify patient 
populations based on the expression levels of various markers. This will aid appropriate 
treatment planning and disease management.
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Figure 4.24. Cell capture based on surface EpCAM/nucleolin expression in various cell 
lines on aptamer modified chip 1. 
Representative bright field images of various cancer cells captured on EpCAM LNA aptamer 
(upper panel) and nucleolin LNA aptamer (middle panel) functionalized microchannels of 
chip 1. Figures (I) and (J) are representative images of methylene blue stained FHs 74 Int and 
RWPE-1 cells respectively. Arrowheads in figures (K) and (L) represent captured FHs 74 Int 
cells (blue) along with cancer cells. The experiments were repeated twice.
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Figure 4.25. Cancer cell capture based on EpCAM/Nucleolin expression on aptamer 
functionalized chip 1. 
Cancer cells (1x105 cells per ml) mixed in equal proportion with methylene blue stained 
normal cells were flowed through EpCAM LNA aptamer and nucleolin LNA aptamer 
functionalized microchannels of chip 1. Percentage EpCAM and nucleolin expression in 
various cancer cell lines was estimated based on capture efficiency. Capture purity was 
deduced based on the total number of methylene blue stained normal cells captured on chip. 
Error bars represent standard deviation obtained from two repeats.
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4.4.8. Efficient capture of cancer stem cells on aptamer modified surfaces
Cancer cells showing stem cell like properties were also flowed through aptamer modified 
surfaces of chip 1 to evaluate the capture efficiency. Cancer cells (DU145, MCF-7, Caco-2) 
were first immuno-magnetically sorted based on cell surface stem cell marker (EpCAM, 
CD44 and CD133) expression. These cancer stem cells were mixed with equal proportions of 
methylene blue stained normal cells (RWPE-1 and FHs74 Int cells) before introducing into 
aptamer modified chip 1.  Greater than 98% cell capture was seen with cancer stem cells on 
both EpCAM and nucleolin aptamer modified devices. The capture purity fell on EpCAM 
aptamer modified devices as all epithelial cells express EpCAM on their cell surface, which
resulted in capture of a few FHs 74 Int and RWPE-1 cells. The isolation and characterization 
of rarely occurring CTCs showing stemness is of enormous benefit to understand various 
processes such as drug resistance, metastasis and tumor recurrence. This strategy of capturing 
rare cells with LNA modified aptamers shows a huge potential for understanding cancer 
related processes to develop novel therapeutic strategies.
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Figure 4.26. Aptamer enabled capture of cancer stem cells on chip 1.  
Cancer stem cells (1x105 cells per ml) mixed in equal proportion with methylene blue stained 
normal cells were flowed through EpCAM LNA aptamer and nucleolin LNA aptamer 
functionalized microchannels of chip 1. Percentage EpCAM and nucleolin expression in 
various cancer stem cells as well as normal cells was estimated based on capture efficiency. 
Capture purity was deduced based on the total number of methylene blue stained normal cells 
captured on chip. Error bars represent standard deviation obtained from two repeats.
                                                                                                                                                 Chapter 4
241 
 
4.4.9. Efficient capture of CTCs from whole blood on LNA aptamer functionalized 
chip 1
Ultimately, to illustrate the clinical applicability of the LNA aptamer functionalized 
microfluidic devices to isolate CTCs with high sensitivity and specificity, whole blood 
samples obtained from head and neck cancer patients were run on chip 1 immobilized with 
EpCAM LNA aptamer. Blood samples obtained from patients with pre-cancerous lesions 
were used as negative controls. Freshly obtained blood samples from patients with advanced 
stage head and neck cancer (n=25) and pre-cancerous lesions (n=8) were processed on chip 1 
immobilized with EpCAM LNA aptamer. The cells captured on-chip were confirmed as 
CTCs using confocal microscopy to evaluate the specificity of cell capture. CTCs captured 
on-chip were identified as nucleated (DAPI stained) EpCAM positive cells (FITC stained).
&7&VZHUHFDSWXUHGIURPFDQFHUVDPSOHVRIZKLFKVDPSOHVVKRZHG&7&VSHU
ml of blood analysed. An average of 5±3 CTCs per ml of blood was identified in the cancer 
samples that were analysed. On the other hand, blood samples obtained from patients with 
pre-cancerous lesions showed zero to negligible number of CTCs. These results demonstrated 
the specificity and sensitivity of LNA aptamer modified devices and their potential 
applicability in a clinical setting to determine therapeutic efficacy or chances of disease 
recurrence based on CTC number in a patient.   
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Figure 4.27. Quantification of CTCs captured from blood samples of cancer patients.
Capture yield of chip 1 functionalized with EpCAM LNA aptamers to efficiently isolate 
CTCs from cancer (n=25) and pre-cancer (n=8) samples. Each sample was run separately on 
two devices to minimize run to run variation.  
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Figure 4.28. Characterization of CTCs captured from cancer samples. Representative 
fluorescence microscopy images of CTCs captured from blood samples of head and neck 
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cancer patients (n=10). CTCs were stained with DAPI (blue) and FITC (green) for EpCAM
expression analysis.
4.5. Discussion
Cancer has been a leading cause of mortality worldwide for many decades. It has kept scores 
of researchers busy in identifying biomarkers for early diagnosis, prognosis or for therapeutic 
targeting of various cancers. Unfortunately only a few identified markers have reached 
clinical utility and several candidate markers await further validation in clinical samples
(Jemal et al. 2011; Zhang & Nagrath 2013). Detection of circulating tumor cells (CTCs) for 
disease diagnosis, prognosis, monitoring of the therapeutic efficacy has also received 
increased attention in the recent years. CTC detection and capture from blood samples of 
cancer patients is of immense importance in cancer staging, clinical decision making and also
for evaluating the metastatic spread of cancer. Although numerous platforms for CTC capture 
from blood samples of metastatic cancer patients have been reported, only one of them 
namely CellSearch technology has been approved by FDA. Microfluidics offers a wide 
variety of applications in developing CTC detection platforms that can be fabricated 
inexpensively while offering high capture sensitivity and specificity. Several CTC capture 
microfluidic devices have been reported which depend on affinity based isolation such as 
immobilized antibodies or aptamers (Harris et al. 2013).
Aptamers as detection probes for cell surface markers has shown true potential for molecular
recognition and targeting. Use of antibodies as ligands for capturing rare cells on 
microfluidics is limited only to those few known markers that are specifically expressed in 
each cancer type for which high-affinity antibodies are available. To overcome this obstacle, 
use of aptamers that can be synthesized for any cell type has been exploited to capture rare 
cells in microfluidic devices. The ease of immobilization on a variety of substrates, their 
thermal stability, and high specificity to target molecules has made aptamers attractive targets 
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for biosensors and microfluidics based CTC capture studies (Breaker 2004; Phillips et al.
2008). Several groups have reported the efficient capture of CTCs on aptamer functionalized 
devices. Use of flat channel devices for immobilizing sgc8, TD05, and Sgd5 aptamers for 
multiplexed capture of various leukaemia cell lines with high specificity was reported by Xu 
et al (Xu et al. 2009). Microfluidic devices engineered with microstructures have also been 
used to increase surface area for aptamer functionalization to enhance capture efficiency. 
Sheng et al reported the development of a device with micropillars coated with KDED2a-3
and KCHA10 aptamers to specifically isolate DLD-1 and HCT 116 cells (colorectal cancer 
cells) spiked in whole blood (Sheng et al. 2012).    
As discussed in the previous chapter, various microfluidic devices were designed and 
fabricated for the capture of specific cells from a vast background of non-specific cells based 
on immunoaffinity. This involved the immobilization of anti-EpCAM antibodies to 
specifically capture Caco-2 cells (human colorectal cancer cell line) spiked in low numbers in 
a mixture containing vast number of FHs 74 Int cells (normal colon epithelial cells).
Although this method demonstrated efficient capture of rare cells there is a need for a more 
robust platform that offers reusability of the same device for more than one sample. Such a
microfluidic device that not only shows improved capture sensitivity and specificity but also 
allows reusability of the chip after specific capture and controlled release of the captured cells 
would be of tremendous help in a clinical setting. 
Aptamers are promising alternatives to antibodies for efficient capture of CTCs. One of the 
most important requirements for aptamers as diagnostic or therapeutic tools besides high 
specificity to target molecules is adequate stability in in vivo conditions or in biological 
fluids.  As any oligonucleotide, aptamers are easily degraded by nucleases. Several aptamer 
modifications have been reported to overcome this limitation for more efficient targeted 
intracellular drug delivery and other biological applications. Modifications with locked nuclei 
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acid (LNA) has been the most commonly used method to for increasing stability of aptamers. 
LNA modified aptamers are known to exhibit increased thermal stability, specificity to 
targets, high cellular uptake and increased half-life in blood (Shangguan, Tang, et al. 2007).
LNA are ribonucleotides consisting of bicyclic high affinity analogues which mimic RNA 
conformation by introducing a methylene bridge that connects the 2’-oxygen of ribose with 
the 4’-carbon. Upon hybridization of DNA/RNA with LNA there is a rise in the melting 
temperature (Tm) of the duplex. A DNA-LNA duplex shows an increase of 2-5°C in Tm with 
every base of LNA added. However the RNA-LNA duplex shows a much higher increase in 
duplex stability of 4-10°C for every LNA base added. Modification with LNA also imparts 
an A-type duplex geometry to the neighbouring DNA. LNA modification of selected 
aptamers is usually done post-SELEX procedures as the enzymes used for SELEX are not 
compatible with LNA duplexes. (Campbell & Wengel 2011; Kanwar, Roy & Kanwar 2011;
Veedu & Wengel 2010). Other applications of LNA besides increasing the effectiveness of 
aptamers in vitro and in vivo include their role in antisense technology for imparting stability, 
effective gene silencing and for improving the biocompatibility of siRNA and miRNA. The 
quadruplexes and triplexes formed by LNA makes them more compatible with a variety of 
nucleic acid structures (Veedu & Wengel 2009). To study the relationship between the 
structural modifications and activity of LNA aptamers, tenascin-C binding aptamer TTA1 
was modified with LNA and other functional groups. It was reported that hybridization with 
LNA markedly increased target specificity while showing significant stem stabilization and 
stability in plasma (Schmidt et al. 2004).
For this purpose, a novel approach using LNA modified aptamers functionalized on 
microchannels to specifically capture cancer cells was developed. It was hypothesized that 
the thermal stability and resistance to degradation by nucleases offered by LNA modified 
aptamers would allow reusability of the aptamer coated surfaces for capturing rare cells from 
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many samples. To this end LNA modified aptamers were used to functionalize silylated glass 
slides mounted with the PDMS chip devices. Immobilization of the LNA modified aptamers 
occur by Schiff base formation between the amine groups of guanine and cytosine present in 
the aptamers and the aldehyde group on the silylated glass slides (Balamurugan et al. 2008).
The successful immobilization of aptamers on silylated glass was determined using atomic 
force microscopy. This study used LNA modified aptamers targeting EpCAM and nucleolin 
to capture cancer cells. The use of EpCAM LNA aptamers and nucleolin LNA aptamer for 
developing a microfluidics based cell capture system has been reported for the first time.
Stability studies of the LNA modified aptamers showed high serum stability.  The nucleolin 
LNA aptamer showed serum stability for 5 days where as the EpCAM LNA aptamer showed 
complete stability for a period of 3 days with very slight degradation there on. It is possible 
that the nucleolin LNA aptamer was more stable than the EpCAM LNA aptamer because the 
EpCAM aptamer is an RNA aptamer while the nucleolin aptamer is a DNA aptamer. 
Previously published studies have reported that DNA aptamers are comparatively more stable 
than RNA aptamers due to the existence of structural heterogeneity within the RNA,various 
nucleotide modifications and an increased susceptibility to form 3D structures (Marolt et al.
2012; Takei et al. 2002)+RZHYHUWKHDSWDPHUVDUHVWDEOHIRU\HDUVZLWKRXWVHUXPDW࢓& 
These results suggest that LNA aptamers can be used to develop robust cell capture 
platforms.
It was evident from the results obtained in the previous chapter that chip 2 and 3 
showed similar results in terms of capture efficiency with various cell lines. Therefore all 
aptamer based cell capture experiments were performed only with chip 1 and 2. The 
performance of the aptamer functionalized devices was first analysed by capturing Caco-2
cells spiked in serum free media at a concentration of 1000 cells per ml. As discussed in the 
previous chapter optimal cell capture was seen at a flow rate of 10μl per min. Hence the same 
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flow rates were used for all cell capture experiments in this study. Chip 1 showed efficient 
capture of Caco-2 cells with 99% and 97.8% capture yield for EpCAM and nucleolin 
aptamers respectively. These results were however similar to those obtained with the anti-
EpCAM antibodies immobilized surfaces, which can be attributed to the increased surface 
area of chip 1 that ultimately allows capture of EpCAM expressing cells before reaching the 
outlet. Chip 2 on the other hand showed a significant increase in capture yield of Caco-2 cells 
with the aptamer modified surfaces when compared to the antibody enabled capture. EpCAM 
LNA aptamer modified surfaces of chip 2 showed a 25% increase in capture yield when 
compared to that of EpCAM antibodies, while Nucleolin LNA aptamer showed a 20% 
increase. The increased capture yield with aptamer modified surfaces of chip 2 show the 
stable binding of aptamers to the silylated glass surface that is resistant to the shear forces of 
the various wash steps performed prior to introducing cell suspensions. Several steps are 
performed on the devices after aptamer coating and before introducing the cell suspensions 
which include, washes with PBS to remove any impurities within the channels and to wet the 
surfaces for subsequent steps, blocking with 3% BSA 0.1% Tween-20 solution, washes with 
PBS again to remove any traces of Tween-20 or BSA. All these steps were performed at a 
flow rate of 15 μl per min. The same steps are involved with the antibody based cell capture 
experiments also. It is possible that the bound antibodies on the poly-L-lysine slides be 
slightly affected during the washes with PBS as the binding between the antibodies and the 
glass slides is via passive adsorption. On the other hand the LNA modified aptamers besides 
being thermally stable, bind to silylated glass slides via the formation of Schiff base through a 
nucleophilic addition reaction which offers better stability and resistance to shear stress. 
Precautions such as use of serum free media for suspending cells and use of nuclease free 
water for preparing PBS and blocking solutions were taken to reduce any possible 
degradation of the immobilized aptamers that would affect cell capture efficiency. Upon 
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introducing Caco-2 cell suspensions into devices without aptamer coating at the same flow 
rates (10μl per min), it was seen that negligible number of cells were bound on the surface. 
This proved the specificity of cell capture on aptamer coated devices. This was further 
confirmed by flowing FHs 74 Int cells (normal colon epithelial cells) on EpCAM LNA 
aptamer coated and non-coated slides. Similar to the results obtained with Caco-2 cells, no 
FHs 74 Int cells were captured on the devices without aptamer coating while the aptamer 
coated devices showed a higher percentage of cell capture (11% on chip 1and 5.7% on chip 
2) which can be due to the epithelial origin of these cells (Armstrong & Eck 2003; Balzar et 
al. 1999). These results confirm the cancer cell capture specificity on the aptamer modified 
devices. The use of scrambled oligonucleotides as control was eliminated as previous studies 
reported non-specific capture of target and control cells on surfaces immobilized with random 
oligonucleotides (Phillips et al. 2008). Both the EpCAM and nucleolin aptamers used in this 
study have been reported to have anti-cancer properties and have been used extensively for 
targeted therapy (Bates et al. 1999; ĈDSLF et al. 2002; Kanwar et al. 2012; Kanwar, Roy & 
Kanwar 2011; Mongelard & Bouvet 2010; Shigdar et al. 2011). However, it can be said that 
the cancer cell viability is not affected during the cell capture assays as there are no unbound 
aptamers available in the microchannels. Those present are immobilized via Schiff base 
formation on silylated glass surfaces, hence eliminating the possibility of the aptamer 
internalization into the cancer cells. The continuous flow conditions as well as the short time 
periods of interaction between the flowing cancer cells and the immobilized aptamers 
eliminates any possible anti-cancer effects of the aptamers on the cancer cells. The factors 
suggest that the use of these aptamers does not affect cell viability, capture sensitivity or 
specificity.
Microfluidics has been used extensively for capture and isolation of CTCs commonly relying 
on affinity based capture. Many of these cell capture platforms have shown efficient capture 
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of rare cells. However only a few reports have shown the ability of these devices to allow 
subsequent release of captured cells while maintaining them in viable conditions for further 
studies. A recent study by Zhu et al reported the use of sgc8c aptamer modified microfluidic 
devices for efficient capture of CCRF-CEM (acute lymphoblastic leukaemia cells) and 
subsequent temperature mediated release of captured cells while maintaining their viability 
(Zhu et al. 2012).  A similar study employed the use of anti-PSMA (prostate-specific 
membrane antigen) aptamers coated microfluidic devices to efficiently capture prostate 
cancer cells and later release them using trypsin (Dharmasiri et al. 2009). It would also be 
highly beneficial if the devices can be readily reused after releasing bound cells for running 
more samples without the loss of cell capture function. To address this, LNA modified 
aptamers targeting EpCAM and Nucleolin were immobilized on silylated glass slides 
separately to validate the reusability of the modified microfluidic devices. Caco-2 cells 
spiked in serum free media at a concentration of 1000 cells per ml were introduced into the 
aptamer modified devices repeatedly to evaluate the capture efficiency after each run. 
Trypsin-mediated release of captured cells was performed after each run (for a total of 10 
runs) to remove all bound cells on-chip. To eliminate any inconsistencies or variations 
between devices, the experiments were performed in two different devices. With optimized 
flow rates obtained from earlier studies it was seen that the EpCAM LNA aptamer modified 
chip 1 devices offered reusability for upto six times while maintaining the capture efficiency 
above 90%, whereas the nucleolin LNA aptamer modified devices showed  similar capture 
efficiency for upto four repeats.  It is however important to note that both aptamers showed 
>80% capture yield for upto eight repeats on chip 1. These results show the regenerative 
ability of LNA modified aptamer functionalized device for repeated cell capture. Chip 2 also 
showed a similar trend in cell capture function after repeated runs. Although lower than that 
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of chip 1, chip 2 showed a higher capture yield (for upto six runs) compared to that on anti-
EpCAM antibody immobilized devices.  
It is widely accepted that most cancer related deaths occur as a result of metastasis. The 
central cause of metastasis is the dissemination of tumor cells from the primary cancer site to 
distant organs using blood circulation or bone marrow as carriers. Dissemination of tumor 
cells has also been reported to be an early stage process of tumor progression. Hence analysis 
of CTCs holds a great potential in early diagnosis, therapeutic planning and prognosis of
cancer. Detection of CTCs, considered as a “liquid biopsy” reduces the requirement of 
invasively obtained biopsy samples from bone marrow (Adams et al. 2008; Alix-Panabières 
& Pantel 2013; Wang, Liu, et al. 2011).  One major challenge in the development of CTC 
detection assays is the rarity of occurrence of these cells among a vast background of blood 
cells. The complexity and heterogeneity that exist within CTCs also minimizes the possibility 
of development of a single CTC capture device for efficient capture of CTCs in all cancer 
types. A better understanding of the molecular markers specific to CTCs specific to the site of 
origin is necessary for developing efficient CTC capture devices. Therefore there is a need for 
development of a CTC capture device that can effectively capture CTCs present in extremely 
low numbers in blood samples. Besides being able to specifically capture only CTCs from the 
vast majority of non-specific cells, the device should also allow release of captured CTCs 
while maintaining their viability to further characterize these cells. To address this, Caco-2
cells were spiked in serum free media at concentrations of 10, 100 and 1000 cells per ml to 
evaluate capture sensitivity on aptamer modified devices. It was seen that EpCAM LNA 
aptamer functionalized chip 1 device showed a capture of upto 8 cells of the 10 cells that 
were flowed through, while the nucleolin aptamer modified chip showed a capture of upto 7 
cells.   The chip 1 modified with aptamers also showed efficient capture of CTCs (>93%) 
from suspensions containing only 100 cells per ml. Similar results were also obtained with 
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Hep-G2 cells (human liver cancer cells) when flowed at concentrations of 10, 100 cells per 
ml. . Although published reports suggest overexpression of nucleolin in colon cancer (Reyes-
Reyes & Akiyama 2008) and other cancers (Farin et al. 2011), expression levels of surface 
nucleolin in comparison with EpCAM has not been studied well. Therefore it can only be 
postulated that Caco-2 cells express higher levels of EpCAM in comparison to surface 
nucleolin based on the capture yield with these aptamers. On the other hand, chip 2 showed 
capture of approximately 30% of cells when flowed with suspensions containing 10 cells per 
ml. A 10% increase in capture efficiency was seen with Hep-G2 cells at the same 
concentration, suggesting a higher expression of EpCAM and nucleolin in these cells 
compared to that of Caco-2. These results showed the ability of chip 1 to efficiently capture 
rare cells suspended in media. 
To further evaluate the ability of these aptamer modified devices to capture rare cells from a 
heterogeneous mixture, Caco-2 cells were spiked in whole blood samples. This was done to 
simulate CTC capture form blood samples of cancer patients. Caco-2 cells were first spiked 
into whole blood at a concentration of 1000 cells per ml to determine the capture specificity 
of the aptamer modified devices. The cell suspensions in whole blood samples were flowed at 
a flow rate of 10 μl per minute, followed by washing with PBS at 15 μl per minute to remove 
any unbound cells. It was seen that the aptamer modified devices specifically captured cancer 
cells (which are comparatively larger than blood cells) (Maheswaran & Haber 2010; Yusa et 
al. 2013; Zheng et al. 2007). Although the Caco-2 cells were captured with high purity it was 
seen that there was a slight fall in the capture efficiency in blood samples compared to that of 
media. Chip 1 functionalized with EpCAM aptamers showed a 7% fall in the capture 
efficiency of Caco-2 cells when suspended in blood, while nucleolin aptamers coated devices 
showed a fall of approximately 9%. However the percentage decrease in capture efficiency 
using chip 2 was less compared to that of chip 1 with blood samples. Chip 2 functionalized 
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with LNA modified aptamers showed an approximate decrease of 6% in capture efficiency 
when flowed with blood samples spiked with 1000 Caco-2 cells. A study reported by Shen et 
al employing the use of gold nanoparticles immobilized with sgc8 aptamers on microchannel 
surfaces, also reported a fall in capture efficiency when cancer cells were spiked in whole 
blood at predetermined concentrations. However this device showed a much lower sensitivity 
in capture yield (60%) when compared to the results obtained in the present study with chip 1 
(Sheng et al. 2013). To further validate the performance of the aptamer modified devices to 
capture rare cells in whole blood, Caco-2 cells were spiked at concentrations ranging from 10 
to 100 cells per ml. Aptamer modified chip 1 devices showed >80% cell capture when flowed 
with 100 Caco-2 cells. Similar capture efficiencies were also seen with cell concentrations of 
50 cells per ml on chip 1. With cell suspensions containing 10 Caco-2 cells, EpCAM aptamer 
modified chip 1 devices captured upto 6 cells while nucleolin aptamer modified device 
captured 5 cells. Besides efficiently capturing cancer cells, both chip designs showed high 
capture purity percentage. This shows that the flow rates used for the cell capture 
experiments are ideal for specific binding of target cells while minimizing non-specific 
binding. Cell viability analysis (with trypan blue exclusion assay) of the captured Caco-2
cells released using trypsin showed >95% cell viability suggesting that the cells are not 
affected with the shear stress of the flow conditions, therefore enabling further analysis of 
captured cells. The capture efficiency of a dual aptamer modified device was also analysed 
using chip devices modified with both EpCAM and nucleolin targeting aptamers. These dual 
aptamer functionalized devices showed increased cell capture at all cell concentrations 
compared to that of the single aptamer modified devices. Furthermore, EpCAM LNA 
aptamer functionalized chip 1 showed efficient capture of CTCs from blood samples obtained 
from head and neck cancer patients while samples obtained from patients with pre-cancerous 
lesions showed zero or negligible number of CTCs. CTCs ranging from 1-15 cells per ml of 
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blood were isolated successfully with EpCAM LNA aptamers, suggesting the enhanced 
sensitivity of the capture method. These results suggest the potential role of the aptamer 
modified devices in clinical cancer diagnostics. These devices can also be used in 
combination with other aptamers to target cell-specific markers for developing screening 
assays for various cancers. They can also be put to use for detecting minimal residual disease 
(MRD) for leukaemia as well as for solid tumors. The presence of a small number of cancer 
cells in circulation post treatment is a major cause of cancer relapse and metastasis (Kim & 
Jung 2010; Kraeft et al. 2000). These aptamer modified microfluidic devices can be used to 
accurately detect MRD for monitoring treatment response and also as a predictive tool for 
cancer recurrence. The simple design, the low cost for the fabrication of these devices and the 
ease of modification with aptamers targeting various cancer specific markers enables their 
use as important diagnostic tools for a wide range of cancers.  
Microfluidic devices besides being able to specifically capture rare cells from heterogeneous 
cell mixtures, should also allow capture and identification of subpopulations of CTCs based 
on their marker expression. Aptamers targeting various markers known to be involved in 
increased invasiveness of tumor or with drug resistance can be used to isolate populations of 
CTCs that are more aggressive. Based on the aptamers used, protein expression profiles of 
the captured cells can be determined depending on the number of cells captured. With this 
information it would be possible to determine the site of origin of the CTCs, which would 
give a better clinical judgement of the tumor status and the therapeutic strategies that can be 
used. Therefore it is of crucial importance to characterize the CTCs based on their surface 
marker expression to be able to monitor treatment responses and to detect MRD after 
undergoing treatment. Understanding the specificity of various tumor markers to CTCs of 
different tissue origins would be beneficial in developing targeted treatment strategies. To 
address this, various cancer cells were flowed through aptamer modified devices to analyse 
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the percentage of EpCAM and nucleolin expression. The cells used were DU145 (human 
prostate cancer cells) mixed with RWPE-1 cells (human prostate epithelial cells); MCF-7
cells (human breast cancer cells) mixed with RWPE-1 cells; HepG2 cells mixed with FHs 74 
Int cells (colon epithelial cells) and Caco-2 cells mixed with FHs74 Int cells. The normal 
epithelial cells (FHs 74 Int and RWPE-1) were pre-stained with 1% methylene blue before 
mixing in equal proportions with the cancer cells.  Staining of cells with methylene blue 
allows real time analysis of capture purity. It was seen that DU145 and MCF-7 showed the 
highest capture yield on EpCAM LNA aptamer modified device suggesting higher EpCAM 
expression compared to that of Caco-2 and Hep-G2. Highest nucleolin expression was seen in 
DU145 and MCF-7 cells. It was also seen that approximately 12% of RWPE-1 cells and 11% 
of FHs74 Int cells were also captured on EpCAM aptamer coated device, which confirms that 
normal epithelial cells show lower EpCAM expression than malignant cells (Balzar et al.
1999). These results suggest that the designed microfluidic assays can be used to study the 
heterogeneity that occurs within the CTCs, to further identify the protein signatures specific 
to each cancer type or a subtype. This will enable better clinical decision making and 
designing better treatment strategies based on patient CTC profile, ultimately aiding in
personalized treatment. These devices can also be used as a platform to validate the pool of 
existing candidate markers for their clinical applicability with limited use of samples and 
reagents.
As discussed in the previous chapter, capture and isolation of cancer cells expressing stem 
cell-like properties would hold a great potential in studying drug resistance, self-renewability 
and tumorigenicity of these cells. A microfluidic device that enables specific capture and 
enrichment of rare cells while maintaining their viability, allows analysis for the presence of 
subpopulations expressing stem cell like properties. Unlike tumor cells the cancer stem cells 
are relatively rare and show unlimited proliferation. Therefore the CTCs captured on chip can 
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be further characterized for stem cell markers that would give better insights for identifying 
novel treatment strategies targeting blood borne disseminated cancer cells (Maheswaran & 
Haber 2010). Thus it is essential to analyse the ability of these microfluidic devices to capture 
cancer stem cells. To address this, various cancer cells expressing stem cell markers were 
flowed through the aptamer modified devices along with methylene blue labelled normal 
cells to validate capture sensitivity and specificity. Cancer cells expressing stem cell markers 
(CD133, CD44, and EpCAM) were sorted from DU145, MCF-7 and Caco-2 cell lines using 
immune-magnetic cell sorting. Percentage capture markedly increased when cells expressing 
stem cell markers were flowed through the device in comparison to unsorted-cancer cells. 
The chip 1 device functionalized with EpCAM and nucleolin aptamers showed >99% capture 
of cancer stem cells. The capture purity on EpCAM aptamer coated device was lower than 
nucleolin aptamer modified device as the normal epithelial cells used also expressed low 
levels of EpCAM on their cell surface. These results demonstrate the ability of the chip for 
capture of both cancer cells as wells as cancer stem-like cells. This is the first study to show 
efficient capture of cancer stem-like cells on LNA-aptamer functionalized microchannel 
surfaces.
The results obtained in this study show that LNA modified aptamer based microfluidic 
devices as CTC capture platforms hold immense potential in cancer detection, monitoring 
and management. Advantages of LNA modified aptamers such as high serum stability and
strong covalent binding with modified glass surfaces allows the development of a robust CTC 
capture platform. These features also extend the applicability of the microfluidic devices for 
multiple samples on a single device functionalized with LNA modified aptamers. This offers 
wide applicability in sample processing and detection in rural or remote areas without the 
need for extensive laboratory reagents and equipment. Sensitive and specific capture of rare 
cancer cells from whole blood samples offered by LNA aptamer functionalized devices on 
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simple flat channel devices further improves their clinical applicability in disease detection at 
early stages and therapeutic monitoring. High sensitivity in detecting rare cells also allows 
detection and characterization of cancer cells showing stem cell properties that are a minority 
among the other CTCs. This information can be used planning appropriate treatment 
strategies and move towards personalized treatments.
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CONCLUSIONS
Proteomics have been a chief support in the field of cancer diagnostics. A combinatorial 
approach involving 2-dimensional gel electrophoresis (2-DE) and mass spectrometry is the 
most commonly used proteomic platform for biomarker discovery. These techniques were 
used to identify 20 significantly upregulated proteins in oral squamous cell carcinoma 
(OSCC). Some of these are heat shock proteins 70 and 27, cytokeratin 19 and 7, epidermal 
growth factor receptor, stathmin, galectin and superoxide dismutase (Mn). However it is 
important to note that 2-DE cannot be used for profiling the entire proteome. Low abundant, 
highly basic, hydrophobic and membrane proteins cannot be detected on 2-DE. This has 
limited the availability of a large number of clinically applicable membrane proteins for 
disease diagnosis. Immunoassays showed significant upregulation of EpCAM and survivin in 
most OSCC tissue lysates which could not be detected using 2-DE. Immunoassays on 
microfluidic devices showed efficient detection of upto 3 different protein markers 
simultaneously in a single run from cancer tissue lysates with four times lesser sample 
volume as compared to that of the conventional 96 well microtiter plate ELISA method. 
These results demonstrated that microfluidics hold immense potential as validation tools for 
evaluating the clinical applicability of the vast number of candidate protein markers with low 
sample and reagent consumption. Furthermore, microfluidic devices functionalized with 
antibodies targeting EpCAM expression on cancer cells were developed to capture cancer 
cells. These devices showed efficient capture of tumor cells besides allowing characterization 
of the captured cells. However there is a need for a more robust cell capture platform that 
does not require stringent storage conditions, offers reusability for multiple samples and does 
not depend on the availability of antibodies for novel protein biomarkers.
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Locked nucleic acid (LNA)-modified aptamer based cell capture microfluidic 
platform was developed that not only allows efficient cell capture but also enables reusability 
of the aptamer functionalized devices for multiple samples. This reusable property will not 
only drastically reduce the costs per run but also enable its use in remote areas. The stability 
offered by the LNA modification to the aptamers minimizes the need for stringent storage 
conditions as well as transportation times. Each of the microfluidic devices showed unique 
properties of cell capture and characterization.  For example, chip 1 showed improved 
sensitivity in capturing rare cells from a vast background of bystander cells. Efficient capture 
of upto 10 cells was seen on this device. Capture of CTCs from blood samples of cancer 
patients further illustrated the sensitivity and the specificity of chip 1 functionalized with 
EpCAM LNA aptamers. This will be of tremendous benefit in a clinical setting to capture 
rarely occurring circulating tumor cells (CTCs) from peripheral blood samples of cancer 
patients. As described earlier dissemination of CTCs has also been reported as an early stage 
phenomenon in tumor progression. Therefore chip 1 holds enormous potential as a tool for 
early stage diagnosis. Monitoring CTC levels in real time in patients undergoing treatment is 
valuable in understanding drug resistance or sensitivity. Detection of CTCs in patients who 
underwent surgical resection of localized tumors can determine the risk of recurrence.  On the 
other hand, chip 2 and 3 allowed on-chip characterization of captured cells for multiple 
biomarkers (intracellular or surface markers) with very low reagent consumption. Cells 
captured in each of the four capture chambers on chip 2 and 3 can be used to stain for 
separate markers allowing improved characterization and molecular analysis of the CTCs.
This will enable identification of novel therapeutic targets that can directly suppress 
metastatic tumor spread. These microfluidic devices can also be used as a validation platform 
for evaluating the clinical applicability of the vast pool of existing protein biomarkers with 
very low sample requirements. 
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APPENDIX
List of Instruments
S.no. Instrument Model Company 
1 Iso-electric focussing setup Protein IEF Cell Bio-Rad
2 SDS-PAGE setup Powerpac Hc Bio-Rad
3 Versa Doc 4000 Bio-Rad
4 MALDI-TOF/TOF 4800 MALDI-
TOF/TOF Analyser
Applied Biosystems
Biosafety Cabinet Safemate 1.2 Laftechnologies
5 5% CO2 incubator Heracell 150i Thermo Scientific
6 Chemidoc XRS XRS Bio-Rad
7 Syringe Pump PHD Ultra 400 Harvard Apparatus
8 Gel electrophoresis setup Major Science MP 300N
9 pH meter - Labchem pH
10 Confocal Microscope LASaf Leica
11 Inverted Microscope - Prism Optical
12 Sonicator Vibra-cell Sonics
13 Microplate Reader SH-1000 Corona electric
14 Fluorescent Reader MTO-601F Corona electric
15 Flow cytometer CantoII BD biosciences
16 Centrifuge CT15RT Techcomp
17 Sample Heater HB-2 Wealtec Corp
18 Atomic Force Microscope Cypher Asylum Research
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List of Antibodies
S.no. Antibody Dilution Catalogue 
number
Company
1. D-8, anti-survivin mouse 
monoclonal antibody
1:500 SC-17779 Santa Cruz
2. Mouse anti-EGFR 1:1000 SC-373746 Santa Cruz
3. Mouse anti-HSP70 1:500 SC-66048 Santa Cruz
4. Goat anti-CD133 1:1000 - Epitomics
5. Mouse anti-EpCAM 1:1000 - Epitomics
6. Anti-mouse FITC 1:100 F9137 Sigma Aldrich
7. Anti-goat FITC 1:100 F2016 Sigma Aldrich
8. Anti-mouse IgG HRP 1:80,000 A2304 Sigma Aldrich
 
List of Chemicals
S.no. Reagent/Chemical/Antibody/Buffers Company
1. Acetone Chem Supply 
2. Acetonitrile Sigma Aldrich
3. Acrylamide Sigma Aldrich 
4. Agarose Sigma Aldrich
5. Ammonium bicarbonate Sigma Aldrich
6. Ammonium persulfate (APS) Sigma Aldrich
7. Anti-Goat-FITC Sigma Aldrich 
8. Anti-mouse horse radish peroxidise (HRP) Sigma Aldrich 
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9. Bisacrylamide Sigma Aldrich
10. Bradford-Coommassie plus protein assay reagent Thermo Scientific
11. Bovine serum albumin (BSA) Sigma Aldrich 
12. Bromophenol blue Sigma Aldrich 
13. CHAPS Sigma Aldrich 
14. CHCA matrix Sigma Aldrich
15. Chloroform Sigma Aldrich 
16. Dithiothreitol (DTT) Sigma Aldrich 
17. Dimethyl sulfoxide (DMSO) Sigma Aldrich 
18. Dulbecco Modified Eagles’ Media (DMEM) high 
glucose 
Gibco 
19. Ethanol Chem Supply 
20. EpCAM locked nucleic acid aptamer Exiqon
21. Ethylenediamine tetra acetic acid (EDTA) Sigma Aldrich
22. Fetal bovine serum (FBS) Bovogen 
23. Fluoro shield 4’,6-diamidino-2-phenylindole 
(DAPI)
Sigma Aldrich
24. Glacial acetic acid Panreac 
25. Glycerol Sigma Aldrich 
26. Glycine Sigma Aldrich 
27. Goat anti-CD133 monoclonal antibody Santa Cruz USA
28. Iodoacetamide Bio-Rad
29. Isopropyl alcohol Chem Supply 
30. Methylene blue Sigma Aldrich
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31. Mineral oil Bio-Rad
32. Mouse anti-EGFR monoclonal antibody Santa Cruz
33. Mouse anti-EpCAM monoclonal antibody Santa Cruz
34. Mouse D-8 (anti-survivin) monoclonal antibody Santa Cruz
35. Nucleolin locked nucleic acid aptamer Exiqon
36. Paraformaldehyde Sigma Aldrich 
37. Promega Trypsin Gold Promega
38. Protease max surfactant Promega
39. Protein marker, wide range Sigma Aldrich
40. Propidium Iodide (PI) stain Sigma Aldrich 
41. Protease inhibitory cocktails Sigma Aldrich
42. ReadyStrip IPG strips Bio-Rad
43. Sodium azide Sigma Aldrich 
44. Sodium borohydride Sigma Aldrich
45. Sodium Chloride Sigma Aldrich 
46. Sodium citrate Sigma Aldrich
47. Sodium do-decyl sulphate (SDS) Sigma Aldrich 
48. Sodium thiosulphate Sigma Aldrich
49. Thiourea Bio-Rad
50. Tris base Sigma Aldrich
51. Trifluoroacetic acid Sigma Aldrich
52. Triton X-100 Sigma Aldrich 
53. TRIzol reagent Life Technologies 
54. Trypan Blue Sigma Aldrich 
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55. Trypsin/EDTA (0.25%) Life Technologies 
56. Tween-20 Sigma Aldrich 
57. Urea Bio-Rad
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